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 Drug discovery evolution leading to an abundance of poorly soluble 
drugs 
People have been using drugs since the dawn of mankind. Some historians believe the first 
indications of drug use can be seen on prehistorical cave paintings 1. The first written record 
of medical therapy has been found on a papyrus scroll describing treatments used in Ancient 
Egypt. This scroll has been dated back to about 1500 BC 2. Until 150 years ago, humans still 
solely relied on natural resources to provide pharmacologically active substances, but mind 
you, until today this source still provides a significant source for new drug leads 3. By the 
second half of the nineteenth century, organic chemistry and pharmacology had evolved in 
such a way, that it laid a platform for a whole new class of molecules: synthetic drugs. The 
origin of synthetic drug development can be traced back to the textile industry, and more 
specifically to the emerge of synthetic dye development. The first synthetic dyes were derived 
from coal-tar, a by-product formed after coal distillation. Coal-tar is rich in aromatic 
molecules, including naphthalene and acetanilide, which are among the first developed 
synthetic drugs 2, 4. 
In the twentieth century, drug discovery evolved from active compound identification of 
traditional medicines or serendipitous discovery to a more systematic approach, namely the 
discovery and development of combinatorial chemistry and high throughput screening 5, 6. 
Combinatorial chemistry allows for the synthesis of hundreds or thousands of structural 
analogue molecules, hereby creating a compound library which is then up for screening 7. 
which is performed in a high throughput set-up that allows for these large numbers molecules 
to be tested for their biological or pharmacological activity. Ultimately and ideally this will lead 
to the discovery of chemical structures (so-called leads) which can be further developed into 
marketable drugs 8. 
Despite the massive growth in the number of compounds and the highly efficient screening 
methods to generate leads, this has not been translated into a higher number of marketed 
drug compounds 9. So, despite the generation of these highly specific, highly potent drug 
candidates that work well in the early stages of drug development, drug attrition rates are still 
high. Drug attrition is caused by various factors: clinical safety, commercial reasons, patent 
issues, but also formulation, pharmacokinetic and bioavailability issues 10. Some data suggests 
that an estimated 50% of drug candidates display poor absorption, distribution, metabolism, 
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elimination or toxicity (ADMET) properties. The number of drugs on the market having 
ADMET problems is also estimated being half 11. Circumventing ADMET problems can be 
achieved by screening compound libraries and drug candidates for potentially disadvantageous 
ADMET properties. An example to address the absorption part of ADMET is Lipinski’s ‘rule 
of five’, where compounds can be screened for properties which have an adverse influence on 
solubility and permeability. These properties are: more than 5 hydrogen bond donors, more 
than 10 hydrogen bond acceptors, a molecular weight in excess of 500 Da, a calculated log P 
greater than 5 12. Still today new improved methods are developed for rapid drug candidate 
screening on solubility and permeability characteristics for absorption estimation 13. Solubility 
and permeability are of utmost importance in oral drug delivery. After all, if drugs don’t 
dissolve they are unable to permeate, and if they are unable to permeate, they are not taken 
up by the systemic circulation, which is important for drugs with the ambition to display 
systemic effects. 
To establish a firm grip on solubility and permeability problems, first, a clear definition of 
poor solubility and/or permeability needs to be defined. In 1995, Amidon et al. introduced the 
biopharmaceutics classification system (BCS) to correlate in vitro drug dissolution and in vivo 
bioavailability 14. Four classes have been defined in this classification system. Class 1 drugs 
exhibit high solubility and high permeability, class 2 drugs combine poor solubility with high 
permeability, class 3 drugs high solubility with poor permeability and class 4 drugs show poor 
solubility and poor permeability. Poor solubility is defined as the inability of the highest dose 
of the drug to dissolve in less than 250 ml of a medium with pH 1-7.5. A drug displays poor 
permeability when less than 90% of the highest dose strength is absorbed in humans 15. A 
classification of the top 200 drug products on the market in several countries showed that 
around 70% can be classified as class 2, 3 or 4, and thus showed solubility and/or permeability 
issues 16. 
 Gastro-intestinal absorption and solubility/dissolution rate 
promoting formulation strategies  
Another path can be gone down when trying to tackle absorption and solubility/dissolution 
rate problems in drug candidates. Instead of screening and removing candidates displaying 
disadvantageous physicochemical properties, different formulation strategies can be applied to 
enhance drug permeability or solubility. Permeability of drugs can be increased by creating a 
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pro-drug which has increased permeability (e.g. valacyclovir or tenofovir diisoopropyl 
fumarate)17 or formulating the drug together with so-called ‘absorption enhancers’. These are 
functional excipients that can enhance membrane permeation by dilating tight junctions in cell 
membranes (paracellular penetration enhancement) or increase penetration inside cell 
membranes (transcellular penetration enhancement). An example of an excipient which can 
perform both action mechanisms, is sodium caprate 18. 
Over the last few decades, numerous strategies have been developed to enhance drug 
solubility and/or dissolution rate. What follows is a non-exhaustive summary of the main 
mechanisms: 
 Salt formation: often seen as the primary approach in enhancing dissolution rate and 
solubility of weakly acidic and basic poorly soluble drugs. The solubility of these drugs as 
function of pH dictates whether salt formation might be suitable 19. 
 Pro-drug formation: a pro-moiety, enhancing drug solubility, is covalently linked to the 
drug. After the desired effect, a pro-drug can be chemically or enzymatically converted to 
the native drug substance 20. 
 Particle size reduction: drug particles, preferably in nanometre size scale, exhibit 
increased dissolution rate due to higher surface area and increased solubility under critical 
particle size. Addition of a stabilizer is needed to prevent spontaneous aggregation 21.  
 Lipid-based systems: from simple lipid solutions to more advanced self-emulsifying drug 
delivery systems, lipid based systems can enhance drug solubilisation, reach the systemic 
circulation via lymphatic drug transport and/or interact with enterocyte based transport 
22, 23. 
 Cocrystals: crystal composed of a drug and a coformer. Solubility of cocrystals is 
determined by a range of coformer properties and possible interactions with the drug 
crystal 24. 
 Cyclodextrins: cyclic oligosaccharides, able to form inclusion complexes with poorly 
soluble drugs, thus enhancing apparent drug solubility 25. 
 Mesoporous silica: inert mesoporous material which can confine single drug molecules 
inside of its pores. Upon contact with release medium, the drug molecules exit the pores 
displaying a higher apparent solubility and release rate 26, 27. 
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 Amorphous systems: exploitation of the higher energy state and lack of long range order 
of amorphous drugs, compared to their crystalline counterparts. Formulations comprising 
drugs in the amorphous state will be discussed in more detail in the next paragraph. 
 Drug amorphisation 
The amorphisation of a substance, drug or otherwise, can be envisioned as the freezing of 
a liquid into the solid state. Contrary to their crystalline counterpart, amorphous solids only 
possess short range order, whereas crystalline solids show three-dimensional long range order 
of molecules into repeating patterns (the crystal lattice). The smallest molecular groups 
exhibiting these repeating patterns are called a unit cell. Because of this higher disorder, 
amorphous solids (or glasses) show higher molecular mobility and increased enthalpy, entropy 
and volume compared to the corresponding crystalline solid but these same thermodynamic 
properties are lower compared to the liquid state. This phenomenon is visualized in Figure 
1.1, where enthalpy, entropy or volume is plotted in function of temperature at constant 
pressure. 
 
When a crystalline solid is heated, it will melt and become a liquid at Tm which is the melting 
temperature. Melting is a first order transition and the liquid state is reached by a jump in H, 
S and V values compared to the crystalline state. When this liquid is cooled slowly, it will allow 
for sufficient time for the molecules to rearrange into a crystal. But if this liquid is cooled fast 
Figure 1.1: Schematic plot of enthalpy (H), entropy (S) or free volume (V) in function of 
temperature (T) for molecular substances at constant pressure.  
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enough to bypass the rearrangement into a crystal, the liquid can be cooled below Tm and go 
to the supercooled liquid state, which is in equilibrium with the liquid state. When further 
cooled, the molecules in the supercooled liquid will exhibit a sudden loss in translational 
motion, fall out of equilibrium and will transform into an amorphous solid at the glass transition 
temperature (Tg). The supercooled liquid is ‘frozen’ into a disordered state, which is 
thermodynamically unstable, nonequilibrium state and displays a higher viscosity compared to 
the liquid state. Since crystalline solids are the lowest energy state, molecules will strive to 
this state. This makes amorphous solids inherently unstable. Not only are the thermodynamic 
parameters of the amorphous solid higher than that of the crystalline solid, also the molecular 
mobility is enhanced. This is also responsible for the higher instability of the amorphous form. 
Nucleation is a result of localized faster molecular mobility 28. 
Certain conditions like elevated temperature or humid environments for an extended 
period of time can provoke ‘structural relaxation’ to amorphous solids. Here, the amorphous 
solid loses energy, gains order and may approach the energy values of the crystalline state. 
Ultimately, structural relaxation can lead to a conversion to the crystalline state. There is also 
a phenomenon opposite to structural relaxation which is called ‘enthalpic recovery’, here 
energy is added to the system (e.g. in the form of heat) converting it again to its original 
energetic state. It can also be argued that the glass transition is a thermodynamic prerequisite 
for supercooled liquids, since otherwise they could reach enthalpy values equal or lower than 
the crystalline state. The temperature at which this would happen is called the Kauzmann 
temperature (Tk). It is practically impossible for glass transition temperatures to reach the 
Kauzmann temperature, since the cooling rate would have to be infinitesimally fast. The glass 
transition is also not a fixed value since it can vary due to different heating and cooling rates, 
molecular mass, history, geometry or purity of the sample 29. 
Amorphous solids can not only be prepared by melt quenching (as described above), but 
also from a solution by rapid solvent evaporation, crystal lattice disruption or vapor 
condensation (some of these methods will be discussed when introducing preparation 
methods for solid dispersions). 
To avoid crystallization of the amorphous form, this last can be stored at temperatures well 
below Tg. An empirical rule, known as the ‘Tg-50’-rule, stipulates that when an amorphous 
material is stored at 50°C below the glass transition temperature, molecular mobility values 
have dropped low enough to provide acceptable stability 30. 
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As shown in the previous paragraph, amorphous solids have higher free energy compared 
to a crystal and lack the highly-ordered crystal lattice. This gives them a benefit in solubility 
since they don’t have to overcome lattice energy. However, due to their inherent instability 
and propensity to crystallize, amorphous forms of drugs are rarely formulated as such. 
 Solid dispersions 
The first step towards the notion of solid dispersions was made in 1961 by Sekiguchi and 
Obi 31. In their study, eutectic mixtures were made up of sulfathiazole and urea, showing higher 
absorption compared to sulfathiazole as such. Since urea doesn’t display any solubilizing action 
or enhances absorption , it was concluded that the physical state of sulfathiazole in the eutectic 
mixture was responsible for the accelerated absorption. 10 years later, a first definition and 
classification of solid dispersions was formulated by Chiou and Riegelman 32. A solid dispersion 
was defined as ‘the dispersion of one or more active ingredients in an inert carrier or matrix 
at solid state prepared by the melting (fusion), solvent, or melting-solvent method’. A 
classification was also constructed, depending on the crystalline, amorphous or molecularly 
dispersed state of the drug and the crystalline or amorphous state of the carrier 32, 33. An 
overview is provided in Table 1.1. 
Table 1.1: classification of solid dispersions, adapted from Dhirendra et al. 34.  
Type of solid dispersion Drug Carrier # Phases 
Eutectic mixtures Crystalline Crystalline 2 
Amorphous precipitate in a 
crystalline carrier 
Amorphous Crystalline 2 
Solid solutions Molecularly dispersed Crystalline 1 
Glass suspensions Crystalline or amorphous Amorphous 2 
Glass solutions Molecularly dispersed Amorphous 1 
As mentioned previously, the first solid dispersion created was a eutectic mixture. In this 
mixture, two compounds are miscible in the liquid state, but not in the solid state. At the 
eutectic composition, both compounds will simultaneously crystallize from the melt and form 
a very fine dispersion. If one compound is a poorly soluble drug and the other a highly soluble 
carrier, this will increase the surface area of the drug improving dissolution rate and ultimately 
the bio-availability. An amorphous precipitate in a crystalline carrier is seldomly created and 
has no value to the solid dispersion research. 
  General Introduction 
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Solid solutions are characterized by the presence of a molecularly dispersed drug in the 
crystal lattice of the carrier. This can be achieved by replacing a molecule in the lattice 
(substitutional solid solution) or occupying the space within the crystal lattice structure 
(interstitial solid solution). A solid solution can be continuous (unlimited miscibility) or 
discontinuous (limited miscibility). All in all, the role of solid solutions in solid dispersions is 
also limited. The most relevant examples of eutectic mixtures/solid solutions created, are 
combinations of a drug with the semi-crystalline polymers polyethylene glycol (PEG)35-37 or 
Pluronic 38.  
Glass suspensions combine an amorphous carrier with an amorphous (or crystalline) drug 
compound. The advantage of using amorphous carriers is that a greater extent of miscibility 
with an amorphous drug can be achieved. Finally, in a glass solution, there is solid solubility or 
miscibility between drug and carrier, resulting in a molecularly dispersed drug phase in an 
amorphous carrier forming a one phase system. These amorphous carriers are for the most 
part hydrophilic polymers. Nowadays in almost all solid dispersion formulations, there is a 
strive for the creation of glass solutions, where the drug particle size is reduced to the absolute 
minimum, resulting in a maximized dissolution rate. This can be evidenced by the Nernst-
Brunner (or modified Noyes-Whitney) equation 39: 
𝑑𝐶
𝑑𝑡
=
𝐷𝑆
𝑉ℎ
(𝐶𝑠 − 𝐶)     Eq.1.1 
In this equation, 
𝑑𝐶
𝑑𝑡
 (mol/(l.s)) is the dissolution rate, C (mol.l) the concentration at time t, 
Cs (mol/l) the saturation solubility, D (cm²/s) the diffusion coefficient, S (cm²) the surface area, 
V (ml) the volume of the dissolution medium and h (cm) the thickness of the diffusion layer. 
This equation shows that the surface area is proportional to the dissolution rate. A molecularly 
dispersed system has a minimized particle size, and thus ultimately a maximized surface area. 
As mentioned before, the creation of a stable glass solution requires the equilibrium or 
thermodynamic solid solubility of the drug in the carrier not to be exceeded. In practice, 
however, this thermodynamic solid solubility is often exceeded, which can be because of 
energy intensive processing, creating glass solutions which are unstable over time. Note that 
thermodynamically unstable glass solutions will turn into glass suspensions, with either 
amorphous or crystalline separated phases being formed 40. Although long term stability has 
always been the main concern of formulation scientists concerning amorphous solid 
dispersions, a recent publication has shown a kinetically stabilized amorphous solid dispersion 
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of nifedipine to remain fully amorphous for 25 years 41. Specific drug-polymer interactions like 
van der Waals, dipolar, hydrogen bonding or Coulomb interactions can enhance the miscibility 
and solid solubility 42. Miscibility is the tendency of an active pharmaceutical ingredient (API) 
in its supercooled or glassy state, to mix with the carrier. Solid solubility can be described as 
the carrier acting as a solvent to dissolve the crystalline API. Presence of crystalline API does 
not necessarily point to immiscibility of the drug-polymer system 43, 44. 
To avoid the creation of unstable glass solutions, a lot of efforts have been put into 
theoretical or experimental determination of the thermodynamic solid solubility and miscibility 
of poorly soluble drugs and amorphous carriers 45-48. Miscibility determination can be assessed 
with qualitative methods like glass transition measurement, solubility parameter 
determination, computational data mining and micro-Raman, or with quantitative methods like 
computational analysis of X-ray diffraction measurements, solid-state nuclear magnetic 
resonance, Flory-Huggins interaction parameter and a combination of techniques (atomic 
force microscopy, electron microscopy…). For a more complete overview of these different 
possibilities, the reader is referred to a mini-review by Meng et al. 49. As intermolecular 
interactions can have a beneficial effect and solubility and miscibility, factors like humidity 
(plasticization effect of water) and heat (elevated molecular mobility) can have a negative 
influence on the stability of glass solutions 50, 51. 
 Carriers used in the formulation of solid dispersions 
Carriers for solid dispersions have evolved to a great extent since urea was used to make 
the first solid dispersion 31. Whereas in the early stages of solid dispersion development, 
crystalline carriers were predominantly used, nowadays the focus has almost entirely shifted 
to amorphous (polymeric) carriers 52.  
1.5.1  Crystalline carriers 
The disuse of crystalline carriers was the result of their inability to contain drugs in the 
amorphous or molecularly dissolved state, their lower drug loading and the inferior stabilizing 
effect compared to amorphous carriers, due to less availability of interaction sites 53. The 
exception here is the use of the semi-crystalline carrier polyethylene glycol (PEG), due to its 
hydrophilic nature and slight surface active properties. However, the very diverse influence of 
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PEG on the stability (crystallization) of drugs 35, or of drugs on the stability of PEG 54, make it 
currently still a very unpredictable and therefore less used polymer. 
1.5.2  (hydrophilic) Amorphous carriers 
Amorphous polymers are, generally considered, the most suitable option for glass solution 
formulation. Because of the amorphous nature, full miscibility with amorphous drugs can be 
achieved. Polymers with a high glass transition temperature can have an anti-plasticization 
effect on the amorphous drug, effectively avoiding crystallization of the drug by reducing 
molecular mobility and thus increasing stability 55. This can be seen as an application of the Tg-
50 rule, where the Tg is increased to allow stability near room temperature. The Tg-50 is a 
rule of thumb, rather than universally applicable in this situation, since some exceptions have 
been observed 56. This stable glass transition temperature of a drug-polymer mixture can be 
predicted using the Gordon-Taylor equation 57: 
𝑇𝑔 =
𝑤1𝑇𝑔1+𝑘𝐺𝑇(1−𝑤1)𝑇𝑔2
𝑤1+𝑘𝐺𝑇(1−𝑤1)
    Eq. 1.2 
Since Tg1 ≤ Tg2, the former usually represents the Tg of the drug and the latter the Tg of the 
polymer. w is the weight fraction and kGT is a constant equalling 
𝜌1∆𝛼1
𝜌2∆𝛼2
. Here, ρ  is the density 
of the components and Δ α  the change in thermal expansivity. When applying the Simha-
Boyer rule 58, this constant can be approached as 
𝜌1𝑇𝑔1
𝜌2𝑇𝑔2
. Other, less used, equations to predict 
the resultant mix-Tg of a drug-polymer system are the Fox, Couchman-Karasz or Kwei 
equations 55. Deviations from the calculated Tg can point to presence of a plasticizer (residual 
solvent or water) or to a decrease in density of the mixture in case of a decreased 
experimental Tg Strong interactions between drug and polymer result in an increased 
experimental Tg. These strong interactions like ionic interactions or hydrogen bonding can 
also play an important role in the formation of stable solid dispersions 59.  
Amorphous polymers used in the formulation of solid dispersions are mostly hydrophilic 
polymers, capable of rapidly dissolving in the entire (or part of the) pH range. Per their 
chemical structure, 3 main groups can be identified. The names and abbreviations of the most 
important polymers of each group are shown in Table 1.2 together with their Tg, molecular 
weight (Mw) and the pH range in which they are soluble. 
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Table 1.2: Different groups of amorphous polymers used as carriers for solid dispersions, 
adapted from Newman 60 
Group Name Abbreviation Tg (°C) Mw (kDa) Soluble pH 
C
e
ll
u
lo
se
 
d
e
ri
v
a
ti
ve
s 
Hydroxypropylmethylcellulose HPMC 160-180 10-1500 1-10 
Hydroxypropylcellulose HPC 100-150 50-1250 1-10 
Hydroxypropylmethylcellulose 
acetate succinate 
HPMCAS 113 55-93 > 5.5-6.5 
P
o
ly
vi
n
y
l 
p
o
ly
m
e
rs
 
Polyvinylpyrrolidone PVP 120-174 2,5-3000 1-10 
Polyvinyl alcohol PVA 
180-190* 
228 
20-200 1-10 
Polyvinylpyrrolidone – polyvinyl 
acetate 
PVPVA 106 45-70 1-10 
Polyvinyl caprolactam – polyvinyl 
acetate grafted on PEG 
Soluplus® 60-70 64 1-10 
M
e
th
a
c
ry
la
te
 p
o
ly
m
e
rs
*
*
 
Basic Butylated Methacrylate 
Copolymer 
E100 57 47 < 5.0 
Methacrylic Acid - Methyl 
Methacrylate Copolymer (1:1) 
L100 195 125 > 6.0 
Methacrylic Acid - Ethyl Acrylate 
Copolymer (1:1)  
Type A 
L100-55 111 320 > 5.5 
Methacrylic Acid - Methyl 
Methacrylate Copolymer (1:2) 
S100 173 125 > 7.0 
*depending on partial (180-190°C) or full (228°C) hydrolyzation **Tg and Mw based on 
61 
The choice of carrier depends on several carrier and drug properties. First, an acceptable 
miscibility and solid solubility between drug and carrier should be achievable, allowing the 
formation of stable glass solutions. Preferably, there is also a possibility of drug-polymer 
interactions such as hydrogen bonding or ionic interactions. The carrier should be able to 
release the drug from its matrix at the preferred target site. Depending on the production 
method of the formulation, the carrier should possess either thermal stability or acceptable 
solubility in an array of organic solvents. Another critical quality of a good carrier is its ability 
to maintain supersaturated drug concentrations. It has been stipulated that a polymeric carrier 
can do this by forming solute-polymer interactions which hinders the reorganization of a 
cluster of solute molecules into an ordered crystal structure 62. Once a suitable carrier is 
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found, different grades of the same polymer can have an influence on stability or release. For 
example: the hydrolyzation of PVA, different molecular weight or substitution grades of 
cellulose derivates 63, or different chain lengths (Mw) of PVP 64, 65. 
The success of hydrophilic amorphous polymers as carriers for solid dispersions is reflected 
in the amount applied in marketed solid dispersions. Table 1.3 represents a compilation of 
marketed products using solid dispersion technology. As can be seen, all of these products 
use hydrophilic amorphous polymers, except for Gris-PEG, which uses the semi-crystalline 
PEG as a carrier. 
Table 1.3: List of marketed solid dispersion products, adapted from Williams et al. 66 
Product Drug Carrier Company 
Gris-PEG griseofulvin PEG Pedinol Pharmacal Inc. 
Certican everolimus HPMC Novartis Pharmaceuticals 
Intelence etravirine HPMC Tibotec 
Nivadil nilvadipine HPMC Fukisawa Pharmaceutical Co., Ltd 
Prograf tacrolimus HPMC Astellas Pharma US, Inc 
Sporanox itraconazole HPMC Janssen Pharmaceuticals 
Isoptin-SRE verapamil HPC/HPMC Abbott Laboratories 
Incivek telaprevir HPMCAS Vertex Pharmaceuticals 
Zelboraf vemurafenib HPMCAS Roche 
Cesamet nabilone PVP Valeant Pharmaceuticals 
Kaletra lopinavir/ritonavir PVPVA Abbott Laboratories 
Norvir ritonavir PVPVA Abbott Laboratories 
1.5.3 New carrier approaches 
In recent years, different strategies have been reported to address some of the drawbacks 
in using hydrophilic amorphous polymers in solid dispersion technology. 
 Co-Amorphous drug formulations: combination of two low molecular weight 
components that form a single phase amorphous system. This can be either a combination 
of two drugs or a drug combined with a low molecular weight excipient such as an amino 
acid. This approach tries to reduce the amount of excipient to stabilize the formulation. It 
also reduces the hygroscopic nature of many ‘classic’ solid dispersions 67. 
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 ‘in-situ’-amorphisation: drugs are converted to the amorphous state upon contact with 
dissolution medium, vapour or lipolysis thus conveniently avoiding storage related 
instability 68.  
 Controlled release of solid dispersions: sometimes labelled as fourth generation carriers 
for solid dispersions. Controlled release formulations of poorly soluble drug compounds 
can offer similar advantages to other controlled or sustained formulations, like improved 
compliance by reduced dosing frequency, decreased side effects, and prolonged 
therapeutic effects 69. Polymers frequently used in the controlled release of solid 
dispersions include cellulose derivates like ethyl cellulose (EC), 
hydroxpropylmethylcellulose acetate phthalate (HPMC-AP) and some grades of HPMC 
and HPC, polyethylene oxide (PEO, high Mw PEG) and methacrylates like Eudragit RL and 
RS grade. These polymers release the drug by diffusion rather than by dissolution. 
Controlled release polymers can be applied as (part of) the matrix or as an outer layer 
through which the drug has to diffuse before being released 70, 71. Moreover, it has been 
observed that although rapidly dissolving polymers lead to fast generation of high 
supersaturated drug concentration levels, it does not always result in an optimal 
enhancement of bio-availability 72. Hence controlled release polymers could slow down 
this fast increase and prolong the supersaturated drug concentrations. This has been 
demonstrated by Sun and Lee and their results are bundled in an interesting commentary 
about the interplay between dissolution and precipitation 73. 
 Manufacturing techniques of solid dispersions 
Of the four techniques to render drugs amorphous named earlier on, three are actively 
used in solid dispersion manufacturing. The choice of a manufacturing technique is dependent 
upon drug and polymer properties and can have a vast impact on the stability and 
pharmaceutical performance of the solid dispersion. 
1.6.1 Crystal lattice disruption 
The disruption of the crystal lattice of drugs, also called mechanical activation is performed 
by high-intensity milling. Although the fundamental aspects of the amorphisation processes are 
still not fully understood, this technique has been shown to be effective in amorphisation of 
drugs as such 74. This method has been successful in the creation of co-amorphous systems67 
and only very recently, some successful efforts in making polymeric solid dispersions have 
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been reported 75-77. Some benefits of using milling for the creation of solid dispersions include 
the omission of possibly toxic or destabilizing solvents, and its potential for thermolabile 
compounds. 
1.6.2 Melt quenching 
Melt fusion with subsequent quenching was the technique used in the creation of the first 
solid dispersion 31. Since then, optimized techniques have been developed to produce 
amorphous solid dispersions. Hot melt extrusion is the most investigated technique applying 
the melting method 78. In hot melt extrusion, a physical mixture of drug and polymer are 
introduced into a heated barrel. One or multiple screws provide propulsion and mixing of the 
molten mixture. Finally, this melt is pushed out of the extruder via a dye, which allows to 
produce extrudates of different diameters. The temperature decrease out of the dye allows 
for solidification. The barrel temperature, screw speed, screw design and feed rate are process 
parameters which can influence the quality of the end product 79. The main advantages of hot 
melt extrusion are solvent free production and the possibility for continuous processing. 
Disadvantages are inability to use thermally degradable products and, often, the need for post 
processing operations like milling or pelletizing (which can have a disadvantageous effect on 
solid dispersion stability). Although it has to be noted that these post processing steps can be 
avoided by shaping the extrudates into tablets via calendering 80. Different products 
manufactured with hot melt extrusion are on the market today, not only solid dispersions but 
also sustained delivery products like eye implants or contraceptives 81. A variation on this 
technique is co-extrusion, which can provide a multi-layered extrudate suitable for fixed dose 
combinations or controlled release drug delivery 82. 
In recent years, two additional melting methods have come to the forefront. The first 
technique is thermal injection moulding. A technique which is already established for a long 
time in the plastics industry and medical device manufacturing, has now been proposed for the 
proposed for the production of immediate release tablets 83. 
A second method is fused deposition modelling (extrusion based 3D printing technique) to 
produce oral drug formulations. This technique has a tremendous potential in the application 
for personalized medicine, with possibilities of individual doses, amounts, release properties,… 
Contemporary hurdles include compatibility of drugs and excipients with the 3D printing 
technique and regulatory challenges that need to be overcome 84, 85. 
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1.6.3 Rapid solvent evaporation 
When formulating solid dispersions through rapid solvent evaporation, the well-established 
go-to method is spray drying. In this technique, a drug-polymer solution is fed through a nozzle 
and mixed with pressurized air to form fine droplets (atomization). Other nozzle types, using 
centrifugal, pressure, kinetic or vibration energy for atomization are available as well. These 
droplets are further transported and dried along a heated air flow or carrier gas through a 
drying chamber and a cyclone, where particles within a desirable size range fall out of the air 
stream in a collector. Extensive reviews have been written about the formulation of solid 
dispersions through spray drying with considerable attention to the influence of process and 
formulation variables on the final product 86, 87. The subsequently formed powder can be 
processed in a wide array of drug delivery systems (capsules, tablets, dispersible powders…). 
Spray drying is also a suitable method for thermally degradable compounds since the 
temperature during spray drying is less high compared to hot melt extrusion. The presence of 
residual solvent, which can act as a plasticizer or is potentially toxic, is seen as one of the 
techniques’ main disadvantages. 
Recently developed or introduced solvent removal techniques for producing solid 
dispersions include inkjet printing88, 89, electrospinning and electrospraying 83, 89. Scaling-up 
challenges currently form the biggest pitfall for the further implementation of these techniques 
of solid dispersion research. 
1.6.4 Fluid bed coating 
A manufacturing technique using the solvent method, which has been long overlooked in 
solid dispersion research, is fluid bed coating. Although there is a drug formulation on the 
market that uses this technique, Sporanox (Janssen Pharmaceuticals) which is a solid dispersion 
of itraconazole and HPMC layered on inert sugar spheres and this has been used as a reference 
in some comparative studies90-92, there has not been done a lot of research on the technique 
itself, or on what makes it suitable for solid dispersion exploitation. Fluid bed coating, on the 
other hand, can be considered an established technique in controlled drug release formulation 
with numerous articles being published on the layering of controlled release polymers like 
ethylcellulose93, poly(meth)acrylates94, polyvinylacetate95 or blends thereof 96, 97Fluid bed 
coating uses the constant patterned movement of starter cores to apply a cyclic layering of a 
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drug polymer solution. Figure 1.2 shows a schematic representation of a fluid bed coating 
device. 
 
The movement of the inert particles is provided by fluidization through an inlet air stream. 
In fluidization, particles are suspended in fluidizing air, which moves upwards and thereby 
counteracts gravitational forces. This inlet air stream should be accurately selected since the 
superficial velocity of the air should exceed the minimum fluidization velocity of the particles, 
but cannot exceed their terminal velocity. For this reason, a small particle size range is 
preferred98. 
Fluid bed coating can consist of 3 set-ups. In a top spray configuration, the nozzle is place 
above the fluidized bed, resulting in opposed directions of sprayed liquid and air flow. This set-
up is mainly used for granulation purposes. The set-up displayed in Figure 2 is a bottom spray 
configuration with an optional Würster insert (conical cylinder placed over the nozzle with a 
slightly decreasing diameter). In this set-up sprayed liquid and air flow are unidirectional, which 
increases contact between droplets and particles, and increases droplet drying time compared 
to top spray and this generally results in more efficient and homogenous coating. A third set-
up consists of a rotary disk at the bottom equipped with slits where the air flow enters. The 
Figure 1.2: Schematic representation of bottom spray fluid bed coating using a Würster insert. 
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nozzle or nozzles are located on the side of the coating chamber. This gives rise to a tangential 
spray on the fluidized particles, hence the name ‘tangential spray’ set-up. This set-up gives rise 
to a particular ‘rope-like’ particle motion, which results in dense and spherical shapes. The 
high agitation in the equipment is seen as the most important drawback to the system 99. It 
must be noted that coating and granulation processes share some similar equipment, the 
difference is that process and formulation parameters in granulation are chosen so 
agglomeration is promoted, while in coating this must be avoided. 
In a bottom spray set-up with a Würster insert, which is the most common configuration 
for coating purposes, inert pellets are fluidized and make a circular movement (as indicated 
with arrows on Figure 1.2). This made possible by the air plate configuration which directs air 
flow to the centre of the plate, near the nozzle. Furthermore, the bead movements benefit 
from the narrowing diameter of the Würster insert to accelerate through acceleration of the 
air flow on one hand, and the increasing diameter of the coating chamber causing deceleration 
of air flow and beads on the other hand. The Würster insert has additional benefits in the fact 
that it separates and directs the upward moving beads away from the downward falling beads. 
In this way, a more effective coating can be achieved. The nozzle atomizes the spraying liquid 
and these fine droplets hit the surface of the beads. After the beads have been wetted they 
move upwards and fall back down at the side of the coating chamber, this allows for a sufficient 
drying time and they are redirected to the centre of the coating chamber where the entire 
coating process can restart. This circular movement of the beads allows for repeated layering 
of a sprayed solution or dispersion onto these beads until the desired coating level is achieved, 
this process is schematically shown in Figure 1.3.  
 
Figure 1.3: Schematic representation of the cyclic layering of inert beads. The beads are wetted 
by droplets from the spraying solution and subsequently dried. This process is repeated until a 
desired coating level is applied to the bead. Fluid bed coating allows for the application of 
multiple layers to be coated consecutively. 
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Adjustable process parameters for fluid bed coating include:  
 Air flow rate: allows for fluidization, optimal particle movement and drying (time) of the 
wetted particles 
 Air flow temperature: adjusted for optimal solvent or water evaporation 
 Air flow humidity: humidity control can influence the air drying capacity 
 Atomizing air flow: adjustment of droplet size of the supplied liquid 
 Feed rate: needs to be adjusted for optimal film formation around the bead 
Suboptimal process parameters can result in agglomeration, when the wetted beads are 
not dried fast enough, or spray drying, when the sprayed liquid solidifies before hitting a 
substrate. 
Fluid bed coating can address some issues encountered in solid dispersion research. First, 
drying of the layered beads can be performed within the coating device itself, omitting 
additional drying steps, minimizing residual solvent levels, and thus increasing stability. 
Secondly, it has been shown that post processing steps can have a negative influence on the 
stability of solid dispersions. Ayenew et al. for example showed demixing of naproxen-PVP 
solid dispersion upon compression 100. By applying fluid bed coating, compressional forces can 
be avoided since coated beads can be immediately filled into capsules. Thirdly, it has been 
shown that API crystallization happens faster at the surface of solid dispersion particles as 
compared to the bulk 101. This issue can be addressed by applying a second protective coating 
on top the solid dispersion (see Figure 1.3). Application of the second coating also does not 
require transfer and handling steps as it can be performed in the same device. This multi-
layering approach is also an ideal prerequisite for controlled release coating. A controlled 
release coating can be applied immediately after the solid dispersion coating without extra 
handling steps. Coating multiparticulates also provides benefits over tablet coating like: a better 
spread over the gastrointestinal tract, reduced risk of dose dumping and transit times are 
more predictable 102. 
 Characterization techniques for solid dispersions 
1.7.1 Bulk characterization 
Due to the (potentially) complex physicochemical properties of solid dispersions, an in-
depth characterization of these systems is required. The primary indicator of a glass solution 
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is its glass transition temperature. The most widespread method to detect the glass transition 
is through thermal analytical techniques, and more specifically differential scanning calorimetry 
(DSC) analysis. DSC can differentiate between glass solutions, displaying a single Tg and phase 
separated systems displaying a double Tg. Single Tg’s of glass solution can be compared with 
theoretical Tg’s from the Gordon-Taylor equation (Eq. 2). Furthermore, crystallization into 
and melting of crystalline fractions are also detectable. In case of small heat capacity changes 
or solvent loss in the region of interest, modulated temperature differential scanning 
calorimetry (mDSC) can be used. Here, a sinusoidal waveform is superimposed on the heating 
rate, allowing for a separation into heat capacity related (or thermodynamic) phenomena and 
kinetic phenomena. Baird and Taylor described the full potential of using of thermal analysis 
techniques in solid dispersions in an interesting review 103. 
X-ray powder diffraction (XRPD) is a powerful method to identify crystal species in solid 
dispersions which become apparent by their Bragg peaks. It has been used extensively in 
tandem with (m)DSC to identify polymorphic transitions or exclude crystallization or 
amorphisation induced by heating. Recent advances in instrumentation and insights in 
amorphous structures have enabled the use of XRPD in the characterization of amorphous 
materials as well 104. 
Other techniques used for bulk characterization of solid dispersions: 
 Thermogravimetric analysis (TGA): investigation into solvent/water content of 
formulations and assessment of drying kinetics. It can be coupled (so-called hyphenated 
set up) with gas chromatography, infrared spectroscopy or mass spectrometry to identify 
volatile compounds. 
 Infrared (IR) and Raman spectroscopy: application for the detection of different 
crystalline or amorphous phases, also a preferred technique in molecular interaction 
identification. Their non-invasive nature also allows for quality control and process 
analytical technology purposes 105. Some comparative studies between XRPD, Raman and 
IR spectroscopy have been performed 106. 
 Dielectric spectroscopy (DES): molecular mobility investigation in glasses and 
supercooled liquids, insight into the different relaxation processes and crystallization 
kinetics 107. 
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 Terahertz spectroscopy: relatively novel analytical technique depicting fast molecular 
dynamics of molecules determining the onset and strength of molecular mobility to predict 
stability of the amorphous state 108. 
 Solid-state nuclear magnetic resonance (ssNMR): very powerful, but also very complex 
tool to determine molecular dynamics and phase compositions of solid dispersions 109. 
1.7.2 Spatially resolved (or imaging) characterization 
As powerful and detailed the bulk characterizing techniques may be, sometimes there is a 
need for spatially resolved information of solid dispersions. These characterization techniques 
allow for the separation into different parts or regions of interest within a drug delivery system 
which can be of interest in complex systems, differentiation between bulk and surface 
properties or during dissolution.  
Lots of the spectroscopic techniques mentioned in the previous paragraph can be used for 
imaging purposes as well. Infrared110, Raman105 or Terahertz111 spectroscopy have all been 
successfully applied in imaging set-ups. Raman imaging has also been successfully applied for 
real time and in situ investigation of the dissolution mechanisms in solid dispersions 112. 
Scanning electron microscopy (SEM) has been very useful for the topographical 
investigation of drug delivery systems. Also, crystal identification and form can be observed 
through SEM. This technique is unable to distinguish between different amorphous phases 
within one system. The detection of crystal structures can also be performed using polarized 
light microscopy (PLM) which is an ideal platform (fast, inexpensive) for initial screening studies 
of solid dispersions. 
Atomic force microscopy is a probe based surface analysis technique, which uses a 
nanometre scaled tip to raster scan a sample surface. The sharper the probe tip, the higher 
the resolution that can be achieved. Adhesion and repulsion forces on the probe provide 
topographical, morphological and phase distribution information. AFM has been shown to be 
able to determine drug-excipient miscibility in solid dispersions 113. AFM probes have also been 
used for nanoscale thermal analysis purposes. Here, the tip of the AFM probe is heated and 
deflection of the tip can be measured in function of temperature. This technique allows the 
determination of glass transition temperatures on a nanometer scale 114. AFM can also be 
coupled to infrared spectroscopy to obtain chemical information of a sample at the high spatial 
resolutions obtained by AFM 115. 
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Special emphasis should be put here on Time of Flight Secondary Ion Mass Spectrometry 
(ToF-SIMS) as a surface analysis technique capable of chemical identification and distribution 
(mapping). ToF-SIMS is based upon the bombardment of a sample surface with primary ions 
which will detach, among other structures, ion fragments from the surface. These are the 
secondary ions. The secondary ions are accelerated and injected into a Time-of-Flight analyser 
where the positive or negative ions (depending on the set polarity of the equipment) will be 
separated, depending on their mass-to-charge ratio. The spectra can lead to a complete 
identification of chemical structures present on the surface with a very low detection limit 
(ppb range). Because the primary ion beam can be focused, a sample can be raster scanned, 
providing spatial distribution information with a very high spatial resolution (0.2 µm). Because 
of the non-penetrating nature of the primary ion beams, sample information from the upper 
few nanometres of the sample is acquired. By using less destructive primary ion beams like 
C60
+ ions, depth profiling of the surface can be performed with an in-depth resolution of a few 
nanometers 116. A disadvantage of ToF-SIMS is that it can only provide semi-quantitative 
information on the chemical composition of the sample surface, therefore the analysis is 
sometimes performed together with X-ray photoelectron scattering (XPS) which can allow 
quantitative analysis through information on atomic concentrations and chemical bonding 114. 
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After more than fifty years of extensive research into solid dispersions, the enabling strategy 
for poorly soluble drugs still faces tough challenges. Despite its tremendous potential to 
enhance solubility and dissolution rate, a limited number of solid dispersions are on the market 
today. Amongst the primary reasons for this restricted output are poor stability and the 
inability to maintain supersaturated drug concentrations for extended periods of time. 
Some of the known causes for instability can be bypassed by using fluid bed coating. This 
solid dispersion production method has long been overlooked in solid dispersion research, 
despite being used in the successful production of one marketed solid dispersion (Sporanox®). 
This manufacturing technique has some advantages over other solvent methods: efficient 
drying post production inside the device, no additional stress inducing processing steps and 
protection from surface crystallization by adding a protective coating layer.  
Although the dissolution behaviour of coated solid dispersions on inert carriers has been 
investigated, very few research efforts have been put into the investigation of its phase 
behaviour. For this reason, the first objective of this thesis is the development of an mDSC 
method for the characterization of indomethacin-PVP glass solutions layered on inert carriers. 
In order to control and optimize the drug release behaviour of these coated glass solutions, 
an additional controlled release coating layer was added. The second objective was to 
investigate the phase behaviour of these complex coated systems, which make use of two 
different controlled release polymers. Additionally, the influence of a pore former and coating 
from a solution or a dispersion on the phase behaviour was investigated. A complete phase 
behaviour analysis is made possible by combining surface characterization (ToF-SIMS) and bulk 
characterization (mDSC and XRPD). 
The third objective focused on the pharmaceutical performance of these multilayer 
coatings. The influence of the aforementioned formulation changes and the controlled release 
coating thickness on the drug release behaviour was investigated and special emphasis was put 
on the role of a charge interaction between drug and controlled release polymer on the 
release rate. 
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Controlled release polymers are not only investigated as a rate controlling membrane on 
top of glass solutions, their potential role as a solid dispersion carrier is assessed as well. So, 
in the fourth objective of this thesis, Eudragit® RL is tested as an alternative carrier for solid 
dispersions, either alone or in combination with a hydrophilic polymer in order to enhance 
drug bio-availability. For the manufacturing of these drug delivery systems, spray drying will be 
used. The phase behaviour of the solid dispersions will be investigated together with the 
dissolution rate, with special attention to the generation of supersaturation. 
Throughout this work different model drugs have been used. The main API, recurring in all 
chapters, is indomethacin, which is a non-steroidal anti-inflammatory drug (NSAID) which is 
poorly soluble (in acidic media), weakly acidic, and has the potential to form interactions with 
solid dispersion carriers through its carboxyl function. Results obtained with indomethacin are 
compared with naproxen (NSAID, poorly soluble, weak acid) and ketoconazole (anti-fungal, 
poorly soluble, weak base) in Chapter 3, and with naproxen and cinnarizine (anti-histaminic 
drug, poorly soluble, weak base) in Chapter 6.
  The peculiar behavior of the glass 
transition temperature of amorphous drug-polymer 
films coated on inert sugar spheres 
 
 
 
 
 
 
 
Results of this chapter are based on:  
Dereymaker, A.; Van den Mooter, G. The Peculiar Behavior of the Glass Transition Temperature of 
Amorphous Drug–Polymer Films Coated on Inert Sugar Spheres. J. Pharm. Sci. 2015, 104, 1759-
1766. 
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 Abstract 
Fluid bed coating has been proposed in the past as an alternative technology for 
manufacturing of drug-polymer amorphous solid dispersions, or so-called glass solution. It has 
the advantage of being a one step process, and thus omitting separate drying steps, addition 
of excipients or manipulation of the dosage form. In search of an adequate sample preparation 
method for mDSC analysis of beads coated with glass solutions, glass transition broadening 
and decrease of the glass transition temperature was observed with increasing particle size of 
crushed coated beads and crushed isolated films of indomethacin and polyvinylpyrrolidone. 
Substituting indomethacin with naproxen gave comparable results. When ketoconazole was 
probed or the solvent in INDO-PVP films was switched to DCM or a methanol-DCM mixture, 
two distinct Tg regions were observed. Particles with small sizes had a glass transition in the 
high Tg region, large sized particles in the low Tg region. This particle size dependent glass 
transition was ascribed to different residual solvent amounts in the bulk and at the surface of 
the particles. A correlation was observed between the deviation of the glass transition 
temperature from that calculated from the Gordon-Taylor equation and the amount of 
residual solvent at the glass transition temperature of particles with different sizes. 
  
Broadening the Scope of Amorphous Solid Dispersions 
 
40 
 
 Introduction 
Solid dispersions are considered to be one of the promising formulation strategies to 
increase the solubility and bioavailability of poorly soluble active pharmaceutical ingredients 
(API).1 Despite being reported for the first time over 40 years ago2, only a limited number of 
approved drug formulations are on the market today.3 While there are many subdivisions of 
solid dispersions, attention nowadays is focused on glass solutions where the drug is 
molecularly dispersed into an amorphous carrier (mostly polymers), resulting in a one phase 
system.4,5 Because solid dispersion manufacturing often leads to supersaturated glass solutions 
which are in thermodynamical non-equilibrium, risks of phase separation into drug rich and 
polymer rich regions are constantly present, which can ultimately lead to crystallization of the 
API and the subsequent loss of its solubility advantage.6 Phase separation risk can even be 
increased by absorption or adsorption of water from the environment, residual solvent or 
manipulations of the glass solutions into final dosage forms. 
In addition to spray drying as a well-established manufacturing procedure for glass solutions 
via the solvent method, fluid bed coating can be proposed as a viable alternative. As compared 
to spray drying, fluid bed coating is a largely unexplored manufacturing method and has 
numerous potential advantages. It allows the formulation to be dried immediately into the 
coating device. This is very important to remove residual solvents from the system, because 
these are often toxic and can cause unwanted plasticization of the system. Also, the coating of 
beads omits any additional processing steps, like milling or compression, to acquire a final 
dosage form. These additional processing steps have been shown to lead to solid state changes, 
for example compression which induced amorphous-amorphous phase separation in spray 
dried solid dispersions.7 
Few studies have been previously reported in literature, mostly emphasizing on the 
solubility advantage of the solid dispersions prepared by coating in comparison with the pure 
drug substance. However, a thorough understanding of the physical structure and phase 
behavior is of the utmost importance for the estimation of the stability of the produced solid 
dispersions. To analyze this phase behavior, differential scanning calorimetry (DSC) is one of 
the tools of choice. It is able to detect the most important markers of instability in solid 
dispersions, namely amorphous-amorphous phase separation, enthalpic recovery of 
amorphous materials and the presence of crystalline API. Due to solid dispersions being multi-
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component systems and the production method, some transitions can overlap in a standard 
DSC. In modulated differential scanning calorimetry (mDSC), where the total heat flow can 
be mathematically separated (a deconvolution operation) into a reversing heat flow (a measure 
of the sample’s heat capacity) and a non-reversing heat flow signal (heat flow associated with 
kinetic or kinetically controlled processes), these overlapping transitions can be clearly 
distinguished. For example, when preparing solid dispersions using the solvent evaporation 
method, some residual solvent can remain present in the system, upon evaporation due to 
heating in the DSC. This will be visible in the thermogram as a broad endotherm masking all 
other thermal events (glass transition). Due to the kinetic nature of solvent evaporation, this 
will be explicitly visible into the non-reversing heat flow signal in mDSC, provided a well 
optimized modulation program. 
When glass solutions are produced, they are monophasic systems which will show one 
single glass transition, showing full miscibility of polymer and API. One of the most commonly 
used ways to calculate this mix-Tg is by using the Gordon-Taylor equation8: 
 𝑇𝑔 =
𝑤1𝑇𝑔1+𝑘𝐺𝑇(1−𝑤1)𝑇𝑔2
𝑤1+𝑘𝐺𝑇(1−𝑤1)
      Eq. 3.1 
In this equation: Tg1≤ Tg2 so Tg1 usually represents the glass transition of the drug and Tg2 
the glass transition of the polymer. w is the weight fraction and the constant kGT =
𝜌1∆𝛼1
𝜌2∆𝛼2
≈
𝜌1𝑇𝑔1
𝜌2𝑇𝑔2
 9, where ρ  is the density of the component and Δ α  the change in thermal expansivity 
of the component at Tg .
10 
In previously performed studies involving coated solid dispersions onto inert carriers, a lot 
of variation is seen in methodology of DSC/mDSC analysis. Hsiu-O et al.11 and Zhang et al.12 
performed DSC analysis with the coated pellets loaded as such into the aluminium pans. Sun 
et al. did not analyze the produced solid dispersions with DSC.13 In the study of Li et al. solid 
dispersion samples were prepared by spraying into the drying chamber without sugar pellets 
under the same coating conditions, and then the solid dispersions were peeled off carefully 
and ground to a fine powder for DSC analysis.14 Nikowitz et al. did not specify any DSC sample 
preparation method in their paper about the study of recrystallization in coated pellets.15 
Lastly, in a recent study of Mahmoudi et al. amorphous solid drug dispersions were prepared 
via either rotary evaporation or fluid bed drug layering. Only powder samples from the rotary 
evaporation were analyzed by DSC.16 
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The aim of this study is to develop a reliable mDSC method for glass solutions, coated on 
an inert carrier, and the investigation of an interesting glass transition phenomenon associated 
with this method development. 
Naproxen (NAP), indomethacin (INDO) and ketoconazole (KETO) were used as model 
drugs. Polyvinylpyrrolidone (PVP) K25 was selected as a model hydrophilic polymer. NAP and 
INDO both have hydrogen donors which can form hydrogen bonds with PVP, whereas KETO 
is unable to form hydrogen bonds with the polymer. NAP-PVP and INDO-PVP are well known 
solid dispersion systems which have been extensively studied in the past.17-21  
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 Materials and methods 
3.3.1 Materials 
Naproxen and Indomethacin were purchased from FAGRON Ltd. (Waregem, Belgium), 
ketoconazole was a kind gift from Janssen Pharmaceutica (Beerse, Belgium), 
polyvinylpyrrolidone K 25 was a generous gift from BASF (Ludwigshafen, Germany). Sugar 
spheres (diameter 710 - 850 µm) were kindly donated by Hanns G. Werner GmbH (Tornesch, 
Germany). 
3.3.2 Methods 
Fluidized bed coating 
A 30-70% IND-PVP (1:2 weight ratio to beads) glass solution was coated onto 500g of 
beads from a 6.67% (w/v) ethanol solution, using bottom spray fluid bed coating. The sugar 
spheres were loaded into the preheated coating chamber of an Aeromatic MP 1 
multiprocessor (GEA, Switzerland). The sugar beads were heated for half an hour. The drug-
polymer solution was coated onto the sugar beads using a bottom spray set-up with a Würster 
insert. When the spraying was finished, the pellets were dried until immobilization due to 
electrostatic charges. The coated spheres where unloaded, weighed and dried for an additional 
48 hours in an oven at 40°C. In the formation of the INDO-PVP beads, the air volume was 
set at 1566.3L/min, inlet temperature was 50°C, atomizing air pressure 1.5 bar and the feed 
rate was 6 ml/min. After 48 hours of drying in a hot air oven at 40°C, sugar beads were 
crushed with a pestle in a mortar and sieved into different particle size ranges. 
Film formation by rotary evaporation 
Glass solution films were made using a Büchi Rotavapor R-210 (Flawil, Switzerland). API-
polymer (30-70% w-w) was dissolved into a common solvent (ethanol, Dichloromethane 
(DCM) or a 1:1 (v/v) mixture of DCM and methanol) to form a 10% (w/v) solution. The water 
bath was set to 60°C for ethanol solutions and 40°C for DCM and DCM-methanol solutions. 
A round bottom flask with the solution was rotated into the water bath under vacuum. After 
formation of a film, the glass solution was dried for an additional 48 hours in an oven at 40°C. 
In accordance with the coated beads, the films were crushed and sieved in different particle 
size ranges for analysis. 
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Modulated temperature differential scanning calorimetry (mDSC) 
 mDSC measurements were carried out with a TA instruments Q2000 modulated DSC 
(Leatherhead, UK) equipped with a refrigerated cooling system (RCS90). During analysis, the 
DSC cell was purged with a nitrogen flow of 50 ml/min. Mathematical analysis of the data was 
performed using TA Instruments Universal Analysis software (version 4.4, Leatherhead, UK). 
TA Instruments standard aluminium pans (Brussels, Belgium) were used for all measurements. 
Glass transition temperatures were measured at half height in the reversing heat flow. The 
step jump in heat capacity observed in the reversing heat flow signal was further examined in 
the corresponding derivative signal after Savitsky-Golay smoothing with points of window set 
at 20. The first derivative of the reversing heat flow was chosen to visualize the glass transitions 
because discrete changes are much better visible in the peaks of the derivative reversing heat 
flow, as compared with the small baseline shifts of the original reversing heat flow. Octadecane 
and indium were used to calibrate the DSC temperature scale, the enthalpic response was 
calibrated with indium. The heat capacity was calibrated using sapphire disks. All sample masses 
were between 4-7 mg (accurately weighed). The samples were kept isothermal at 40°C for 60 
minutes, followed by heating from 40°C to 180°C (or 0-200°C depending on the experiment) 
for the glass solution films and 0°C to 165°C for the coated beads. A heating rate of 2°C/min 
was applied with a temperature modulation of 0.636°C every 40s. All samples were measured 
in duplicate. 
Thermo gravimetric Analysis 
The prepared samples (coated beads and films, crushed and sieved) were analyzed using a 
TA instruments SDT Q600 (Leatherhead, UK) to determine moisture and volatile contents. 
The samples were heated at 5°C/min from 25 °C to 150 °C in a continuous mode in a first 
type of experiment. In the second type of experiment, samples were kept isothermal at 50°C 
for 20 hours, heated to 140°C at 10°C/min and kept isothermal for 2 hours, and finally cooled 
again to 50°C at 10°C/min and kept isothermal for 1 hour. Finally, in a third experiment 
samples were kept isothermal at 40°C for 1 hour and subsequently heated at 2°C per minute 
to 170°C. A dry N2 purge of 100 mL/min was used to be able to maintain an inert environment. 
Weight loss due to solvent and moisture evaporation was calculated as percentage weight loss 
compared to the original sample mass. Sample masses are between 10 and 20 mg (accurately 
weighed). 
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 Results and discussion 
3.4.1 mDSC analysis of INDO-PVP (30/70% w/w) glass solutions, coated onto sugar 
beads 
As mentioned above, no universally applicable sample preparation method exists for the 
DSC analysis of coated beads. In search of effective sample preparation for mDSC analysis, the 
bottom of a DSC pan was filled with coated beads and analyzed. This approach produced no 
visible signal other than the melting peak of sucrose. It was clear that the contact area between 
the coating and the bottom of the pan was insufficient. In a second attempt, beads were 
crushed to improve thermal contact. However, the only visible transition was the melting of 
the sucrose beads, leading to the observation that there was, proportionally, too much sucrose 
present. In a next step, beads were crushed gently with a pestle and mortar and sieved to 
separate different particle sizes in an attempt to find a specific particle size range where more 
coating was present relative to the sucrose content. This sieving was performed using seven 
sieves (pore diameter: 32µm, 63µm, 90µm, 150µm, 250µm and 355µm). After sieving for an 
adequate time the material on top was discarded (larger than 355µm), the other material was 
collected and stored separately for each particle size range. Subsequently, six different particle 
size ranges were stored in closed containers: 0-32µm, 32-63µm, 63-90µm, 90-150µm, 150-
250µm and 250-355µm. Figure 3.1 shows the first derivate of the reversing heat flow in 
function of temperature for the different particle sizes of crushed and sieved INDO-PVP beads. 
 
Figure 3.1: Derivative reversing heat flow in function of temperature for different particle size 
ranges of crushed and sieved INDO-PVP (30/70% w/w) coated sucrose beads. 
Surprisingly, the data show a shift and broadening of the glass transition region with 
increasing particle size. Table 3.1 lists the numerical values of the mean glass transition onset, 
offset, range and half-height temperature of 3 replicate experiments. There is a difference of 
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26.2°C between mean glass transition temperature of the smallest and largest particle size 
range. The glass transition range has also increased with ca. 18°C, which means the mean 
width has become more than doubled, hence a large broadening of the glass transition region. 
This glass transition shift is probably also the reason why it only becomes visible in DSC after 
sieving. When the beads are only crushed, there is a large particle size variety present, so the 
sample will have multiple small glass transitions which will lead to a very broad signal in the 
reversing heat flow, which is not detectable by mDSC. 
Table 3.1: Mean glass transition onset, offset, range and half-height temperature of different 
particle size ranges of INDO-PVP coatings onto sucrose beads (n=3). 
n=3 Glass transition temperature (°C) 
Particle size 
(µm) 
Onset Offset Range Half Height 
St dev Half 
Height 
0-32 105.9 122.6 16.7 114.2 0.7 
32-63 104.8 121.2 16.4 113.0 0.8 
63-90 101.8 123.3 21.5 112.4 2.9 
90-150 84.1 116.0 31.9 100.0 0.4 
150-250 69.3 108.6 39.3 89.1 2.2 
250-355 70.4 105.4 34.9 88.0 0.2 
 
3.4.2 mDSC analysis of INDO-PVP (30/70% w/w) glass solution films 
To confirm this particle size induced glass transition temperature decrease and broadening 
in a more simple formulation, INDO-PVP films were made by rotary evaporation. In essence, 
this is the way the glass solutions are formed on the sucrose beads during fluid bed coating. 
Droplets form miniature films around the inert carrier and are dried during cycling in the 
fluidized bed. When reentering the Würster insert and being sprayed upon, this process 
repeats itself. Derivative reversing heat flow signals in function of temperature for the different 
particle size ranges are shown in Figure 3.2 for a first and second heating cycle. After the first 
heating cycle is completed, the sample is cooled at maximum capacity of the Q2000 DSC 
(around 30°C/min). After temperature equilibration at 0°C the second heating cycle is initiated 
with the same heating rate and modulation parameters used during first heating. 
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Figure 3.2: Derivative reversing heat flow in function of temperature for INDO-PVP films in the 
first 5 (A) and second (B) heating cycle for different particle sizes. 
All numerical information about the glass transition is given in Table 3.2. From the INDO-
PVP films, it’s also evident that Tg shifts to lower temperatures and broadens as the particle 
size increases. There is an 18.4°C difference in temperature shift and a 16.6°C broadening 
between the values of the smallest and largest particle size. These differences disappear 
respectively to 3.6°C and 1.9°C when the sample is cooled and reheated. 
Table 3.2: Mean glass transition onset, offset, range and half-height temperature of different 
particle size ranges of INDO-PVP films in first and second heating cycle (n=3). 
1st heating cycle  Glass transition temperature (°C) 
Particle size 
(µm) 
Onset Offset Range Half Height 
St dev Half 
Height 
0-32 104.0 118.7 14.7 111.3 0.1 
32-63 101.6 119.6 18.0 108.9 1.0 
63-90 94.4 116.3 21.8 105.4 0.6 
90-150 87.3 113.8 26.5 100.6 0.3 
150-250 77.2 108.5 31.3 93.0 0.6 
2nd heating cycle Glass transition temperature (°C) 
Particle size 
(µm) 
Onset Offset Range Half Height 
St dev Half 
Height 
0-32 107.3 123.1 15.9 115.2 0.6 
32-63 107.7 123.2 15.4 115.5 0.1 
63-90 106.8 122.9 16.0 114.8 0.3 
90-150 105.9 122.3 16.3 114.0 0.4 
150-250 102.8 120.5 17.7 111.6 0.0 
The dependence of the glass transition temperature on the particle size has, to the best of 
our knowledge, never been reported before. Contrary to the well-known melting point 
depression related to particle size reduction22, there is no fundamental physical phenomenon 
known to explain the dependence of the glass transition temperature on the particle size.21 
The trend observed in the coated beads was thus confirmed and even more pronounced in 
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the glass solution films. Furthermore, when samples are cooled and reheated in the mDSC, all 
differences virtually disappear. These observations lead to two possible explanations. First, 
there can be a difference in mixing for different particle sizes. When a particle with a larger 
size would have a higher ratio of indomethacin compared to the particles with smaller size, 
the glass transition would be lower. This could be seen as different phases in different particle 
sizes. However, this would be highly unlikely because the films are prepared from a solution 
where drug and polymer are fully dissolved. It is evenly unlikely that these different drug-
polymer ratios are induced while crushing the films or beads because the samples are crushed 
with the same intensity and during the same amount of time. A second hypothesis can be 
proposed where different particle sizes have different amounts of residual solvents, which can 
act as a plasticizer and thus cause a decrease in glass transition temperature of the system.  
The heat-cool-heat experiment cannot exclude one of the hypotheses. Residual solvent will 
be completely removed when heating up to 180°C and plasticizing effects of these solvents 
will be eliminated when the sample is reheated. However heating above the glass transition 
also increases the mobility of the (amorphous) drug and polymer, which can affect the mixing 
of drug and polymer, also eliminating the observed differences in the first heating step. 
Previous studies provide the data to calculate the glass transition temperature of glass 
solutions with the Gordon-Taylor equation for this drug-polymer system. Glass transition 
temperature (430 K) and density (1.14 g/cm³) for PVP K25 are taken from Paudel et al.17, glass 
transition temperature (315 K) and density (1.31 g/cm³) of indomethacin from Matsumoto and 
Zografi21. Calculation yielded a glass transition temperature of the glass solution of 118°C. 
Glass transitions of the second heating cycles are closest to this ideal mixing Tg. The reason is 
of course that in the second heating cycle most of the residual solvents (which act as 
plasticizer) are eliminated from the glass solutions and not that the system is approaching ideal 
behavior (as the values are close to those calculated from the Gordon-Taylor equation in the 
second heating cycle). When considering the first heating cycle, particles with the smallest size 
have a glass transition temperature closest to 118°C, which points out that at the glass 
transition, the smallest particles contain the least residual solvent. 
Different observations were made when the same film fragments, divided in different size 
ranges, were stored at room temperature for 7 weeks and reanalyzed with mDSC. The 
thermograms of the different particle size ranges are shown in Figure 3.3. The observed glass 
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transition shift observed in the initial thermogram, has now disappeared. Only the particles 
with the largest size still show a decrease in Tg. 
 
Figure 3.3: Derivative reversing heat flow in function of temperature for different particle size 
INDO-PVP films after storage at room temperature for 7 weeks. 
Storage at room temperature can enable the samples to further dry and get rid of the 
residual solvents, but storage at room temperature, which is far below the glass transition 
temperature of the glass solutions, does not provide the necessary mobility to spontaneously 
induce mixing of the systems. It can be reasonably assumed that larger particles, which have a 
much smaller surface area to mass ratio, and thus contact surface with the surroundings (air), 
need a longer time to lose their residual solvent. This is the reason why the particles with the 
largest size range still have a decreased glass transition temperature. This experiment thus 
reinforces the residual solvent hypothesis. 
3.4.3 mDSC analysis of glass solution films of Naproxen-PVP and Ketoconazole-PVP 
(30-70% w-w) 
In order to confirm the generality of the observed phenomenon, systems with a different 
API (Naproxen and Ketoconazole) were selected and compared with the same polymer and 
in the same ratio to solely investigate the influence of changing the active component. 
Ketoconazole was chosen because, contrary to INDO and NAP, it does not have any hydrogen 
donor groups and is thus unable to form hydrogen bonds with PVP. Figure 3.4 shows the 
derivative of the reversing heat flow for NAP-PVP (30-70% w/w) and KETO-PVP (30-70% 
w/w) in function of temperature for 5 different particle size ranges. 
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Figure 3.4: Derivative reversing heat flow thermogram of NAP-PVP (A) and KETO-PVP (B) for 
5 different particle sizes. 
The different particle sizes for the NAP-PVP glass solution again show a distinct glass 
transition decrease for increasing particle size, although this decrease is mainly observed 
between the two smallest particle sizes, further decrease is more discrete. KETO-PVP shows 
a different pattern, as in these glass solution particles, two different glass transition regions 
can be distinguished. Particles with smaller sizes (0-32µm and 32-63µm) predominantly reside 
in the high Tg region, around 115-120°C. Particles with larger sizes (150-250µm and 250-
355µm) are mainly in the low Tg region, around 60-70°C. The particles with an intermediate 
size range (between 63-90µm) have two Tg peaks, one in each region. 
While the NAP-PVP samples confirmed the trend observed with the INDO-PVP samples, 
KETO-PVP showed a slightly different behavior, though still a particle size dependent glass 
transition temperature.  
For the calculation of the Gordon-Taylor equation, glass transition temperature (279K) and 
density (1.25 g/cm³) of naproxen are taken from Paudel et al.17 and Tg (317.5K) and density 
(1.30g/cm³) of ketoconazole from Van den Mooter et al.23 Glass transition temperature for 
naproxen is calculated at 100°C and for ketoconazole at 119°C. It is again obvious that glass 
transitions from the smallest particles are closest to the calculated mixing Tg, thus reinforcing 
again the role of the available surface area for solvent evaporation. 
3.4.4 mDSC analysis of INDO-PVP (30/70% w/w) glass solution films from a 10% (w/v) 
DCM and DCM-methanol (50-50% v-v) solution 
To investigate the influence of different solvents on the phase behavior and resulting glass 
transition decrease with particle size, ethanol as solvent was replaced by dichloromethane and 
a 1:1 mixture of dichloromethane and methanol. For the pure DCM, 5 particle size ranges up 
to 250µm were tested, for the DCM-methanol mixture 7 particle size ranges were tested, up 
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to 425µm. Figure 3.5 represents the derivative reversing heat flow in function of temperature 
for the different particle size ranges of DCM (A) and DCM-methanol (B). 
 
Figure 3.5: Derivative heat flow in function of temperature for the different particle size ranges 
of a INDO-PVP glass solution film, prepared from a DCM (A) and DCM-Methanol (B) solution. 
With the change of solvent, the same phenomenon was observed as in the KETO-PVP glass 
solutions, produced from an ethanol solution. For DCM as well as DCM-methanol, a 
distinction can again be made between a high Tg region with predominantly the particles with 
smaller size ranges on one hand, and a low Tg region with the particles with larger size ranges 
on the other hand. Intermediate particle size ranges again show a glass transition in the high 
Tg region as well as in the low Tg region. These experiments show the separation in Tg regions 
is not a phenomenon that can be solely described to KETO-PVP, but something as simple as 
a change in solvent can induce this separation. 
3.4.5  TGA analysis of INDO-PVP (30-70% w-w) glass solution films 
To be able to take into account the role of the residual solvent, present in the film particles, 
and/or the amount of absorbed water from the environment into the particles, TGA analysis 
was performed on all of the particle size ranges. Table 3.3 represents the average weight loss 
of different particle size ranges of INDO-PVP using a heating program of 5°C/min from 25°C 
to 150°C.  
Table 3.3: weight loss (%) for different particle size ranges of INDO-PVP film 
INDO-PVP FILMS Sample 1 Sample 2 Mean 
Particle size (µm) Weight loss (%) Weight loss (%) Weight loss (%) 
0-32 3.877 4.793 4.335 
32-63 4.488 4.280 4.384 
63-90 4.565 4.431 4.498 
90-150 3.983 4.157 4.070 
150-250 4.690 4.220 4.455 
Broadening the Scope of Amorphous Solid Dispersions 
 
52 
 
These experiments clearly show a more or less equal amount of solvent in particles of a 
different size range. This seems to disprove the solvent hypothesis. However, a second TGA 
analysis was performed on 3 particle sizes of the INDO-PVP films, to differentiate between 
weight loss sub-Tg (50°C) and above-Tg (140°C). Figure 3.6 represents the weight (%) and 
temperature (°C) in function of time (min) for 0-32µm, 90-150µm and 250-355µm particles. 
 
Figure 3.6: Weight (%) and temperature (°C)in function of time (min) for INDO-PVP film 
particles with a size range of 0-32µm (blue line), 90-150µm (red line) and 250-355µm (green 
line). 
In the first isothermal step at 50°C, the smaller the particles, the more weight is lost due 
to evaporation of residual solvent, which can be explained by its higher surface area to mass 
ratio. Despite being dried for 20 hours, all particle size samples still contain residual solvent, 
which isn’t released before heating above the glass transition temperature. After completion 
of the experiment, particles in the range between 90-150µm and 250-355µm have lost almost 
exactly the same mass, the 0-32µm particle size range is only slightly higher. 
These findings lead to the conclusion that there is a difference in residual solvent amount, 
but specifications need to be made. The glass transition shift with increasing particle size range 
is a result of differences in sub-Tg residual solvent evaporation. Due to the much higher surface 
area to mass ratio of the small particle size ranges, residual solvent can evaporate to a higher 
extent than from the particles with larger size ranges, where more bulk solvent will be present. 
When looking at mDSC thermograms with two distinct Tg regions, the high Tg region can be 
represented by the glass transition of the solvent poor surface of the film particles and the 
low Tg region by the solvent ‘rich’ bulk of the film particles. Gradually shifting of the glass 
transition can be seen as a more discrete transition than separation into two distinct Tg 
regions. These differences can be achieved during heating in the DSC cell or during the 
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isothermal step of 40°C for 1 hour, programmed before every run. The fact that this glass 
transition decrease has disappeared after 7 weeks also supports this hypothesis because here 
the residual solvent could have had enough time to evaporate, except in the largest particle 
size range where a Tg decrease is still visible. These findings can shine another light on DSC 
experiments of solid dispersions, prepared by solvent methods like for instance spray drying, 
which may contain a very broad range of particle sizes. When only DSC analysis is performed 
on particles with an intermediate particle size range (see Figures 3.4 and 3.5), two glass 
transitions may theoretically be observed and falsely interpreted as a phase separated system, 
which in reality really are particles with different solvent poor surface/solvent rich bulk ratios. 
The broadening and gradual shift of glass transitions has already been reported before.24 In this 
article, this shift and broadening is a result of moisture sorption, which results in a depressed 
Tg in the outer layers of glassy maltodextrin particles. It can be stated that this effect is in fact 
a similar phenomenon of what was observed in this article but in the opposite direction. 
In an attempt to prove the residual solvent hypothesis, a third TGA experiment was 
performed where the heating method was equal to the mDSC method, namely an isothermal 
step at 40°C for 1 hour and subsequently a heating step of 2°C/min to 170°C. When 
simultaneously performing these TGA and mDSC experiments on a freshly prepared INDO-
PVP (30-70% w/w) film (from a 10% ethanol solution w/v), which was crushed and separated 
into different particle size ranges, it was possible to determine the exact residual solvent 
amount at the glass transition temperature of the different size ranges. Glass transition 
temperatures were determined in the mDSC experiment. Previously, the glass transition 
temperature of INDO-PVP (30-70% w/w) had been calculated using the Gordon-Taylor 
equation and was 118°C. From this temperature, we can calculate the deviation for each 
particle size range. This is described in Table 3.4 together with the solvent loss from the glass 
transition temperature to 170°C for each particle size range.  
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Table 3.4: Weight loss from the glass transition temperature (%) and Gordon-Taylor Tg 
temperature depression (%) for the different particle size ranges of INDO-PVP film 
INDO-PVP FILM (30-70% w/w) 
Particle size 
(µm) 
Solvent loss from Tg to 
170°C (%) 
Gordon-Taylor Tg temperature 
depression (%) 
0-32 1.35 95.29 
32-63 1.86 87.40 
63-90 2.21 84.54 
90-150 2.51 78.07 
150-250 2.74 77.65 
250-355 3.15 70.77 
When the deviation from the Gordon-Taylor temperature is put in function of the solvent 
loss from Tg to 170°C, a correlation can be found, this is represented in Figure 3.7.  
 
Figure 3.7: Depression on the Gordon-Taylor glass transition temperature in function of solvent 
loss from the glass transition to 170°C for all different particle size ranges, with trendline and 
R² value. 
As can be seen from Figure 3.7, the correlation has a good fit (R²= 0.983). This indicates 
that the glass transition temperature decrease with increasing particle size is a result of the 
presence of the amount of residual solvent at the glass transition temperature, and not of the 
total amount of residual solvent. The glass transition temperature decrease is not in 
correspondence with the total amount of residual solvent because of the different evaporation 
rates, due to the different surface area to mass ratio’s, discussed in the previous TGA 
experiment. This evaporation is an imminent consequence of the manner in which DSC 
measures the glass transition temperature, namely by heating up the sample. When performing 
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(m)DSC analysis on glass solutions, prepared by the solvent method, caution is necessary when 
interpreting glass transitions from particles with wide particle size ranges.  
 Conclusions 
In search of a suitable mDSC sample preparation method for glass solutions of INDO-PVP, 
coated on inert carriers, an interesting phenomenon arised. When crushed and sieved into 
different particle size ranges, glass transitions of the coated beads shifted to lower 
temperatures and broadened with increasing particle size range. These findings were 
confirmed for INDO-PVP films prepared by rotary evaporation. Substituting indomethacin 
with naproxen gave comparable results. When the API was ketoconazole and the solvent in 
INDO-PVP films was switched to DCM or a methanol-DCM mixture, two distinct Tg regions 
were observed. Small particle sizes had a glass transition in the high Tg region, large particle 
sizes in the low Tg region. TGA experiments showed that, while total mass loss due to residual 
solvent evaporation for all particle sizes are more or less the same, there is a distinct difference 
for sub Tg and above Tg mass loss, due to huge differences in surface area to mass ratio. 
Differences in glass transition for different particle size ranges can be ascribed to differences 
in solvent-free surface and solvent-rich bulk ratios. A correlation was found between the 
solvent loss from the glass transition temperature on and the deviation from the Gordon-
Taylor derived glass transition temperature for the different particle size ranges. This further 
indicates that the glass transition decrease in glass solution particles with increasing particle 
size is due to the amount of residual solvent present at the glass transition temperature of the 
particles. 
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 Abstract  
Fluid bed coating has been shown to be a suitable manufacturing technique to formulate 
poorly soluble drugs in glass solutions. Layering inert carriers with a drug-polymer mixture 
enables these beads to be immediately filled into capsules, thus avoiding additional, potentially 
destabilizing, downstream processing. In this study fluid bed coating is proposed for the 
production of controlled release dosage forms of glass solutions by applying a second, rate 
controlling membrane on top of the glass solution. Adding a second coating layer adds to the 
physical and chemical complexity of the drug delivery system so a thorough understanding of 
the physical structure and phase behavior of the different coating layers is needed. This study 
aimed to investigate the surface and cross-sectional characteristics (employing SEM and ToF-
SIMS) of an indomethacin-polyvinylpyrrolidone (PVP) glass solution, top-coated with a release 
rate controlling membrane consisting of either ethyl cellulose or Eudragit RL. The implications 
on the addition of a pore former (PVP) and the coating medium (ethanol or water) were also 
considered. In addition, polymer miscibility and the phase analysis of the underlying glass 
solution were investigated. 
Significant differences in surface and cross-sectional topography of the different rate 
controlling membranes or the way they are applied (solution vs. dispersion) were observed. 
These observations can be linked to the polymer miscibility differences. The presence of PVP 
was observed in all rate controlling membranes, even if it is not part of the coating solution. 
This could be attributed to residual powder presence in the coating chamber. The distribution 
of PVP among the sample surfaces depends on the concentration and the rate controlling 
polymer used. Differences can again be linked to polymer miscibility. Finally, it was shown that 
the underlying glass solution layer remains amorphous after coating of the rate controlling 
membrane, whether formed from an ethanol solution or an aqueous dispersion. 
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 Introduction 
Although the potential of solid dispersions to increase the apparent solubility/dissolution 
rate and consequently the bio-availability of biopharmaceutics classification system (BCS) class 
II drugs has been widely demonstrated in the last couple of decades, there is still a huge 
discrepancy in the research input and the commercial output. The main challenges of 
commercializing solid dispersions remain the long term physical stability of such systems, with 
the amorphous or molecularly dispersed drug inherently prone to phase separation, 
crystallization and ultimately a decrease in solubility. Not only can long term stability issues 
potentially arise, processing solid dispersion powders into their final dosage form can also lead 
to phase separation, as recently shown by Ayenew et al. during the compression of Naproxen 
polyvinylpyrrolidone (PVP) solid dispersions1. This is a hurdle which can be overcome by 
coating solid dispersions onto inert carriers and thus avoiding the requirement for major 
additional downstream processing steps.  
Coating glass solutions onto inert carriers can also be exploited to transform them into 
controlled release formulations. Coated pellets in the size range of 100µm-1mm for controlled 
release purposes have already been demonstrated as beneficial as compared to controlled 
release coated tablets. This is thought to be as they are less prone to variability in stomach 
emptying rates in the fasted state2. In the fed state there are additional factors to take into 
consideration including the composition and caloric value of the administered meal and the 
size and density of the particles. Therefore, no real consensus has been reached yet on 
stomach residence times of controlled release formulations. Pellets also show a more even 
spread in the gastrointestinal tract in comparison with a single coated tablet. Having a high 
number of coated pellets also reduces the risk for dose-dumping3, 4. Furthermore, the surface 
of amorphous materials has also been shown to be more vulnerable to crystallization, it has 
been shown that an additional coating layer could potentially stabilize these glasses 5. 
The first and foremost reason to produce a controlled release formulation from glass 
solutions is to maximize the absorption window for poorly soluble drugs by allowing an 
appropriate amount of dissolved drug to be available for absorption at extended time intervals. 
Moreover, a slower release rate will reduce the precipitate rate of poorly soluble drugs from 
their supersaturated state. Controlling the release of glass solutions also allows for a decreased 
dosing scheme, a better patient compliance and a reduced risk of side effects6. It could, 
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however, be argued that poorly soluble drugs already inherently possess a slow release 
dissolution profile, but this is compound specific, and non-adjustable.  
The overarching goal of this study is to investigate the potential of coated glass solutions 
to control or reduce the release rate of poorly soluble drugs. For this purpose, bilayer coated 
sucrose carriers (pellets), of which the first layer consists of a glass solution of indomethacin 
(INDO) in polyvinylpyrrolidone K25 (PVP) in a 30:70 (w:w) ratio were generated. To control 
the release of indomethacin from this glass solution, a top layer was applied, consisting of the 
insoluble polymer ethyl cellulose (EC) and the insoluble but swellable polymer Eudragit RL® 
(ethyl acrylate: methyl methacrylate: trimethylammonioethylmethacrylate co-polymer in a 
molar ratio of 1:2:0.2) (ERL). One has to keep in mind that applying a top coating will add to 
the overall pill burden. Hence, in some specific cases, the dose strength will be a limiting factor 
in the application of this type of dosage form. 
Owing to the complex composition of the coated glass solutions, typical solid state 
analytical techniques such as modulated differential scanning calorimetry (mDSC) 7 or X-ray 
powder diffraction (XRPD) are inadequate for this specific multi-layer samples because they 
only provide bulk analysis (no spatial resolution). Thermal analysis by (m)DSC can detect two 
separate amorphous phases, provided they are larger than the critical length scale of the 
technique (~30nm)8. In conventional wide angle XRPD, transmission geometry doesn’t allow 
depth resolution as incident x-rays go completely through the sample. Also, in reflection 
geometry, the penetration depth of the x-rays doesn’t allow in depth resolution, spatial 
resolution can only be achieved in combination with other techniques9. Glancing angle x-ray 
techniques can be used to measure varying sample thicknesses since penetration depths are 
lower and can be calculated according to the incident x-ray beam angle10, 11. This leads to 
conclude that mDSC and/or XRPD don’t provide adequate information on the different layers 
of complex coated systems. It has even been shown recently that the phase behavior study of 
a single layer glass solution onto an inert carrier is not straightforward12.  
Time of Flight Secondary Ion Mass Spectrometry (ToF-SIMS) has been used as a surface 
analysis technique in a wide array of research fields; from biological samples (cells, tissues, 
proteins, lipids) 13-17, over material science18 to pharmaceutical formulations19-24. ToF-SIMS is 
based upon the bombardment of a sample surface with a primary ion beam (e.g. Ar+, Cs+, Bi3
+) 
under ultra-high vacuum conditions. The impact of the kinetic energy of these primary ions 
upon the sample surface will result in desorption of electrons, atoms, molecular fragments and 
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whole molecules. The ionized molecular fragments are of particular interest for ToF-SIMS. 
These secondary ions are accelerated and injected into the Time-of-Flight analyzer. For ions 
with an equal charge, this will result in equal kinetic energy and thus the velocity of these ions 
will depend on their mass-to-charge ratio (m/z). Hence, the time needed to reach the detector 
is indicative for the m/z of the detected molecular fragment and will result in a negative or 
positive mass spectrum, depending on the charge of the collected molecular fragments19, 20, 25-
27 ToF-SIMS has a very low detection limit (ppb range), a high surface sensitivity and high spatial 
resolution (0.2µm) 28. Owing to these properties, ToF-SIMS is highly suited for surface chemical 
identification and surface chemical distribution (mapping) and will therefore be used to analyze 
the layered beads, and by doing so, elucidate their chemical structure. 
The purpose of this study (“part 1”) is to investigate the phase behavior of the surface and 
physical cross-sections of sucrose beads coated with two layers: an inner layer made up of a 
glass solution of indomethacin in PVP K25 and an outer layer consisting of a rate controlling 
membrane made up of ethylcellulose or Eudragit RL. In addition, the influence of a pore former 
(PVP K25) in the outer layer and application of the outer layer from an organic solution or an 
aqueous dispersion on the phase behavior was investigated. Surface and cross-sectional 
morphology was investigated by scanning electron microscopy (SEM), the chemical 
composition and distribution of the bead surfaces and cross-sections was analyzed using ToF-
SIMS. Physical structure of the glass solutions was assessed by XRPD, while polymer mixing 
was tested using mDSC. 
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 Experimental section 
4.3.1 Materials 
Indomethacin was purchased from FAGRON Ltd. (Waregem, Belgium). 
Polyvinylpyrrolidone K 25 was a generous gift from BASF (Ludwigshafen, Germany). Sucrose 
spheres (diameter 710 - 850 µm) were kindly donated by Hanns G. Werner GmbH (Tornesch, 
Germany). Ethyl cellulose (ethoxy content 48.0 - 49.5% w/w) powder and triethyl citrate were 
purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands). Eudragit RL® PO and 30 D 
were purchased from Evonik Industries (Darmstadt, Germany). 
4.3.2 Fluid bed coating 
Coated beads were prepared using an Aeromatic MP 1 multiprocessor (GEA, Bubendorf, 
Switzerland) in a bottom spray setup, equipped with a Würster insert. A 30 : 70 (w:w ) INDO-
PVP (w/w) glass solution with a total solid content of 250,0 g was coated onto 500,0 g of 
sucrose beads from a 10% (w/v) ethanol solution. The sucrose spheres were loaded into the 
preheated coating chamber at 50 °C and heated for 10 minutes. The drug-polymer solution 
was coated onto the sucrose pellets at a feed rate of 13 cm3/min and this feed was atomized 
at an air pressure of 1.5 bar. Meanwhile the heated air stream was passing through the fluid 
bed coater at a rate of 1.78 m3 /min. When the spraying was finished, the pellets were dried 
until immobilization due to electrostatic charge was observed. The coated spheres were 
unloaded, weighed and dried for an additional 48 hours in an oven at 50 °C. In the case when 
a top layer (rate controlling membrane) was applied, the feed solution was immediately 
changed after completion of the glass solution layer. The controlled release top layer consisted 
of a rate controlling polymer (ERL or EC) which was applied from a 10% w/v ethanolic solution. 
Additional batches were prepared that contained PVP K25 as a pore former in the rate 
controlling membrane (in a concentration of 10% or 25% w/w relative to the total solid 
content) or the plasticizer TEC, added in a concentration of 20% w/w relative to the amount 
of rate controlling polymer. Finally ERL was also applied as an aqueous dispersion (10% w/v) 
instead of an ethanolic solution. Controlled release top coating total solid content was 200,0 
g. The coating process parameters are the same for the top coating layer as for the glass 
solution layer, except for the feed rate with the ERL ethanolic solutions. Here the feed rate 
was reduced to 6.5ml/min because of the electrostatic charges created inside of the fluid bed 
coater. After completion of the coating, the beads were also dried in the coater for at least 
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10 minutes, removed from the coater and additionally dried in an oven for at least 48 hours. 
Ethanolic solutions are dried at 50°C, aqueous dispersions at 60°C to allow for curing of ERL. 
4.3.3 Spray drying 
The miscibility between PVP K25 and EC or ERL was investigated for spray dried samples. 
ERL or EC were combined with PVP K25 in different ratios: 100-0, 75-25, 50-50, 25-75 and 0-
100 % w/w. Each composition was spray dried from a 10% w/v ethanol solution using a Büchi 
Mini Spray Dryer B-191 (Büchi, Flawil, Switzerland). The inlet air temperature was 50°C, the 
heated air flow rate 0,56 m3/min, the atomizing air flow rate 0.02 m3/min and the feed rate 4.8 
cm3/min. The obtained polymer mixtures were additionally dried for 48 hours in a vacuum 
oven at 25°C (Mazzali Systems, Monza, Italy), prior to mDSC analysis to investigate polymer 
miscibility.  
4.3.4 Scanning electron microscopy 
The morphology of the coated beads was investigated with SEM using a Philips XL30 ESEM-
FEG instrument (Philips, Eindhoven, The Netherlands) equipped with a field emission electron 
gun. Whole beads and cross-sections (made with a scalpel under an optical microscope) were 
fixed on an aluminum stub using double-sided carbon tape. The samples were coated with gold 
by sputtering for 45 s at 20 mA. The SEM was used with an acceleration voltage of 2.00 kV to 
acquire as much surface detail as possible by minimizing secondary electron loss. This way 
charge accumulation on the sample is also low. A spot size of 3 and a secondary electron 
detector were used. 
4.3.5 Time-of-flight secondary ion mass spectrometry 
For chemical composition and distribution analysis, ToF-SIMS was performed using a ToF-
SIMS IV (ION-TOF Gmbh, Münster, Germany). This spectrometer was equipped with a pulsing 
bismuth liquid metal gun (Bi3
+) and a single stage reflectron analyzer. A flood gun was applied 
to produce low energy electrons to compensate surface charging from the primary ion beam 
(positive charges). For surface analysis, samples were fixed to glass slides using double sided 
tape prior to analysis. When analyzing whole beads, only the uppermost part of the bead was 
analyzed due to the shape and size of the beads. This surface analysis comprised of an analysis 
area of 200 × 200 µm with a raster scanned resolution of 256 × 256 pixels. For cross-sectional 
analysis, beads were embedded into EpofixTM cold-setting resin , and sliced using a glass knife 
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on a RMC ultramicrotome PowerTome. For the cross-sectioned beads, an analysis area of 
500 × 500 µm was raster scanned with a resolution of 256 × 256 pixels. All samples were 
analyzed in the negative ion polarity mode and analyzed using SurfaceLab 6 (ION-TOF Gmbh, 
Münster, Germany). Firstly, controls were analyzed with reference material of all components. 
Different characteristic ions were chosen as the most selective to the specific compound. The 
chosen indomethacin marker was C7H10O4-, the PVP marker was C3H4N2O
-, the EC marker 
was C2H5O
-, the ERL marker CH3O- and the sucrose marker C12H21O11
-. Marker intensities 
and ion peaks for the control samples are shown in Figure A of Supporting Information. 
Measured secondary ion intensities for every component were normalized to total intensity 
count to allow for a semi-quantitative comparison between samples. It should be noted that 
the control ion for EC is also formed in the ERL control spectrum. Since there are no samples 
where both polymers are present at the same time, this didn’t pose any interpretation 
problems. 
4.3.6 Modulated differential scanning calorimetry 
 mDSC analysis of spray dried polymers and polymer mixtures was carried out with a TA 
instruments Q2000 modulated DSC (Leatherhead, UK) equipped with a refrigerated cooling 
system (RCS90). The DSC cell was purged with a nitrogen flow of 50 ml/min during analysis. 
Data processing was performed using TA Instruments Universal Analysis software (version 
4.4, Leatherhead, UK). TA Instruments standard aluminium pans (Brussels, Belgium) were used 
for all measurements. All sample masses were between 5-6 mg (accurately weighed). The 
samples were heated from 0°C to 180°C. A heating rate of 2°C/min was applied with a 
temperature modulation of 0.636°C every 40s. All samples were measured in triplicate. Glass 
transition temperatures were measured at half height in the reversing heat flow. The step jump 
in heat capacity observed in the reversing heat flow signal was further examined in the 
corresponding derivative signal after Savitsky-Golay smoothing with points of window set at 
10°C. n-Octadecane and indium were used to calibrate and validate the DSC temperature 
scale. Indium was also used to calibrate and validate the enthalpic response. The heat capacity 
was calibrated and validated using sapphire disks. 
4.3.7 X-ray powder diffraction 
Coated beads and reference powders were analyzed at room temperature using an 
automated X'pert PRO diffractometer (PANalytical, Almelo, the Netherlands). All samples 
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were placed in the sample holders, clamped between Kapton foil and analyzed in transmission 
mode using a Cu tube (Kα  1.5418 Angstrom; generator at 45kV and 40mA). Analysis was 
performed in continuous scan mode in 2θ  range from 4° to 40° with a 0.0167° step size and 
200 seconds counting time per step. The X'pert Data Collector and the X'pert Data Viewer 
(PANalytical, Almelo, The Netherlands) were used for data collection and analysis. 
 Results 
4.4.1 Surface and cross-sectional investigation of the coated beads with SEM 
The structures of the outer surface of whole beads with different outer coatings are shown 
in Figure 4.1.  
 
Figure 4.1: SEM micrographs of INDO-PVP coated glass solution bead (A), EC top coated bead 
(B), ERL top coated bead from an ethanolic solution (C) and ERL top coated bead from an 
aqueous dispersion (D) 
Figure 4.1A shows an INDO-PVP glass solution coated bead which appears spherical in 
shape with a smooth surface. Such beads exhibit surface cracks with different lengths and 
depths. In this example there is one major dent in the coating. Figure 4.1B shows beads which 
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were coated with an inner layer of INDO-PVP and an outer layer of EC. These beads are 
spherical but and no cracking is observed. The surface appears slightly rougher compared to 
the INDO-PVP surface. An INDO-PVP glass solution inner layer combined with an ERL outer 
layer, coated from an ethanol solution, is displayed in Figure 4.1C. No cracks were observed 
but now the surface is rough and shows pitted ‘golf ball-like’ surface structure. Finally, Figure 
4.1D presents an INDO-PVP glass solution layer with an ERL top coating sprayed from an 
aqueous dispersion. This resulted in smooth, spherical beads with a few rougher spots. A few 
very minor cracks or crescent shaped holes can be observed. 
 
The SEM analysis of the cross-sectioned beads revealed the different coating layers and 
inner morphology of the different formulations as illustrated in Figure 4.2. Figure 4.2A depicts 
a cross-section of the INDO-PVP coated bead. There is a distinct difference in morphology 
between the inner sugar core, which has a rough morphology, and the glass solution coating 
which has a smoother appearance. There are also cracks visible in the cross-sectioned view. 
Figure 4.2B and 4.2B’ show the sugar core, INDO-PVP inner layer and EC outer layer. The 
sugar core and glass solution layer possess the same features as described in the previous 
figure. The EC outer coating layer has a distinct ‘layered’ structure and seems to be loosely 
attached to the inner glass solution layer with a distinct gap between the two coating layers. 
Beads with a top coating of EC and 20% w/w of TEC were also analyzed (Figure B of Supporting 
Information), but no differences were observed when compared to Figure 4.2B and 4.2B’. The 
EC layers are morphologically very different from the ERL top coating, which is shown in 
Figures 4.2C and 4.2C’, where it is sprayed from an ethanol solution and in Figure 4.2D from 
an aqueous dispersion. The ERL layer is much smoother compared to the EC layer and equally 
smooth compared to the glass solution layer but with the absence of cracks. In this case, the 
two different coating layers are also attached to each other.  
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Figure 4.2: SEM micrographs of INDO-PVP coated glass solution bead (A), EC top coated bead 
(B) and a detailed view on the coating layers (B’), ERL top coated bead from an ethanolic 
solution (C) with a detailed view on the coating layers (C’), and, an ERL top coated bead from 
an aqueous dispersion (D). 
4.4.2 Chemical surface composition and distribution of the coated beads by ToF-SIMS 
Using the data obtained from the control samples, sample spectra were investigated for the 
presence or absence of each marker upon the samples. Secondary ion images are then 
constructed for chosen ions. ToF-SIMS secondary ion spectra and images of the surface of the 
INDO-PVP glass solution layer are shown in Figure 4.3. Figure 4.3a Shows the presence of ion 
peaks at the marker positions of PVP (left) and INDO (right), Figure 4.3b shows, from left to 
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right, the total ion image, the PVP marker ion (C3H4N2O
-) image, the INDO ion marker 
(C7H10O4
-) image and the overlay of the PVP (green) and INDO (blue) marker ion. The total 
ion image shows the presence and intensity of (any) detectable ions, this shows where different 
components can be present. The PVP marker ion image shows where the ions, which have 
been determined to be specific for PVP are present on the sample surface. The same 
observations can be made for the INDO ion marker image. To easily detect distributional 
differences between different marker ions (and thus the distribution of different components 
of the system), overlays can be created where different marker ions are assigned to a different 
colour. 
From the ion spectra (Figure 4.3a), it is apparent that both molecules are present in the 
glass solution coating. From the total ion image, the cracks in the surface are also visible. In 
terms of distribution, by observing the markers of INDO, PVP and the overlay of both, it is 
clear that the presence of both molecules along the entire surface shows a homogeneous 
distribution.  
 
Figure 4.3: ToF-SIMS ion spectra of INDO-PVP coated glass solution (a) at PVP and INDO 
marker positions. ToF-SIMS ion images of INDO-PVP coated glass solution (b) with the total 
ion image, the PVP marker image, the INDO marker image and an overlay of PVP marker image 
(green) and INDO marker image (blue). 
Secondary ion images of ERL coated formulations are provided in Figure 4.4. Figure 4.4a-d 
show ion images of ERL 100%, ERL-PVP 90-10%, ERL-PVP 75-25% and ERL latex 100% 
respectively. Secondary ion spectra are provided in Figure C of Supporting Information. All 
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ERL top coated formulations show presence of PVP marker ion on the sample surface, as can 
be seen in in the secondary ion spectra. The presence of PVP is expected for the ERL-PVP 90-
10% and ERL-PVP 25% coatings, because PVP is used here as a pore former in the rate 
controlling membrane, but it was not anticipated in coatings made up of pure ERL. Although 
all of the formulations show PVP presence at the surface, the distribution is different. From 
the ion images in Figure 4.4 it can be seen that in the formulations where PVP is used as a 
pore former, the distribution of PVP is more homogeneous throughout the surface. In both 
ERL 100% samples, which contained no pore former, the secondary ion images show PVP ‘hot 
spots’, i.e. local areas with a high marker intensity of PVP (column 3 of Figure 4.4a and 4.4d) 
and a low marker intensity of ERL (column 2 of Figure 4.4a and 4.4d). Secondary ion spectra 
of ERL based samples also show a very small INDO marker intensity for ERL 100% and ERL 
100% latex. For ERL-PVP 90-10% and ERL-PVP 75-25%, no clearly defined peaks could be 
observed in the spectra. This is also shown in the INDO marker ion images of Figure 4.4 
where only very few localized INDO spots can be observed in ERL 100% and ERL 100% latex. 
ERL-PVP 90-10% and ERL-PVP 75-25% only show background noise. It has to be remarked 
that not the entire surface is represented in the ion images of the sample as it was not possible 
to obtain data from the full 200 × 200 µm range. The system seems to cope with the 
topography but not with the curvature of the sample as it progressively goes out of focus. The 
loss of SIMS data due to the sample curvature is illustrated for each sample in the effect upon 
the total ion image which is provided for each system in column 1 of Figure 4.4.  
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Figure 4.4: ToF-SIMS ion images of ERL coated formulations, 100% ERL (row a), ERL-PVP 90-
10% (row b), ERL-PVP 75-25% (row c) and 100% ERL latex (row d). Column 1 represents the 
total ion images of all formulations, column 2 the ERL marker images, column 3 the PVP marker 
images, column 4 the INDO marker images and column 5 an overlay image of ERL marker 
(red), PVP marker (green) and INDO marker (blue). 
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As the ToF-SIMS is a semi-quantitative analysis method, only trends can be derived from 
the ion intensities obtained. To be able to compare different measurements and different 
formulations, the ion intensities presented were normalized by total ion intensity. Figure 5 
illustrates the intensities for the PVP and ERL diagnostic ions. Although the ERL ion intensity 
decreases with decreasing ERL content in the outer layer, the same cannot be said of the PVP 
marker intensity. Surprisingly, there seems to be a similar PVP marker intensity in both 100% 
ERL outer layers, either sprayed from an ethanol solution or aqueous dispersion, and ERL-
PVP 90-10%. Additionally, when PVP is added to the formulation as a pore former, a large 
variation between three independent measurements was observed. ERL-PVP 75-25% shows 
the highest PVP marker intensity. Since no INDO marker peaks can be observed in ion spectra 
of ERL-PVP 90-10% and ERL-PVP 75-25%, the marker intensities for INDO in Figure 4.5 
represent background noise, INDO marker intensities for ERL 100% and ERL 100% latex are 
barely larger than this background noise intensities. 
 
Figure 4.5: Ion intensities for the different formulations containing an ERL-based outer coating 
layer. ERL marker intensities are represented in filled grey bars, PVP marker intensities are 
striped blue bars and INDO marker intensities are orange dotted bars. Ion intensities are 
measured as a mean of 3 surfaces and the area is normalized by total ion statistics. 
Secondary ion spectra from the EC coated samples were also analyzed for marker ion 
intensities. The ion spectra of EC coated samples are shown in Figure D of Supporting 
Information. Secondary ion images were constructed from these spectra. These images are 
shown in Figure 4.6. In this figure, rows A, B, C and D represent the EC 100% coated sample, 
EC-PVP 90-10%, EC-PVP 75-25% and EC 100% with the addition of 20% TEC as a plasticizer 
(EC 100% - TEC) respectively. Once again, from the ion spectra, the presence of PVP can be 
observed in every sample, even in those samples that would not be anticipated to contain PVP 
in their outer layer, namely EC 100% and EC 100% - TEC. Local PVP regions are again visible, 
but this time they are even more pronounced and spread out diffusely along a large area of 
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the analyzed surface. From the overlay ion images of the samples with PVP as a pore former 
(Figure 4.6b and 4.6c, column 3), it can be observed that the distribution of PVP is more 
heterogeneous, compared to both EC 100% samples and also compared to ERL samples with 
identical pore former amounts. Ion peaks for the INDO marker ion can be distinguished in all 
EC samples (Figure D of Supporting Information), although they have very small intensities (10-
5 range). Only in the EC-PVP 90-10% sample, one specific INDO spot can be observed (Figure 
4.6b, column 3).  
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Figure 4.6: ToF-SIMS ion images of EC coated formulations, 100% EC (row a), EC-PVP 90-10% 
(row b), EC-PVP 75-25% (row c) and EC 100% - TEC (row d). Column 1 represents the total ion 
images of all formulations, column 2 the EC marker images, column 3 the PVP marker images, 
column 4 the INDO marker images and column 5 an overlay image of EC marker (red), PVP 
marker (green) and INDO marker (blue). 
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For the marker ion intensities of EC samples in Figure 4.7, the EC marker intensity is similar 
for EC 100%, EC 100% - TEC, and EC-PVP 90-10%. EC-PVP 75-25% has a decreased EC 
marker intensity. Contrary to ERL top layer samples, samples containing PVP as a pore former 
also have higher ion intensities for the PVP marker as compared to the 100% EC coated 
formulations. However, the ion intensity for the PVP marker is higher for the EC-PVP 90-10% 
sample, compared to the EC-PVP 75-25% sample. Similar to ERL samples, INDO marker 
intensity is very low and is for the most part background noise. 
 
Figure 4.7: Ion intensities for the different formulations containing an EC-based outer coating 
layer. EC marker intensities are represented in filled grey bars, PVP marker intensities are 
striped blue bars and INDO marker intensities are orange dotted bars. Ion intensities are 
measured as a mean of 3 surfaces and the area is normalized by total ion statistics. 
4.4.3 Chemical cross-sectional composition and distribution of the coated beads by ToF-
SIMS 
Physical cross-sections of each bead formulation were also analyzed with ToF-SIMS. The 
same markers for all components were used plus an additional sucrose bead marker ion. 
Presence of all marker ion peaks was checked and secondary ion images are then constructed 
for these marker ions. ToF-SIMS secondary ion spectra are shown in Figure E of Supporting 
Information and images of the INDO-PVP glass solution cross-section are shown in Figure 4.8. 
From the distribution of the different marker ions, a well-defined INDO-PVP glass solution 
layer can be observed as an outer layer on top of the sucrose bead. It is interesting to note 
here that inside the sucrose bead core, there seems to be presence of INDO and PVP marker. 
This was also observed when a control sample was analyzed, as seen in the sucrose control 
sample ion intensities (Supporting Information Figure F). This shows that the presence of 
INDO and PVP marker ions is inherent to the sucrose bead, which molecular constitution is 
not fully known, as they were purchased as such. Furthermore, the glass solution layer does 
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not show a homogeneous distribution of INDO and PVP across the diameter of the bead. 
INDO seems to be more present at the inner part of the glass solution layer, while PVP is 
more present at the outer part of the glass solution layer. This observation in particular is 
observed in one specific sample since the cross sections are not measured in triplicate. Since 
this inhomogeneous distribution is also not observed in top-coated glass solutions, no general 
claims can be made about this observation. The presence of two sugar spots in the glass 
solution layer is probably due to chipping during cross-sectioning. 
 
Figure 4.8: ToF-SIMS ion images of a cross-section of an INDO-PVP glass solution coated bead. 
Column 1 represents the total ion images of all formulations, column 2 the sucrose marker 
images, column 3 the PVP marker images, column 4 the INDO marker images and column 5 an 
overlay image of sucrose marker (yellow), PVP marker (green) and INDO marker (blue). 
Secondary ion images of the cross-sections of ERL based outer layer formulations are 
provided in Figure 4.9. Figure 4.9a-d show ion images of cross-sections of sugar cores, coated 
with an INDO-PVP glass solution and outer coating of ERL 100%, ERL-PVP 90-10%, ERL-PVP 
75-25% and ERL latex 100% respectively. Secondary ion spectra are provided in Figure G of 
the Supporting Information and show, not surprisingly ion peaks for all ion markers in every 
formulation. From the ion images it can be seen that INDO and PVP show a well-defined glass 
solution layer on top of the sucrose core. This glass solution layer in turn is again separated 
from the ERL top layers. PVP distribution along the ERL 100% layer is not seen and is very 
diffuse along the ERL 100% latex layer. As PVP is incorporated as a pore former, its intensity 
along the outer layer increased (Figure 4.9 column 3). In all formulations, INDO marker 
intensity is noticed solely in the glass solution layer, except for the ERL 100% latex layer where 
an INDO marker presence is observed right above the glass solution layer (Fig. 4.9d, Column 
4). ERL marker presence is limited to the outer coating layer. 
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Figure 4.9: ToF-SIMS ion images of the cross-sections of ERL top coated formulations, ERL100% 
(row a), ERL-PVP 90-10% (row b), ERL-PVP 75-25% (row c) and ERL 100% latex (row d). Column 
1 represents the total ion images of all formulations, column 2 the sucrose marker images, 
column 3 the PVP marker images, column 4 the INDO marker images, column 5 the ERL marker 
images and column 6 an overlay image of ERL marker (red), PVP marker (green), INDO marker 
(blue) and sucrose marker (yellow). 
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Cross-sections of EC based outer layer formulations were analyzed similarly to the ERL 
based outer layer formulations. Figure 4.10a-d provides ion images of the cross-sections of all 
different formulations, while all ion spectra are provided in Figure H of Supporting Information. 
Again, presence of all ion markers of the different components of the formulation was 
observed. Ion images show clearly defined INDO-PVP glass solution and EC based coating 
layers. PVP marker ion presence is observed in all EC coating layers, but is becoming more 
intense when applied as a pore former. This minor presence is attributed to the EC itself as 
can be seen from the control intensities (Supporting Information Figure I), and is similar to the 
sucrose control mentioned earlier. A similar phenomenon is not observed for the INDO 
marker and has no visible marker intensity in the EC based top layer. The smearing of the 
outer EC 100% layer (Figure 4.10a, column 5) is a result of physical damage during the bead 
cross-sectioning process. 
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Figure 4.10: ToF-SIMS ion images of the cross-sections of EC top coated formulations, EC 100% 
(row a), EC-PVP 90-10% (row b), EC-PVP 75-25% (row c) and EC 100% - TEC (row d). Column 
1 represents the total ion images of all formulations, column 2 the sucrose marker images, 
column 3 the PVP marker images, column 4 the INDO marker images, column 5 the ERL marker 
images and column 6 an overlay image of ERL marker (red), PVP marker (green), INDO marker 
(blue) and sucrose marker (yellow). 
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In order to investigate if INDO or PVP can migrate into the outer ERL or EC based coating, 
this coating layer is divided into several regions of interest, forming an inner, middle and outer 
layer of the top coatings (One example of the EC 100% sample is given in Figure J of Supporting 
Information). The different regions of interest intensities and total intensity of the INDO and 
PVP ion markers of the ERL top coatings are shown in Figure 4.11. Figure 4.11a represents 
PVP marker intensities and Figure 4.11b shows INDO marker intensities.  
 
Figure 4.11: Total, inner layer, middle layer and outer layer intensities of the PVP (a) and INDO 
(b) ion markers of ERL top coatings. ERL 100% intensities are shown in blue bars, ERL 100% 
latex intensities in red bars, ERL-PVP 90-10% intensities in green bars and ERL-PVP 75-25% 
intensities in purple bars. 
Identical intensity plots for EC top coatings are represented in Figure 4.12, where Figure 
4.12a shows PVP marker intensities and Figure 4.12b represents INDO marker intensities. 
PVP marker intensities are higher in ERL (Fig. 4.11a) and EC (Fig.4.12a) coatings where PVP 
was used as a pore former, which confirms previous results from the ToF-SIMS surface 
analysis. All ERL top coating formulations show a PVP intensity gradient from the inner to the 
outer layer. INDO marker total intensity (Fig. 4.11a) is largest in ERL 100% latex top coating. 
ERL 100%, ERL-PVP 90-10% and ERL-PVP 75-25% show similar INDO marker intensities. 
Similar to PVP marker intensities, there is an intensity gradient from the inner to the outer 
layer of all ERL based top coatings. A PVP marker intensity gradient is also observed in all EC 
formulations, except for EC-PVP 75-25%. This gradient is less pronounced than the one in ERL 
formulations. An INDO marker gradient is also observed for all EC top coatings (Fig. 4.12b), 
except EC-PVP 75-25%, but INDO marker intensities are slightly lower compared to ERL top 
coatings. The intensity difference is also most pronounced between the inner and middle layer 
of the EC based top coatings. The INDO marker intensity of the EC or ERL top coatings are 
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still considerably small when compared to the marker intensity of the glass solution layer. This 
ranges from 4.5% for EC-PVP 75-25% to 14% for ERL-PVP 75-25% and ERL 100% latex. 
 
Figure 4.12: Total, inner layer, middle layer and outer layer intensities of the PVP (a) and INDO 
(b) ion markers of EC top coatings. EC 100% intensities are shown in blue bars, EC 100% - TEC 
intensities in red bars, EC-PVP 90-10% intensities in green bars and EC-PVP 75-25% intensities 
in purple bars. 
4.4.4 Polymer miscibility 
Polymer blends were prepared by spray drying from an ethanol solution and analyzed by 
mDSC to investigate polymer miscibility. Miscibility was evaluated based on the position and 
number of glass transition (Tg) events. The glass transition temperature was measured in the 
reversing heat flow (half height in the heat capacity step change) and first derivative of the 
reversing heat flow (peak value). mDSC thermograms with these signals are presented in 
Figure 4.13 with ERL based samples in figure 4.13a and EC based samples in figure 4.13b.  
 
Figure 4.13: mDSC thermogram overlay of the reversing heat flow (full lines) and the first 
derivative of the reversing heat flow (dotted lines) of the different spray dried ERL-PVP (a) and 
EC-PVP (b) polymer mixtures. 
The glass transition temperatures of all analyzed samples are given in Table 4.1 (EC-based 
samples) and Table 4.2 (ERL-based samples). The mean glass transition temperature of spray 
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dried pure PVP, EC and ERL is 156.8°C, 125.1°C and 53.5°C respectively. Two Tg’s can be 
observed in the spray dried polymer blends, indicating that PVP is not miscible (or only to a 
certain extent) with ERL or EC. The major difference between EC-PVP mixtures and ERL-
PVP relates to the fact that in the EC-PVP systems both Tg’s remain more or less at the same 
temperature, while in coatings consisting of ERL-PVP the Tg of PVP decreases with increasing 
ERL content. No glass transition event due to the PVP fraction could be observed in the ERL-
PVP 75-25 blend, while no clear ERL Tg can be observed in ERL-PVP 50-50% and ERL-PVP 
25-75%. 
Table 4.1: Glass transition temperatures of the different spray dried EC-PVP polymer mixtures.  
EC/PVP ratio (%) 
Glass transition temperature (C°) 
EC-fraction PVP-fraction 
Mean SD Mean SD 
100/0 125.1 0.8   
75/25 125.0 0.7 161.1 1.0 
50/50 125.1 0.1 162.2 1.0 
25/75 125.5 0.6 156.9 0.4 
0/100   156.8 0.2 
All formulations are measured in triplicate with the mean and standard deviation. 
Table 4.2: Glass transition temperatures of the different spray dried ERL-PVP polymer mixtures.  
ERL/PVP ratio (%) 
Glass transition temperature (C°) 
ERL-fraction PVP-fraction 
Mean SD Mean SD 
100/0 53.5 0.7   
75/25 52.0 1.3 - - 
50/50 - - 123.7 2.2 
25/75 - - 137.5 1.1 
0/100   156.9 0.7 
All formulations are measured in triplicate with the mean and standard deviation. 
4.4.5 Physical structure of the glass solution layer 
Different reference materials and coated beads were investigated by XRPD to investigate 
the stability of the solid state properties of the glass solution when applying a rate controlling 
membrane. Figure 4.14 shows the diffractograms of the reference materials, an INDO-PVP 
glass solution coating and different ERL based membrane top layers.  
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Figure 4.14: XRPD diffractogram of reference substances (ERL, PVP K25, sucrose pellet and γ -
indomethacin), INDO-PVP glass solution coating and different ERL based coatings (ERL-PVP 
90-10%, ERL-PVP 75-25% and ERL latex coating). Characteristic peaks of γ -indomethacin are 
marked with arrows at 12.80° and 17.35° 
All coated samples show the Bragg peaks from the sucrose pellets, but none of them show 
the typical Bragg peaks of γ -indomethacin, which is the most stable crystalline form. 
Representative indomethacin Bragg peaks are indicated with arrows at 2θ  angles of 12.80° 
and 17.35°. EC based samples were also analyzed and neither showed indomethacin Bragg 
peaks (data not shown). 
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 Discussion 
4.5.1 Coated bead surface and cross-sectional topography 
The SEM image of the INDO-PVP coated bead (Figure 4.1A) shows a smooth surface with 
cracks of different sizes running all along the surface. These cracks are proposed to be a result 
of the drying of the glass solution. The spraying solvent, in this case ethanol, acts as a plasticizer 
of the INDO and PVP mixture, and as this solvent evaporates, the drug polymer mixture 
becomes more brittle as a result of an increasing glass transition temperature. This, together 
with contraction forces due to solvent evaporation from the spherical bead surface, could 
result in a cracked INDO-PVP glass solution layer. A cross-sectional image (Figure 4.2A) of 
these glass solution beads demonstrate that these cracks can extend from the outer surface 
to the sucrose core of the bead. These cracks also remain present when the INDO-PVP glass 
solution is top coated with an EC or ERL membrane (Figure 4.2B, 4.2B’, 4.2C and 4.2C’). No 
cracks are present in any of the EC or ERL membranes themselves due to the probable higher 
flexibility of these films, which solely exist of polymer (or polymer mixtures). The topography 
of these coatings varies from very rough (ERL solution layer), over mildly rough (EC layer), to 
generally smooth (ERL dispersion layer). It is clear that the same polymer, sprayed from a 
solution or an aqueous dispersion generates vastly different surface morphologies. This is not 
unexpected as the film forming process from an aqueous dispersion is significantly different 
from that of a solution. The beads coated with the dispersion were also additionally cured to 
further optimize polymer inter-diffusion and coalescence, and this probably contributes to the 
generation of a smooth surface.  
Although the cross-sectioning procedure applied induced specific features (artifacts) on the 
surface of the cross-section, like an unremoved part of the EC layer at the bottom part of 
Figure 4.2B or cutting traces observed in the glass solution layer of Figure 4.2B’, the difference 
between the glass solution layer with an additional ERL top layer or an EC top layer is very 
clear. Firstly, the EC membrane shows a layered structure along the coated layer, while the 
ERL membrane shows a smooth topography along the cross-section more resembling the glass 
solution layer. A second main difference lies in the attachment of the top layers to the glass 
solution layer. While the border between the ERL coating and the glass solution can only be 
observed through a change in grey tone, the border between the EC layer and the glass 
solution layer is indicated by the presence of a discernible delamination. It is impossible to 
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know if this opening already existed before the cross-sectioning or if it was created during 
cross-sectioning. However, the fact that all samples were cut in the same way, suggests that 
the EC layer is, at the least, much more loosely attached compared to the ERL layer. The 
miscibility data, shown in the mDSC experiments, provide further arguments for this 
observation. 
4.5.2 Composition of coated bead surfaces 
ToF-SIMS surface analysis showed a clear determination of the composition and polymer 
distribution along the surface of the coated beads. We recently reported that INDO-PVP 
coated beads (30-70% w/w) form a glass solution, i.e. one phase systems characterized by a 
single Tg where the drug is molecularly dispersed into the polymer matrix
12. The homogeneous 
distribution observed along the surface of INDO and PVP ions in the present study suggests 
the same excellent miscibility of both components. ToF-SIMS was able to clearly discriminate 
chemically between the four potential components (ERL, EC, PVP and INDO) in samples which 
can contain up to three of these components. This was demonstrated by the components 
marker ions which showed a high specificity. In contrast to the expected presence and 
distribution of INDO and PVP in the glass solutions, EC and ERL layers showed unexpected 
results. Where its presence would not be anticipated, PVP markers are clearly observed in 
pure ERL or EC top coatings (Fig. 4.4a,d and 4.6a,d Column 3 respectively). Two possibilities 
are proposed to explain the presence of PVP in these layers, the first one being a 
contamination with residual PVP, that became attached to the coating processor wall or 
Würster insert from the prior glass solution coating step. This is possible because the two 
coating layers are applied consecutively during the coating process, so there is always a fraction 
of droplets which are not sprayed on the beads and stick to the inner walls of the fluid bed 
coater or Würster insert and dry, or which dry before impinging on the beads. The second 
possibility is that PVP could migrate through the controlled release layer to the surface of the 
bead. Prior to drying of the sprayed polymer in the processor, the wetted particle could give 
rise to enhanced polymer mobility, leading to migration. It must be noted that while there is 
a clear presence of the PVP marker ion, very limited marker ion intensity of INDO was 
observed in the outer layer (only in ERL 100%, ERL 100% latex and EC surfaces). As the 
sprayed solution contains both INDO and PVP, there is no reason why INDO should not be 
present on the coater wall or should not migrate through the ERL layer together with the 
PVP. Firstly the specific ion for INDO has a much higher mass compared to the PVP marker 
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ion, making it more specific but less intense. Secondly, the glass solution only contains 30% 
(w/w) of INDO opposite to 70% (w/w) PVP. These two reasons could account for the smaller 
INDO marker intensities observed on ERL and EC surfaces.  
When PVP is added as a pore former, it is more evenly distributed on the outer surface 
compared to the spots observed in the pure ERL or EC surfaces. For ERL based surfaces, a 
higher PVP marker intensity was observed in coatings containing 25% of PVP compared to 
those containing only 10% of pore former (Figures 4.5). The opposite was observed in EC 
based surfaces (Figure 4.7), but here, the high variability of the PVP marker intensities point 
to high variability in surface distribution and constitution. This could also be concluded when 
taking into account the distribution of PVP along the surface. Whereas in the ERL coated 
samples, the PVP is more evenly spread and present over the entire surface of the coated 
beads (Fig. 4.4b,c Column 3), in the EC coated samples a more localized PVP presence could 
be observed (Fig. 4.6b,c Column 3). This further points to more heterogeneity of EC-PVP 
surfaces compared to ERL-PVP surfaces. 
4.5.3 Composition of coated bead cross-sections 
Although an additional component was introduced in the coated bead cross-sections, the 
sucrose starting core, it was still possible to distinguish all compounds, i.e. finding marker ions 
for all chemical entities despite very similar structural compositions (both sucrose and EC are 
complex carbohydrates). All investigated samples show very distinct layering, namely a glass 
solution layer on top of the sugar core and an ERL or EC based layer on top of the glass 
solution. Consecutively coating both layers, even from an identical solvent did not result in 
some kind of transition layer between both coatings.  
The presence of the PVP ion marker in pure ERL layers is not as pronounced as it was with 
the surface analysis, as only a diffuse presence along the ERL 100% latex layer is observed. 
When PVP is used as a pore former, there is an even distribution along the top coating layers. 
In pure EC layers, the diffuse presence of PVP can be attributed to the properties of the 
control sample. Again, when PVP is added as a pore former, the PVP marker intensity is 
significantly more pronounced along the top coating layer.  
Analyzing cross-sections allowed for the investigation of potential INDO and/or PVP 
migration into the top coating ERL or EC layer. An inner, middle and outer layer was created 
for all samples by defining different regions of interest. The ERL based coating showed 
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decreasing PVP and INDO marker intensities along the top coating membrane, irrespective of 
the membrane constitution. This intensity gradient was higher for INDO marker intensities as 
opposed to PVP marker intensities, pointing to an increased INDO presence in the inner layer 
of the top coating membrane. This was most pronounced in ERL 100% latex membrane. 
Because this membrane is formed from an aqueous dispersion, the water used as a spraying 
vehicle, is not removed from the system as easily as ethanol, despite the higher coating 
chamber temperature (60°C versus 50°C). This in turn can enhance molecular mobility of 
INDO and cause a migration into this outer membrane. Another explanation can be the curing 
step of the latex formulation where beads are stored at higher temperature compared to the 
beads coated from an ethanol solution. Similar intensity gradients are observed at EC top 
coated membranes, although less pronounced. EC-PVP 75-25% is the only membrane not 
showing this gradient. The reason for this is unknown. It has to be remarked that the migration 
of INDO and PVP is very limited along the top coating membranes. INDO for example, has 
an intensity of maximum 15% in the entire EC or ERL top coatings compared to glass solution 
marker intensity. This limited migration of INDO and PVP cannot explain the presence of PVP 
spots, observed along the pure ERL or EC surfaces. Because there isn’t a clear distributional 
evidence for this in the secondary ion images (no or very small and homogeneous marker 
presence), it can be concluded that these PVP spots at the surface are a result of 
contaminations during coating (collisions with dried powder particles on the coating walls). 
When small enough, this could generate spots on the surface which are not visible in cross-
sections of the outer membranes. 
4.5.4 Polymer miscibility 
The mDSC study of miscibility between the rate controlling polymers EC or ERL on one 
hand and the pore former PVP on the other hand, shows a different phase behavior of these 
polymer mixtures. The EC-PVP system does not mix, which is apparent by the presence of 
two Tg’s. Both glass transition temperatures stay fairly constant in all ratios, indicating 
immiscibility between both components. In case of the ERL-PVP blends we can observe an 
increase in the Tg of PVP with increasing PVP content. This shows that both polymers seem 
to be at least partially miscible. In ERL-PVP 50-50% and ERL-PVP 25-75% no ERL Tg could be 
determined because it was either masked by solvent or water evaporation, or because ERL 
was mixed with the PVP fraction. The poor miscibility of both polymer blends corresponds 
with previously made observations with ToF-SIMS, which showed separate PVP domains in 
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EC or ERL based layers. The partial miscibility between ERL and PVP can also explain why the 
ERL top coating is better attached to the glass solution layer. This is in contrast with the EC 
coating, which shows complete immiscibility with PVP, which is, at the most, only loosely 
connected. This immiscibility between EC and PVP can also be the explanation for the more 
localized PVP domains, when PVP is used as a pore former in EC coatings, as observed in ToF-
SIMS surface images. 
4.5.5 Glass solution phase analysis 
It has been previously shown that an INDO-PVP 30-70% (w/w) coating surrounding a 
sucrose pellet forms a glass solution, i.e. a molecularly dispersed drug in a polymeric carrier, 
resulting in a one phase system12. It remains, however, possible that the application of a rate 
controlling membrane on top of this glass solution could potentially cause instability to the 
glass solution through crystallization of indomethacin. This could be especially true when the 
rate controlling membrane was applied from an aqueous dispersion, because it is well known 
that the presence of water, even in the form of water vapor, can potentially result in drug 
crystallization. From the results of the XRPD analysis of the coated beads it became apparent 
that this is not the case. As the measurements were performed in transmission mode, all 
different layers of the beads were scanned which is evidenced by the presence of the 
characteristic Bragg peaks of the sucrose pellets in all diffractograms. However, no 
characteristic Bragg peaks of crystalline indomethacin were present in any of the samples, 
indicating that indomethacin remains X-ray amorphous after the application of a rate 
controlling membrane, whether this is from an ethanol solution or an aqueous dispersion. 
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 Conclusions 
In this study, the composition and polymer distribution of complex coated systems was 
elucidated by combining complementary solid state analytical techniques. Sucrose cores were 
coated with an INDO-PVP glass solution layer and on top of this, a rate controlling membrane 
was applied. These membranes consisted of EC or ERL with or without a pore former (PVP), 
coated from a solution or an aqueous dispersion, and with or without plasticizer (TEC) added. 
SEM images revealed vastly different topography of the surface of the different coated beads 
with a cracked surface for INDO-PVP glass solution, a rough surface for ERL coating from a 
solution and smooth surface for ERL coated from a dispersion. This difference can be 
appointed to the different film formation process and an additional curing step for the 
dispersion. Cross-sections revealed a difference in structure between ERL and EC based layers 
being smooth and well attached to the glass solution substrate or presenting a more layered 
structure loosely attached to substrate respectively. The difference in attachment can be 
attributed to the fact that ERL is partially miscible with PVP and that EC is immiscible. 
ToF-SIMS analysis showed to be an excellent method to provide details regarding the 
chemical composition of the surfaces and the distribution of the different components. The 
ToF-SIMS analysis showed the unexpected presence of PVP in layers made up of pure ERL or 
EC, originating from residual presence in the fluid bed coater. INDO and PVP show very 
limited migration into the outer membranes. Furthermore, there is a different localization in 
the samples containing PVP as a pore former. In the ERL-PVP coatings, the PVP seems to be 
more evenly distributed throughout the surface, whereas in the EC-PVP coatings, the presence 
of PVP seems to be more localized. This difference can be explained by the miscibility 
differences shown in mDSC and can have a significant effect on drug diffusion through this 
layer. 
XRPD analysis revealed that the application of a rate controlling membrane does not affect 
the solid state properties of the underlying glass solution, even when coated from an aqueous 
dispersion. 
This study reveals a unique insight into complex coated systems (glass solution + controlled 
release layer) on inert carriers. Rate controlling polymer selection, pore former selection and 
concentration can all have major consequences for the resulting phase behavior, and 
Broadening the Scope of Amorphous Solid Dispersions 
 
92 
 
deposition onto the carrier. This in turn will have a significant impact on the performance of 
this type of drug delivery system. 
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 Abstract 
This study aimed to investigate the pharmaceutical performance of an indomethacin-
polyvinylpyrrolidone (PVP) glass solution applied using fluid bed processing as a layer on inert 
sucrose spheres, and subsequently top-coated with a release rate controlling membrane 
consisting of either ethyl cellulose or Eudragit RL. The implications of the addition of a pore 
former (PVP) and the coating medium (ethanol or water) on the diffusion and release behavior 
were also considered. In addition, the role of a charge interaction between drug and controlled 
release polymer on the release was investigated. 
Diffusion experiments pointed to the influence of pore former concentration, rate 
controlling polymer type and coating solvent on the permeability of the controlled release 
membranes. This can be translated to drug release tests, which show the potential of diffusion 
tests as a preliminary screening test and that diffusion is the main factor influencing release. 
Drug release tests also showed the effect of coating layer thickness. A charge interaction 
between INDO and ERL was demonstrated, but this had no negative effect on drug release. 
The higher diffusion and release observed in ERL-based rate controlling membranes was 
explained by a higher hydrophilicity, compared to EC. 
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 Introduction 
Research on solid dispersions has been spanning for over half a century. Since being first 
described in 1961 by Sekiguchi and Obi 1 , over being defined and classified 10 years later by 
Chiou and Riegelman 2, to ultimately being a widespread concept as a poorly soluble drug 
formulation strategy, solid dispersions have gathered some attention over time 3. Typically, 
solid dispersions are formulated in combination with hydrophilic polymers as immediate 
release formulations. A lot of hydrophilic polymers (semi-crystalline and amorphous) have 
been tested for their potential use in solid dispersions 4, 5, but only few have been successfully 
utilized into marketed solid dispersions 6. When using these polymers, which show good water 
solubility, supersaturated gastrointestinal drug concentrations occur relatively fast after 
administration. However, supersaturation is not always maintained for a sufficient period of 
time leading to sub-optimal bioavailability enhancement. Even in vitro-in vivo comparisons 
cannot be readily made, as was reported in a study by Six et al. 7. Transforming rapidly 
dissolving but fast-precipitating solid dispersions into slow-release formulations might 
therefore improve their absorption enhancing potential 8. 
Different techniques have been proposed and used to prepare controlled release 
formulations for solid dispersions, like hot melt extrusion, powder compression, granulation 
and emulsion methods, or more recently electrospraying 9. Hot-melt extrusion, for example, 
has been one of the well explored systems to make slow-release drug-polymer systems. The 
drugs incorporated are mainly water soluble compounds that are combined with a controlled 
release polymer 10, 11 that can be part of the matrix or used as a rate controlling membrane 12. 
In the current study, fluid bed coating is proposed as an alternative and relatively unexplored 
technique. Beten et al. showed the feasibility of loading controlled release drug-polymer 
coevaporates of dipyridamole and enteric Eudragit polymers using an industrial scale fluid bed 
coating system 13. One of the main advantages of this process is that additional or multiple 
steps in the preparation process like milling, sieving, compression or additional tablet coating 
can be omitted. The ability of fluid bed coating to produce multiple layered systems is ideal for 
the preparation of controlled release solid dispersions. The solubilization can be maximized 
by choosing an appropriate (polymeric) carrier for the solid dispersion (or, ideally, the glass 
solution) layer. Subsequently, an additional rate controlling membrane can be applied on top 
of the glass solution layer to optimize the release during a well-defined time frame.  
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The feasibility of this approach is described in the companion paper (‘Controlling the 
release of indomethacin from glass solutions layered with a rate controlling membrane using 
fluid-bed processing. Part 1: Surface and cross-sectional chemical analysis’). Two clearly defined 
coating layers were observed. The surface properties of different rate controlling membranes 
applied could be explained to a large extent by the polymer mixing behavior. The physical 
structure of the underlying glass solution layer was also shown not being affected by the slow-
release top coating, even when this last was sprayed from an aqueous dispersion.  
The focus of the current paper is the investigation of the pharmaceutical performance of 
these formulations, i.e. their release behavior and the effect of formulation changes on the 
drug release. The glass solution layer is always made up of indomethacin (INDO) in 
polyvinylpyrrolidone K25 (PVP) in a 30:70 % w/w ratio. Two different rate controlling 
polymers will be tested, ethyl cellulose (EC) and Eudragit RL (ERL). PVP will also be used as a 
pore former and triethyl citrate (TEC) will be used as a plasticizer. Special emphasis in this 
study will be put on the possible charge interaction between negatively charged INDO (above 
pH 4.5) and the positively charged ERL, which is a water insoluble polymer, but the presence 
of quaternary ammonium groups in ERL is responsible for pH-independent swelling 14, 15. Drug 
release from ERL systems however, can be sensitive to the presence of other anionic species 
like buffer components or organic acids 16-18. This charge interaction has also been reported 
with other NSAID’s in the past 19-21. This possible charge interaction will be studied using Solid 
State Nuclear Magnetic Resonance (ss-NMR) and the implications of this interaction will be 
studied in sorption, permeability and drug release tests. 
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 Experimental section 
5.3.1 Materials 
Indomethacin was purchased from FAGRON Ltd. (Waregem, Belgium). 
Polyvinylpyrrolidone K 25 was a generous gift from BASF (Ludwigshafen, Germany). Sucrose 
spheres (diameter 710 - 850 µm) were kindly donated by Hanns G. Werner GmbH (Tornesch, 
Germany). Ethyl cellulose (ethoxy content 48.0-49.5% w/w) powder and triethyl citrate (TEC) 
were purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands). Eudragit RS® PO (ERS), 
Eudragit RL® PO and Eudragit RL® 30D were purchased from Evonik Industries (Darmstadt, 
Germany). 
5.3.2 Fluid bed coating 
Coated beads were prepared using an Aeromatic MP 1 multiprocessor (GEA, Bubendorf, 
Switzerland) in a bottom spray setup, equipped with a Würster insert. A 30:70 (w:w ) INDO-
PVP (w/w) glass solution with a total solid content of 250,0g was coated onto 500,0g of sucrose 
beads from a 10% (w/v) ethanol solution. The sucrose spheres were loaded into the preheated 
coating chamber at 50°C and heated for 10 minutes. The drug-polymer solution was coated 
onto the sucrose pellets, using a feed rate of 13cm3/min. This feed was atomized at an air 
pressure of 1.5 bar. Meanwhile the heated air stream was passing through the fluid bed coater 
at a rate of 1.78 m3 /min. When the spraying was finished, the pellets were dried until 
immobilization due to electrostatic charges was observed. The coated spheres were unloaded, 
weighed and dried for an additional 48 hours in an oven at 50°C. In the case when a top layer 
(rate controlling membrane) was applied, the feed solution was immediately changed after 
completion of the glass solution layer. The controlled release top layer consisted of a rate 
controlling polymer (ERL or EC) with an added pore former (PVP K25) in a 10% or 25% ratio 
to the total solid content and the plasticizer TEC, added in a concentration of 20% w/w relative 
to the amount of rate controlling polymer. The rate controlling membrane was applied from 
a 10% w/v ethanolic solution. Also, ERL-PVP 90-10% (w-w) was applied as an aqueous 
dispersion (10% w/v) instead of an ethanolic solution. The coating process parameters are the 
same for the top coating layer as for the glass solution layer, except for the feed rate with the 
ERL ethanolic solutions, where the feed rate was reduced to 6.5cm3 /min) because of the 
electrostatic charges created inside of the fluid bed coater. After completion of the coating, 
the beads were dried in the coater for at least 10 minutes, followed by further drying in an 
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oven for at least 48 hours. Ethanolic solutions are dried at 50°C, aqueous dispersions at 60°C 
to allow for curing of ERL. 
During coating of the rate controlling membrane, samples of 10-15g were taken at different 
time points to measure the coating layer thicknesses, expressed as percentage weight gain, 
relative to the weight of the glass solution coated beads. 
5.3.3 Drug diffusion 
Drug diffusion through a rate controlling membrane is tested with a diffusion cell set up, 
represented in Figure 5.1.  
 
Figure 5.1: Schematic representation of the diffusion cell set-up. 
The polymer film was clamped between a donor and acceptor compartment. The diameter 
of polymer film in contact with donor and acceptor compartment is 18 or 25mm depending 
on the used cells. The diffusion medium used was a 100mM phosphate buffer solution of pH 
6.8 with 15% propylene glycol to enhance INDO solubility in the donor compartment. For the 
donor solution 1.00mg/ml INDO was dissolved in the diffusion medium, the acceptor solution 
contained the blank medium. Volume of both donor and acceptor compartment was 100ml. 
During diffusion experiments, both compartments were also sealed from the air and constantly 
stirred with magnetic stirrers to ensure homogeneous distribution. 
Controlling rate membranes, tested in the diffusion experiments, were prepared by film 
casting from an ethanol solution or aqueous dispersion onto a Teflon plate and drying it for 
24 h at room temperature under a funnel. After this, they were put into an oven and dried for 
an additional 24h at 50°C for the solutions and for 48h at 60°C for the dispersions. Eudragit 
RL and ethyl cellulose are used as controlled release polymers (ERL100% and EC 100%), PVP 
K25 is optionally added as a pore former in 10 or 25% (w/w) based on the total solid content 
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(ERL-PVP 90-10%, ERL-PVP 75-25%, EC-PVP 90-10% and EC-PVP 75-25%). TEC was added as 
a plasticizer in all membranes in a 20% (w/w) concentration, based on the controlled release 
polymer mass. Ethanol solutions were prepared for ERL and EC based samples and aqueous 
dispersions for ERL based samples, both in a 10% w/v ratio. 
Diffusion tests were performed with an automated sampling device, a Gilson Liquid Handler 
215 (Gilson, Middleton, WI, USA). All rate controlling membranes were tested in triplicate, 
except for EC 100% and EC-PVP 90-10% which were tested in duplicate. At each sampling 
point, a 1ml sample was removed from the acceptor compartment and replaced with 1ml of 
blank medium. Samples are directly injected into the HPLC system for analysis.  
Drug concentrations at different time points were used to calculate the permeability 
coefficient (P, cm/s) using following equation 22: 
2𝑃𝑆
𝑉
𝑡 = −𝑙𝑛 (
𝐶0−2𝐶𝑎
𝐶0
)    Eq. 5.1 
In this equation; S is the diffusion surface area (cm²), V is the volume of donor and acceptor 
(ml), C0 is the initial donor concentration and Ca the acceptor concentration (mg/ml) at time 
t (s).  
5.3.4 High Performance Liquid Chromatography (HPLC)  
Quantitative analysis of the samples was performed using a Merck-Hitachi Lachrom HPLC 
system consisting of a Merck Hitachi L-7100 pump, an L-7420 UV-VIS detector, an L-7200 
autosampler and a D-7000 interface (Merck, Darmstadt, Germany). Injections were run 
through a Chromolith performance RP-18 column of 100mm x 4.6mm (Merck, Darmstadt, 
Germany). The mobile phase was 30% orthophosphoric acid solution (0.5% v/v), 40% 
acetonitrile and 30% methanol. Flow rate was set at 1.0 ml/min and injection volume at 20µl. 
INDO absorption was measured at 320nm and the retention time was approximately 3.3min. 
A calibration curve of area under the curve (AUC) vs. concentration was constructed using 
standard INDO solutions (0.125 mg/ml – 0.244 µg/ml) prepared by diluting a stock solution 
(1mg/ml in ethanol). Linearity was confirmed through linear regression analysis (R2 >0.999). 
Limit of detection (LOD) and limit of quantification (LOQ) were determined and were lower 
than the smallest INDO concentration of the calibration curve. 
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5.3.5 Drug sorption tests 
Powders or films of ERL, ERS and EC were added in a test tube filled with 5.0ml of either 
a 200µg/ml or 100µg/ml INDO solution (medium: phosphate buffer pH 6.8) and rotated for 
48 hours in a rotary mixer. After 48 hours, a sample was taken from the solution, filtered and 
analyzed with HPLC . Drug sorption to the polymer was calculated from the INDO 
concentration decline. All conditions were tested 5 times. 
5.3.6 Solid-state NMR 
The 13C-CP/MAS NMR spectra were recorded at room temperature on an Agilent VNMRS 
DirectDrive 400MHz spectrometer (9.4 T wide bore magnet) equipped with a T3HX 3.2 mm 
probe dedicated for small sample volumes and high decoupling powers. Magic angle spinning 
(MAS) was performed at 15 kHz with ceramic rotors of 3.2 mm (22 µl rotors). The aromatic 
signal of hexamethylbenzene was used to determine the Hartmann-Hahn condition (1H = H 
B1H = C B1C = 1C) for cross-polarization and to calibrate the carbon chemical shift scale (132.1 
ppm). Other acquisition parameters were: a spectral width of 50 kHz, a 90° pulse length of 
2.5 s, a spin-lock field for CP of 100 kHz, a contact time for CP of 1.0 ms, an acquisition time 
of 20 ms, a recycle delay time of 7.5 s and 350-45000 accumulations (350 scans for INDO, 
2700 scans for Eudragit RL® and 45000 scans for the INDO-ERL solid dispersion from an 
ethanol solution (INDO-ERL EtOH) as well as for the INDO-ERL powder isolated from a 
phosphate buffer pH6.8 (INDO-ERL pH 6.8)). High power proton dipolar decoupling during 
the acquisition time was set to 100 kHz. 
Two different INDO-ERL samples were prepared. The first one was prepared by dispersing 
ERL particles in a 200µg/ml INDO solution in phosphate buffer pH 6.8. After 48h of constant 
stirring, ERL particles were filtered and dried in an oven at 50°C. The second sample was 
prepared by spray drying an equivalent INDO-ERL ratio from an ethanol solution (10% w/v) 
using a Büchi Mini Spray Dryer B-191 (Flawil, Switzerland) and applying an inlet air flow rate 
of 0.56 m³/min, an inlet air temperature of 50°C, an atomizing air flow rate of 0.02 m3/min and 
a feed rate of 4.8 cm3/min. After collecting of the powder, it was additionally dried in an oven 
at 50°C. 
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5.3.7 Water permeation through isolated polymer films 
Water permeation through isolated polymer films was tested using aluminium cups 
containing 5.0ml of water. A schematic representation is provided in Figure 5.2.  
 
Figure 5.2/ Schematic representation of the diffusion cup set-up. 
Films were prepared using the solvent casting method described in the drug diffusion 
section. Water evaporation was tested for the ERL 100%, ERL-PVP 90-10%, ERL-PVP 75-25%, 
EC-PVP 90-10% and EC-PVP 75-25% polymer films. Cups were stored at ambient conditions 
and weighed at fixed time intervals for at least 126 hours to constant mass. This allowed 
calculating the percentage loss of water at each weighing interval. Tests were performed in 
duplicate. 
5.3.8 Drug release 
Drug release tests of the different controlled release formulations were performed using a 
Hanson SR8PLUS dissolution station (SpectraLab Scientific Inc., Markham, Canada). The 
release medium was 500ml of a 100mM phosphate buffer pH6.8. Paddle speed was set at 
120rpm and the temperature at 37.0 °C (±1.0). Samples were accurately weighed and were 
equivalent to an INDO dose of 75mg. At sampling time intervals, a 1ml sample was taken, 
filtered (pore size: 0.45µm) and put into an HPLC vial. The sample taken was replaced by 1ml 
of blank dissolution medium. Sampling times were 30, 60, 90, 120, 180, 240, 300 and 360 min. 
The quantitative analysis of the samples was performed with HPLC using the above described 
method. All formulations were tested in triplicate. 
5.3.9 Content analysis 
Accurately weighed formulations (with a theoretical INDO content of 3mg) were 
transferred into a test tube with 5.0ml of ethanol and rotated for 24h. Thereafter 1ml of 
ethanol solution was withdrawn, filtered (pore size 0.45µm) and analyzed with HPLC. 
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5.3.10 Statistical analysis 
Differences between the permeability coefficients of the different membranes were 
evaluated using ANOVA and unpaired t-testing. Results were considered statistically 
significantly different if p<0.05. 
The similarity factor f2 was used to compare drug release profiles of different 
formulations23. Two profiles are considered not significantly different when the f2 value is 
between 50 and 100. 
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 Results 
5.4.1 Indomethacin diffusion through rate controlling membranes 
Permeability coefficients are calculated from the concentration change in the acceptor 
compartment. Values are shown in Figure 5.3.  
 
Figure 5.3: Permeability coefficients of INDO through different rate controlling membranes 
In general, if the amount of PVP increases, the permeability of INDO increased as well. This 
is noticed for all three formulation groups, EC based films casted from an ethanol solution, 
ERL based films casted from an ethanol solution and ERL based samples casted from an 
aqueous dispersion (so-called ‘latex’).The differences in the permeability of the films when 
changing the PVP content are significant, except for ERL-PVP 90-10% and ERL-PVP 75-25% (p 
= 0,2371), ERL 100% and ERL-PVP 75-25% (p= 0,1104), and also, ERL-PVP 90-10% latex and 
ERL-PVP 75-25% latex (p= 0,1493). Apart from differences related to the amount of PVP 
incorporated, also differences related to the rate controlling polymer were observed. The 
permeability of INDO is always higher for ERL based formulations (solution or dispersion) as 
compared to EC based formulations (given the same amount of PVP). All these permeability 
differences are statistically significant, except for ERL-PVP 75-25% and EC-PVP 75-25% (p = 
0,2035). Both of these films show a very large standard deviation in the value of P. Also ERL-
PVP 75-25% latex and EC-PVP 75-25% do not show a significant difference since they have the 
same P-value. Films casted from a solution show higher P-values compared to films prepared 
from an aqueous dispersion, but the difference was only statistically significant for films of ERL 
100% and ERL latex 100%; for films containing10% and 25% PVP the difference was not 
significant (p = 0,1052 and p = 0,2027). 
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5.4.2 Indomethacin sorption to rate controlling polymers 
Because the rate controlling polymers EC, ERL and ERS are not soluble in aqueous media, 
INDO can sorb onto or into the swollen polymer particles. Figure 5.4 shows the amount (µg) 
of INDO that was sorbed into/onto the polymer particles (A) or the films (B) per milligram of 
CR polymer. These graphs clearly show that ERL powder and films incorporated the largest 
amount of INDO, irrespective of the INDO concentration in the medium. Moreover, INDO 
sorption in ERL doubled when the INDO concentration doubled, from 22.4µg/mg to 
44.9µg/mg for the powder and from 20.4µg/mg to 44.0µg/mg for the film. EC showed the 
second largest INDO sorption in powders but lowest in the films, where it almost didn’t sorb 
any INDO (0.0394µg/mg and 0.186µg/mg for 100 and 200µg/ml INDO concentration, 
respectively). INDO sorption in EC powder also almost doubled when the concentration 
doubled (8.76µg/mg and 16.4µg/mg). INDO sorption on ERS only slightly increased with 
increasing INDO concentration in films (from 4.74µg/mg to 6.71µg/mg) and powders (from 
4.63µg/mg to 5.51µg/mg). Sorption in films was also slightly higher than sorption in powders. 
    
Figure 5.4: Sorption of INDO into/onto different controlling rate polymers in the form of 
powder (A) or a film (B) in phosphate buffer medium pH 6.8 
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5.4.3 13C-CP/MAS solid-state NMR investigation into drug-polymer interactions 
INDO and ERL reference spectra, together with the spectra of INDO-ERL solid dispersion 
from an ethanol solution (INDO-ERL EtOH) and INDO-ERL powder isolated from phosphate 
buffer pH6.8 (INDO-ERL pH 6.8) are shown in Figure 5.5.  
 
Figure 5.5: 13C-CP/MAS NMR spectra of INDO (red), ERL (black), INDO-ERL solid dispersion 
from ethanol solution (green) and INDO-ERL powder isolated from phosphate buffer pH6.8 
(blue). In the detailed view on the right, INDO intensity is reduced by factor 3. 
Each INDO carbon nucleus shows a single signal without splitting, indicative for the stable 
γ -form24. Specially the signal at 156.7 ppm, attributed to the aromatic carbon bearing the 
methoxy group, is highly specific and confirms that the INDO starting material was γ -
indomethacin24, 25 (other peak assignments can be found in these references as well). The 
spectrum of INDO-ERL EtOH still shows the characteristic INDO peak at 156.7 ppm next to 
other INDO signals around 114.5 ppm, 131.5 ppm and 167.7 ppm. These peaks are situated 
at exactly the same position as for the INDO reference. The spectrum of the material 
prepared by soaking ERL in an INDO solution above its pKa (INDO-ERL pH 6.8) however 
shows clearly two significant chemical shift changes, i.e. an upfield shift of the signal at 156.7 
ppm to 153.9 ppm, and an upfield shift of the signal at 114.5 ppm to 111.5 ppm. Moreover, the 
167.7 ppm signal is shifted downfield and so coincides with the intense signal of the ERL 
carbonyl carbon. These changes point to an electrostatic interaction between INDO and ERL. 
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5.4.4 Water vapour diffusion through rate controlling membrane 
The permeation of water through the polymer films (expressed as percentage water loss) 
was measured over time and plotted in Figure 5.6. The evaporation rate increased with 
increasing pore former concentration for both ERL based and EC base rate controlling films. 
The time to lose 50% of water was calculated according to the equation of the trendline and 
was found to be 68h for ERL-PVP 75-25%, 80h for ERL-PVP 90-10% and 97h for ERL 100%. 
The time to reach 50% water content was 83h for EC-PVP 75-25% and 103h for EC-PVP 90-
10%. In case the same amount of pore former is present in the films, ERL based films have 
faster mass loss compared to EC based samples. 
 
Figure 5.6: Water evaporation (in content %) through rate controlling membranes as a function 
of time. 
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5.4.5 Drug release 
Crystalline indomethacin and INDO-PVP glass solutions 
The dissolution of crystalline indomethacin and the release from INDO-PVP 30-70% (w/w) 
glass solutions coated onto sucrose beads is shown in Figure 5.7. Already at the first time 
point (60 min), INDO-PVP glass solutions showed full release. Glass solutions were considered 
to have an immediate release profile. Crystalline INDO on the other hand, only gradually 
reached a plateau of 95% release after 5 hours. 
 
Figure 5.7: INDO release in function of time for crystalline INDO (blue dots) and INDO-PVP 
30-70% (w/w) glass solution coated around inert carriers (red squares). 
EC rate controlling membranes 
INDO release was tested for EC-PVP 90-10% and EC-PVP 75-25% coatings on top of 
INDO-PVP glass solutions. Figure 5.8 shows the INDO release (cumulative %) in function of 
time for beads coated with an EC-PVP 90-10% rate controlling outer membrane. The coating 
thickness was varied from 9.7% to 36.6%. Increasing coating layer thicknesses showed 
decreased and slower INDO release. Maximum release after 6h was 96% for 9.7% coating, 
38% INDO release for 19.1% coating, 3% for 28.0% coating and 9% for 36.6% coating. The 
profiles were different. Initial release is slow and shows a lag time, which increases with 
increasing coating layer thickness. This is followed by a period of high release rate for the 9.7% 
(between 60 and 180 min) and 19.1% (between 180 and 360 min) coating level. The lowest 
coating level shows a decreased INDO release between 180 and 360 min. The release profiles 
of the formulations with the highest coating levels (28.0 and 36.6%) were still in a lag phase 
which lasted for the entire 6 hours. All release profiles are significantly different, except for 
28.0 and 36.6% (f2=81.2), which explains why 36.6% coating level has a higher mean release 
compared to 28.0% coating level. 
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Figure 5.8: INDO release in function of time for INDO-PVP 30-70% (w/w) glass solution and an 
EC-PVP 90-10% (w/w) rate controlling membrane. Different coating levels were tested: 9.7% 
(blue), 19.1% (red), 28.0% (green) and 36.6% (purple). 
INDO release from EC-PVP 75-25% beads was quasi immediate. All beads reach their 
maximum release after 60-100min and this irrespective of the coating layer thickness, which 
varied from 9.5% to 35.8% (a release profile has been provided in the Supplementary Data of 
this chapter, Figure A). 
ERL rate controlling membranes 
The INDO release from INDO-PVP glass solutions was tested with ERL-PVP 90-10% 
(coated from either an ethanol solution or an aqueous dispersion) and 75-25% rate controlling 
membranes on top of the glass solutions. The release profiles of ERL-PVP 90-10% rate 
controlling membranes, coated from a solution are shown in Figure 5.9. Also in this case, 
increasing the coating layer thickness resulted in slower and decreased INDO release. While 
a 11.2% coating layer still shows 84% release after 6h, the release drops to 75% for 21.7% 
coating level, to 55% for 31.7% coating level and, ultimately, to a mere 50% for the highest 
coating level (36.3%). ERL-PVP 90-10% beads showed initial high drug release rate (burst 
release) followed by a slower INDO release for the lowest coating level. Formulations having 
higher coating levels showed an initial slow release followed by an increased release rate up 
until 90 minutes followed by a decreased release rate. All release profiles are significantly 
different from each other except for 31.7% and 36.6% (f2=66.2).  
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Figure 5.9: INDO release in function of time for INDO-PVP 30-70% (w/w) glass solution and an 
ERL-PVP 90-10% (w/w) rate controlling membrane. Different coating levels were tested: 11.2% 
(blue), 21.7% (red), 31.7% (green) and 36.3% (purple). 
ERL-PVP 75-25% coated beads also showed an INDO release which was highest (93%) and 
fastest from beads with the smallest coating amount (11.3%). Similar to the other formulations, 
this decreased to 68% and 57% with an increasing coating level of 21.9% and 32.0% 
respectively. The release profiles are shown in Figure 5.10. Formulations having the lowest 
coating level showed a high release rate during 180min, followed by a quasi-plateau level for 
the remaining 3 hours. The higher coating levels both showed a lag phase for 10min followed 
by an enhanced release for 50min and a decreased release rate for the remaining 5 hours. All 
curves with different coating layer thicknesses are significantly different.  
 
Figure 5.10: INDO release in function of time for INDO-PVP 30-70% (w/w) glass solution and 
an ERL-PVP 75-25% (w/w) rate controlling membrane. Different coating levels were tested: 
11.3% (blue), 21.9% (red) and 32.0% (green). 
Finally in Figure 5.11, the ERL-PVP 90-10% rate controlling membrane, coated from an 
aqueous dispersion, also showed a decreased and slower release with increasing coating level. 
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After 6 hours the release was 87% for 8.7% coating level and 69% for 17.1% coating level. 
Beads with 8.7% coating level showed high initial release (68% after 120min) followed by a 
slower release for the remaining 4 hours. After an initial (90min) high release for the beads 
having 17.1% coating level, INDO release approached zero-order release kinetics for the 
remainder of the release experiment. Both profiles showed to be significantly different from 
one another. 
 
Figure 5.11: INDO release in function of time for INDO-PVP 30-70% (w/w) glass solution and 
an ERL-PVP 90-10% (w/w) rate controlling membrane, coated from an aqueous dispersion 
(latex). Different coating levels were tested: 8.7% (blue) and 17.1% (red). 
 Discussion 
The difference of INDO diffusion through the different rate controlling membranes can be 
calculated based on the permeability coefficient. The applied equation has the benefit of being 
independent of membrane thickness. It is, however, important when calculating from a slope, 
that only the linear part of the plot is used. In other words, steady-state diffusion has to be 
reached to be able to calculate the permeability coefficient.  
For EC-based as well as ERL-based samples, it is clear that an increased amount of PVP, 
which is added as a pore former, led to an increased permeability coefficient. This is to be 
expected because PVP is a hydrophilic polymer which is expected to leach out of the rate 
controlling membrane. This allows for a higher permeation of the drug because the EC or ERL 
polymer chains are not as closely packed as they would be in absence of a pore former. In the 
ERL based samples, the permeability coefficient increases gradually from 0% over 10% to 25% 
PVP; in the EC based samples P is very small when 0% and 10% of PVP is added but increases 
significantly when 25% of PVP is added. This can be explained by the miscibility of both 
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polymers, which has been reported in the companion paper. Because PVP and EC are 
completely immiscible, PVP is not able to interpenetrate the EC polymer chains as much as in 
ERL. So while the amount of PVP in EC-PVP 90-10% is not sufficient for an adequate pore 
former functionality (similar P-value with EC 100%), EC-PVP 75-25% led to the formation of 
weak spots in the rate controlling membrane with a higher permeability as a result. The partial 
miscibility of ERL and PVP allowed for a more gradual increase of the rate controlling 
membrane permeability with increasing pore former concentration.  
Increasing pore former concentration also led to a higher variability of the permeability 
coefficient in case films were casted from an ethanol solution. This can also be explained by 
the (partial) immiscibility of the rate controlling polymer and the pore former. Increasing pore 
former concentration increased the heterogeneity of the films, resulting in a larger variation 
in permeability coefficients. When EC-based films are compared to ERL-based samples, a 
lower permeability coefficient was noticed for the same pore former concentration. This was 
most noticeable for the 0% and 10% pore former concentrations. Although there is a 
difference in the 25% PVP samples, this difference is not statistically significant due to the large 
standard deviation. When ERL films from an ethanolic solution are compared to films from an 
aqueous dispersion with equal pore former concentration, the second ones tended to have 
lower permeability coefficients. The main difference between film casting from a solution 
versus casting from a dispersion is that the latter requires a curing step. The polymer disposes 
itself as a small polymer particle (instead of spread out polymer chains in the solution) and 
needs to be stored at a temperature above the minimal film forming temperature for a certain 
amount of time to allow optimal coalescence of the dispersed polymer particles and polymer 
chain inter-diffusion for efficient film formation. 
INDO sorption studies showed clear differences in the amount of INDO incorporated into 
the insoluble controlled release polymers ERL, ERS and EC. ERL showed the highest INDO 
sorption in all conditions, being different concentrations and form (powder or film). INDO 
sorption is the lowest in the case of ERS powder and second lowest in case of the films. As 
with ERL, the sorption into powders or films doesn’t differ much, indicating that sorption in 
this case is independent of the available surface area. There is no relationship between ERS 
sorption and the INDO concentration in the medium. This observation also justifies the 
inclusion of ERS into this test as to show that the sorption of INDO in these polymers is 
independent upon the amount of quaternary ammonium groups present in these polymers 
(the part in the ter-co-polymer mainly responsible for the swelling). This is evidenced by the 
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fact that ERS has half of the quaternary ammonium groups compared to ERL and shows less 
than half of the amount of INDO sorbed. The link between the quaternary ammonium groups 
and INDO sorption also shows that an interplay of different forces is responsible for the 
sorption; not only a charge interaction, but also a decreased swelling of these particles because 
of the decreased amount of quaternary ammonium groups. Since these particles or films swell 
upon contact with the medium, INDO has a certain affinity for the hydrophobic environment 
of the polymers and will diffuse in them. This diffusion does not seem to be dependent on a 
charge interaction because it is also observed in the neutral EC polymer. Here, INDO sorption 
into/onto EC showed the second highest amount sorbed for the powders and lowest for the 
films. In the films almost no INDO is sorbed, which could be an indication for the dependence 
on the available surface area for INDO sorption. It can be presumed that the films have less 
surface area in contact with the medium compared to the powder. In the test with EC powder, 
INDO sorption is doubled when the INDO concentration in the medium is doubled. This can 
be in a direct way, pointing to sorption into or onto the available surface area or in an indirect 
way, meaning that the available surface area relates to the swelling of the polymer and that 
swelling has an impact on the diffusion into the polymer. The sorption of the active 
pharmaceutical ingredient into or onto the controlled release polymer can have certain 
implications towards incomplete drug release. These implications will only be enhanced when 
the coating layer thickness increases or if ERL should be used as part of the matrix of a different 
formulation. 
To confirm the electrostatic charge interaction between INDO (above its pKa at pH 6.8) 
and ERL during drug diffusion through the controlled release membrane, solid-state NMR 
experiments were performed. The significant changes in chemical shift (3ppm) observed for 
INDO-ERL pH 6.8 are undeniably the result of an interaction between INDO and the cationic 
quaternary ammonium groups of the polymer. Moreover, this was not observed for the 
INDO-ERL solid dispersion prepared from EtOH in which INDO was not present in its ionic 
form. Thus, the observed interaction is only present when INDO and ERL are both in their 
ionic form. Due to this interaction, the electron density (chemical environment) of some of 
the INDO carbons is affected, leading to the observed changes in chemical shift 24, 25. 
Diffusion through the rate controlling membranes was not only measured for INDO 
molecules in solution, also water vapor diffusion was monitored. Because of the uncharged 
nature of water molecules, the diffusion through the rate controlling membranes is not 
affected by possible charge interactions. The results of the water vapor diffusion tests were 
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along the same lines as INDO diffusion tests, i.e. diffusion of ERL-based membranes is always 
higher compared to EC-based samples with the same amount of PVP pore former. ERL-PVP 
90-10% and EC-PVP 75-25% have comparable water mass losses in function of time, which is 
in accordance with INDO diffusion results. Water vapor diffusion tests confirm that diffusion 
is generally higher for ERL-samples compared to EC-samples (given an equal amount of pore 
former), and this is irrespective of a possible charge interaction between the diffusing 
molecules (INDO) and (part of) the rate controlling membrane (ERL). This leads to conclude 
that ERL is more hydrophilic, compared to EC. 
When comparing the release from INDO-PVP coated beads and crystalline INDO in Figure 
7, it can be seen that release from the glass solutions is faster and more uniform, opposed to 
crystalline INDO (larger standard deviation). This shows the poor dissolution characteristics 
of the pure crystalline drug, and the need to formulate INDO into a glass solution prior to 
sustaining the release.  
INDO release from coated beads is dependent on the coating layer thickness in all 
formulations, except for those with a top-coating made up of EC-PVP 75-25% where all INDO 
is released immediately irrespective of the coating layer thickness. Increasing the coating layer 
thickness slows down and decreases the release of INDO from the coated beads, which can 
be attributed to the longer diffusion pathways for the drug26 and diffusion through a somewhat 
denser polymer network. Hydrophobic drugs have also been reported to have slower release 
profiles compared to hydrophilic drugs27. The decrease in release can also be attributed to the 
increasing presence of rate controlling polymer which will not dissolve into the medium and 
sorb INDO as observed in the this study. A combination of these effects will lead to a 
decreased drug release rate and amount with increasing rate controlling membrane thickness. 
There is also an increase in lag-time with increasing coating thickness, which is also explained 
by the increased diffusion path for the drug 26. 
Large differences are observed concerning the influence of the pore former depending on 
the rate controlling polymer used. When 10% and 25% PVP are compared in ERL-based 
samples with similar coating levels, the former led to a slightly faster and higher release 
compared to the latter, but the observed differences are never significant. In EC-PVP 90-10% 
and EC-PVP 75-25% on the other hand, differences could not be more remarkable. While 10% 
pore former is able to slow down the INDO release (given an appropriate coating level), EC-
PVP 75-25% does not slow down the release for any coating level. This inability to control the 
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release points to a defect in the coating layer which can originate from a too high pore former 
concentration. The reason behind the coating defect could be explained by results obtained in 
the first part of this study (details are provided in the companion paper). Here, differences in 
polymer miscibility and, subsequently, pore former distribution along the surface were 
observed. The immiscibility between EC and PVP resulted in more isolated PVP presence along 
the surface which could lead to local coating defects when leached out in early stages of release 
experiments. When using 10% pore former concentrations, the isolated PVP regions are 
smaller and the dissolving pore former can still be replaced by the swelling EC polymer, 
successfully slowing down the release. The partial miscibility between ERL and PVP explains 
why the PVP is more homogeneously spread along the rate controlling membrane surface and 
why no coating defects are observed when using a 25% pore former concentration. Miscibility 
studies between rate controlling polymer and pore former can indicate formation of isolated 
pore former regions in the rate controlling membrane and may thus give an idea about the 
success rate in formulating rate controlling membranes. 
 Different release profiles are observed when different rate controlling polymers with equal 
coating levels and an equal pore former concentration (10% w/w) are compared. Only the 
lowest coating level shows a higher INDO release for EC after 6 hours (ERL: 84%, EC 90%). 
With higher coating levels, INDO release is always higher after 6 hours from ERL based 
samples. This difference becomes larger with increasing coating levels up to a point where, at 
ca. 36% coating level, INDO release for EC-PVP 90-10% is 3% and for ERL-PVP 90-10% it is 
49%. All release profiles with comparable coating level have significantly different release 
profiles. Not only the release after 6 hours is smaller for EC, these formulations also show an 
extended lag time. For example, after 120 minutes, beads with coating levels of ca. 20% show 
an INDO release of 6% in EC-PVP 90-10% and 63% in ERL-PVP 90-10%. The burst release in 
the lower coating levels of ERL-PVP 90-10% could point to INDO release before complete 
swelling of the ERL coating. When 25% pore former concentration is applied, the situation is 
quite different. Because of the quasi immediate release (60-90 min) in case of EC-PVP 75-25%, 
these controlling rate membranes are not considered suitable for controlled release purposes. 
ERL-PVP 75-25% is, on the other hand, able to slow down the release in a way similar to ERL-
PVP 90-10%. The reason for this difference is polymer miscibility as discussed in the previous 
paragraph. 
Lastly, a comparison is made between identical rate controlling membranes coated from 
either an ethanol solution or an aqueous dispersion. While release profiles at 10% coating 
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levels are not significantly different (f2: 63,0), at 20% coating level, the rate controlling 
membrane coated from a dispersion shows a slower and lower (after 6h: 69% for latex and 
76% for solution) INDO release compared to the membrane coated from a solution. The 
release curves are significantly different from each other. Already 63% of INDO has been 
released after 120 min from the formulation coated from a solution. In the following 4 hours, 
an additional 13% INDO was released. In the formulation with the latex membrane the release 
after 120 minutes is 42% INDO and in the following 4 hours an additional 27%. This shows 
that the beads with a latex top layer show less burst release which allows for higher release 
after the initial phase. Indeed, after 90 minutes quasi-zero order release kinetics are observed, 
and from linear regression it can be calculated that all INDO will be released (given 
continuation of zero-order) at 10 hours and 42 minutes. 
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 Conclusions 
The pharmaceutical performance of a glass solution coated onto inert carriers with an 
additional rate controlling membrane was assessed. Firstly, diffusion through rate controlling 
membranes showed influence of pore former concentration, rate controlling polymer used 
and coating process, i.e. from a solution or a dispersion. Drug release experiments generally 
showed similar influences of formulation parameters and an additional influence of coating 
layer thickness. A link can be made between permeability coefficients and release behavior 
which shows, on one hand, that diffusion through the rate controlling membrane is the rate 
limiting step during drug release, and on the other hand, that drug diffusion results can be used 
as indicative values when screening for an appropriate controlled release dosage form. 
Although INDO and ERL are an interacting system, this has no negative effect on drug 
release. On the contrary, ERL generally shows higher diffusion rates and faster release, but 
this can be mainly attributed to its more hydrophilic nature, compared to EC.  
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Abstract 
In order to optimize supersaturation levels and avoid early drug precipitation, Eudragit® RL 
was tested as a carrier in solid dispersions, either alone or in combination with a hydrophilic 
polymer (PVP K25). In vitro dissolution performance of the spray dried solid dispersions was 
tested. The phase behavior of the produced solid dispersions was analyzed as well as 
dissolution precipitates. In case of weak acid model compounds (indomethacin and naproxen), 
the incorporation of Eudragit® RL resulted in a prolongation of supersaturation. A combination 
of PVP and Eudragit® RL led to high and stable drug concentrations. Eudragit® RL was only 
suited as a carrier in combination with higher drug loadings. Phase behavior analysis of the 
produced solid dispersions showed that Eudragit® RL could form glass solutions, and 
precipitate analysis showed that these drug-polymer combinations remained amorphous after 
in vitro dissolution for 24 hours. Surprisingly, indomethacin and naproxen also formed 
nanocrystals in presence of Eudragit® RL. These nanocrystals were formed by a dynamic 
interplay of dissolution, sorption and desorption. A charge interaction between anionic drugs 
and a cationic polymer provided a high driving force for sorption, which was necessary for 
nanocrystal formation and supersaturation stabilization. 
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 Introduction 
Solid dispersions are one of the go-to strategies when formulation scientists are confronted 
with poor solubility and dissolution rate of active pharmaceutical ingredients (API). These 
active substances have evolved over the years into increasingly potent but also structurally 
complex molecules. The growing complexity can be mainly explained by advances made in 
computer aided drug design 1, high throughput screening and combinatorial chemistry 2, 3, 
leading to decreased aqueous solubility of newly developed drug substances, with estimations 
ranging from 40-77% of new drug candidates displaying poor solubility, depending on the 
development stage of the drug candidates 4, and 30-35% of marketed drugs 5. To estimate poor 
solubility, one needs to define solubility and this has been done by the introduction of the 
biopharmaceutics classification system (BCS) by Amidon et al. in 1995 6. The U.S. Food and 
Drug Administration (FDA) has adopted this classification system in their biowaiver guidelines 
7. The BCS classification divides drugs or drug candidates in 4 categories according to their 
high/low solubility and high/low permeability. A drug is considered highly soluble when its 
highest dose dissolves in less than 250ml of medium with a pH range of 1-7.5. 
The increasing number of poorly soluble drug candidates created a vast array of enabling 
formulation strategies to overcome poor solubility and dissolution rate 8. Among the enabling 
strategies, amorphous solid dispersions are very promising and intensively investigated 9-11. 
However, 50+ years of research and development of solid dispersion has led to the marketing 
of ca. 20 products 12, 13.  
Solid dispersions are able to create supersaturated drug concentrations. However, the fast 
and high increase in drug concentrations will lead to fast nucleation, crystal growth and 
eventually precipitation of the active substance, which results in a loss of the solubility and bio-
availability advantage created. The emerging awareness of this disadvantage has come to 
attention in recent years 14, 15. Moreover, it has also been shown that in vitro dissolution data 
cannot be readily transposed to the in vivo situation 16, 17. 
The vast majority of carriers used in solid dispersions are polymers, early on mostly 
crystalline or semi-crystalline 18, later on mostly amorphous 19. Only recently, a shift has been 
seen from the traditional hydrophilic polymers, to polymers used for controlled release 
purposes 20. A recent study from Sun & Lee suggests that medium insoluble carriers exhibit a 
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more gradual generation of supersaturation, as a result of a diffusion-controlled release as 
opposed to a dissolution-controlled release, generated by medium soluble carriers 21. 
The goal of this study is to further develop the concept of solid dispersions with altered, 
i.e. decreased dissolution rate properties. More in particular, we will exploit the possibility of 
using the model polymer, Eudragit® RL (ERL) as a carrier for solid dispersions, either by itself 
or in combination with a model hydrophilic polymer, polyvinylpyrrolidone K25 (PVP). The 
research question here is to what extent ERL, being an insoluble but swellable polymer, can, 
as (part of) the solid dispersion carrier, slow down or stabilize the drug precipitation which is 
typically observed in solid dispersions that are only made up of a hydrophilic carrier. The 
combination of ERL with the hydrophilic PVP should potentially allow for sufficiently high initial 
drug concentrations, which is lacking when only a hydrophobic polymer is used as a solid 
dispersion carrier. ERL is a ter-copolymer of ethyl acrylate, methyl methacrylate and 
trimethylammonioethyl methacrylate with chloride as a counterion. ERL is practically insoluble 
in water, but the quaternary ammonium groups are responsible for the swelling and 
permeability of the polymer. Indomethacin (INDO), naproxen (NAP) and cinnarizine (CINN) 
are used as model drugs, with the former two being weak acids which can form a charge 
interaction with ERL above their respective pKa values. Cinnarizine is a weak base, unable to 
form charge interactions with ERL. Spray drying, a well-established solvent evaporation 
method for the production of amorphous solid dispersions 22 was used to prepare all 
formulations starting from an ethanolic solution. The potential of using ERL as a carrier is 
tested by investigating its phase behavior on one hand, and its influence on drug dissolution 
behavior on the other hand, with special emphasis on supersaturation generation. Another 
unexpected property of ERL will be discussed, namely its ability to form drug nanocrystals in 
solution. 
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 Materials and Methods 
6.2.1 Materials 
Indomethacin and cinnarizine were purchased from Fagron Ltd. (Waregem, Belgium), 
naproxen from CERTA Ltd (Braine l’Alleud, Belgium). Eudragit® RL was obtained from Evonik 
(Darmstadt, Germany) and PVP K-25 (Kollidon®25) was kindly donated by BASF SE 
(Ludwigshafen, Germany). Sodium acetate and phosphoric acid were obtained from Chemlab 
(Zedelgem, Belgium), sodium hydroxide from Merck (Darmstadt, Germany), acetic acid from 
VWR chemicals (Fontenay-sous-Bois, France) and potassium phosphate monobasic from 
Sigma-Aldrich (Steinheim, Germany), acetonitrile from Fisher Scientific (Leicestershire, UK) 
and methanol from Acros Organics (Geel, Belgium). Ultrapure water was produced with an 
Elga® Maxima system (Elga Ltd. High Wycombe Bucks, United Kingdom). All solvents used 
were of analytical grade. 
6.2.2 Methods 
Spray drying 
Solid dispersions of drug and polymer(s) were spray dried using a Buchi mini spray-dryer 
B191 (Buchi, Flawil, Switzerland). An accurate amount of drug and polymer(s) was dissolved 
in ethanol (10% solution w/v) and this solution was spray dried using an inlet temperature of 
50°C, an atomizing air flow rate 0.02 m³/min, a drying air flow rate 0.56 m3/min and a feed rate 
of 4.8 cm³/min using a peristaltic pump. All spray-dried samples were additionally dried in a 
vacuum oven (Mazzali Systems, Monza, Italy) at 25°C for at least 2 days.  
Modulated differential scanning calorimetry (mDSC) 
mDSC was used to investigate the phase behavior of the spray dried solid dispersions and 
precipitates, obtained after in vitro dissolution. The analysis was carried out using a Q2000 
Differential scanning calorimeter (TA Instruments, Leatherhead, UK) purged with a nitrogen 
flow rate of 50 ml/min during analysis. The mDSC was equipped with a Refrigerated Cooling 
System (RCS 90) (TA Instruments, Leatherhead, UK). The software used for data processing 
was TA instruments Universal Analysis 2000 (version 4.4, Leatherhead, UK). TA Instruments 
standard aluminum pans (Brussels, Belgium) were used for all measurements. A sample mass 
of 5-6 mg was accurately weighed into the pans and crimped together with a lid. All samples 
were measured in triplicate. Samples were heated from 0 to 180°C. A heating rate of 2°C/min 
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was applied with a temperature modulation of 0.636°C every 40s. Glass transition 
temperatures were measured at half height in the reversing heat flow. The step jump in heat 
capacity observed in the reversing heat flow signal was further examined in the corresponding 
derivative signal after Savitsky-Golay smoothing with points of window set at 10°C. n-
Octadecane and indium were used to calibrate and validate the DSC temperature scale. Indium 
was also used to calibrate and validate the enthalpic response. The heat capacity was calibrated 
and validated using sapphire disks. 
X-ray powder diffraction (XRPD) 
The precipitate samples from in vitro dissolution studies (analyzed immediately after the 
filtration from the dissolution medium) were analyzed at room temperature using an 
automated X’pert PRO diffractometer (PANalytical, Almelo, the Netherlands). The precipitate 
samples were clamped between Kapton foil and placed in sample holders. Analysis was 
performed in transmission mode using a Cu tube (λ (Kα ) 1.5418 Angstrom; generator at 
45kV and 40mA). The analysis was performed in a continuous scan mode in a 2θ  range from 
4° to 40° with 0.0167° step size and 200 seconds step time. The X’pert Data Collector and 
X’pert Data Viewer (PANalytical, Almelo, The Netherlands) were used to collect and analyze 
the data. 
Scanning electron microscopy (SEM) 
Solid dispersion and precipitate morphology was analyzed using a Phillips XL30 ESEM-FEG 
(Philips, Eindhoven, The Netherlands) equipped with a Schottky field emission electron gun. 
Powders were fixed on an aluminum stub using double-sided carbon tape. The samples were 
coated with gold by sputtering for 45 s at 20 mA. The SEM instrument was used with an 
acceleration voltage of 10.00 kV, a spot size of 3 and a secondary electron detector. 
Dynamic light scattering (DLS) 
DLS measurements were performed in a CGS-3 spectrometer (Malvern Instruments, 
Worcestershire, UK) equipped with a goniometry, auniphase 22 mV He-Ne laser operating at 
632.8 nm, an avalanche photodiode and detector and an ALV-5000/EPP multi-angle tau 
correlator. Light scattering was monitored at 90°.  
In vitro dissolution studies 
In vitro dissolution performance of the solid dispersions was evaluated using an SR8PLUS 
dissolution test station (Hanson Research, Chatsworth, USA). The dissolution medium was 
either an acetate buffer at pH 4.5 or a hydrochloric acid solution at pH 1.2. The dissolution 
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volume was 500 ml, maintained at 37 ±0.5 °C. A dose of 150mg API was calculated for each 
sample and weighed accurately. Samples were taken at different time intervals by withdrawing 
2ml of dissolution medium and filtering this medium using a PTFE filter with a pore size of 0.45 
µm (Macherey Nagel, Duren, Germany). The first 1ml was discarded for filter saturation, the 
other 1ml was transferred to a test tube. 0.5 ml of sample was diluted 1:1 with acetonitrile 
(ACN) to avoid sample precipitation. All experiments were performed in triplicate. Drug 
concentrations were assessed using HPLC. At the end of experiment, the vessel content 
(dissolution precipitate) was filtered using a vacuum pump and a cellulose acetate filter with a 
pore size of 0.45 µm. One part of the precipitates was analyzed immediately with XRPD; the 
other part was further dried in the oven at 40°C for two days and analyzed with mDSC. 
Solubility determination 
Falcon™ 50ml conical centrifuge tubes were filled with 50.0 ml of medium (acetate buffer 
pH 4.5 or HCl solution pH 1.2) and rotated (3rpm) at 37 °C until constant API concentration. 
Optionally, an accurate amount of polymer(s) was weighed and added to the oversaturated 
API solution. At each withdrawal, 2 ml of sample was taken, filtered and diluted with ACN. 
Samples were again analyzed using HPLC. All experiments were performed in triplicate. 
Sorption testing 
Falcon™ 50ml conical centrifuge tubes were filled with 50.0 ml of an API solution in acetate 
buffer pH 4.5 and rotated (3 rpm) at 37 °C. The following API concentrations were chosen: 
CINN 0.03 mg/ml, NAP 0.08 mg/ml 0.02 mg/ml. At time zero an accurate amount of ERL (25 
mg, 50 mg, 100mg, 200mg) was added to the test tubes and at several time points, samples 
were collected (1h, 2h, 4h, 6h, 24h, 48h) until constant concentration was reached. Samples 
were filtered using a PTFE filter (pore size 0.45 µm), diluted with ACN and analyzed with 
HPLC. 
To construct sorption isotherms, 5 solutions with varying concentrations of NAP or INDO 
were prepared and 50.0 ml of this solution was transferred in Falcon™ 50ml conical centrifuge 
tubes. An accurately weighed amount of ERL was introduced and the tubes were rotated (3 
rpm) at 37°C until constant concentration. Sorption isotherms were analyzed using the 
Langmuir adsorption model: 
𝑐
𝑦
=
1
𝑦𝑚𝑏
+
𝑐
𝑦𝑚
      (Eq. 6.1) 
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In this equation c is the equilibrium concentration of the adsorbed drug in solution, y is the 
amount of adsorbed material (expressed per unit of mass of adsorbent), ym is the amount of 
adsorbed material per mass unit of adsorbent when a monolayer is formed, and b is the ratio 
of the adsorption rate constant to the desorption rate constant. 
High performance liquid chromatography (HPLC) 
Drug concentrations were measured using HPLC. The set-up consisted of a pump L-7100, 
an autosampler L-7200, a UV-detector L-7420 and an interface D7000 (all from Merck, 
Darmstadt, Germany). The column used was a Chromolith® Performance RP-18e (100-
4.6mm) from Merck kGaA (Darmstadt, Germany). Naproxen (retention time ~ 2.5 min) and 
Indomethacin (retention time ~ 3.2 min) were detected at a wavelength of 320 nm and the 
mobile phase composition was made up of 50% v/v of a 0.5% v/v orthophosphoric acid solution 
in ultrapure H2O and 50% v/v of ACN. Cinnarizine (retention time ~ 5.50 min) was detected 
at a wavelength of 252 nm and the mobile phase was made up of a 35% v/v buffer (potassium 
phosphate 0.05M pH 6.0) and 65% v/v of ACN. All samples were analyzed in duplicate. A 
calibration curve of area under the curve (AUC) vs. concentration was constructed using 
standard drug solutions (0.125 mg/ml – 0.244 µg/ml) prepared by diluting a stock solution 
(1mg/ml). Linearity was confirmed through linear regression analysis (R2 >0.999). Limit of 
detection (LOD) and limit of quantification (LOQ) were determined and were lower than the 
smallest drug concentration of the calibration curve. 
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 Resuts 
6.3.1 Solid state characterization of solid dispersions 
Topography  
The topography of spray dried solid dispersions was determined by SEM. Representative 
micrographs of the different solid dispersions containing INDO are shown in Figure 6.1.  
 
Figure 6.4: SEM micrographs of spray dried solid dispersions of INDO-PVP 30-70% (w/w) (A), 
INDO-ERL-PVP 30-35-35% (w/w) (B) and INDO-ERL 30-70% (w/w) (C)  
INDO-PVP 30-70% (Figure 1A), INDO- ERL-PVP 30-35-35% (Figure 1B) and INDO-ERL 
30-70% (Figure 1C) show different outer surface morphologies. Spray dried powder particles 
consisting of INDO and PVP showed a more irregular surface and shape, compared to particles 
containing ERL. INDO-PVP particles also appeared to be the largest. Spray drying INDO-ERL-
PVP solid dispersion generated spherical particles with a smooth surface. These were also 
smaller compared to INDO-PVP particles and about the same size as INDO-ERL particles. 
INDO-ERL particles are also spherical but slightly less smooth than INDO-ERL-PVP particles. 
Thermal analysis  
 Indomethacin solid dispersions 
Spray dried solid dispersions were assessed on their phase behavior using modulated 
differential scanning calorimetry (mDSC). All formulations containing INDO are presented in 
Figure 6.2. 
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Figure 6.2: mDSC thermograms of spray dried solid dispersions of INDO with different polymers 
(or combinations) and INDO contents of 30% (A), 50% (B) and 10% (C). In panel A, INDO-PVP 
30-70% is represented in red, INDO-PVP-ERL 30-52.5-17.5% in blue, INDO-PVP-ERL 30-35-35% 
in green, INDO-PVP-ERL 30-17.5-52.5% in black and INDO-ERL 30-70% in pink. In panel B, 
INDO-PVP 50-50% is represented in red, INDO-PVP-ERL 50-25-25% in green and INDO-ERL 
50-50% in pink. In panel C, INDO-PVP 10-90% is represented in red, INDO-PVP-ERL 10-45-45% 
in green and INDO-ERL 10-90% in pink. Reversing heat flows are given in full lines, the 1st 
derivative of the reversing heat flows in dotted lines. Arrows indicate glass transitions. 
All formulations containing 30% INDO formed glass solutions, i.e. a one phase system were 
the drug is molecularly dispersed into the polymer matrix. Please note that the term ‘glass 
solution’ does not indicate a thermodynamically stable system since the drug can be 
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oversaturated in these systems. Mean glass transitions ranged from 113.3°C (INDO-PVP 30-
70%) to 57.1°C (INDO-ERL 30-70%). In glass solutions with a PVP-ERL mixture, mean glass 
transition temperatures were 90.9°C, 76.4°C and 62.5°C for INDO-PVP-ERL 30-52.5-17.5%, 
30-35-35% and 30-17.5-52.5%, respectively. 
In solid dispersions containing 50% INDO loadings (Figure 6.2B), single glass transitions 
were still observed at 79.9°C, 81.4°C and 49.8°C for INDO-PVP 50-50%, INDO-PVP-ERL 50-
25-25% and INDO-ERL 50-50% respectively. Although these formulations could still be 
categorized as glass solutions, INDO-PVP 50-50% showed a very wide Tg, and from the shape 
of the derivative heat flow signal, 2 minima could be observed, which pointed to a phase 
separated system. 
At 10% INDO loading (Figure 6.2C), both INDO-PVP and INDO-ERL are glass solutions 
with a mean glass transition at 134.3°C and 64.1°C respectively. INDO-PVP-ERL 10-45-45% 
on the other hand showed 2 glass transitions with means at 64.8°C and 113.6°C. This 
formulation clearly was a phase separated system. 
 Naproxen solid dispersions 
In Figure 6.3, mDSC analysis of NAP solid dispersions (30% drug loading w/w) showed 
single glass transitions (Figure 6.3A) with a mean at 33.0°C, 56.3°C and 64.8°C for NAP-ERL 
30-70%, NAP-PVP-ERL 30-35-35% and NAP-PVP respectively. NAP-ERL 30-70% also showed 
a NAP melting peak at 121°C (Figure 6.3B). NAP-ERL could not be considered as a true glass 
solution because it contained a crystalline NAP fraction. 
 
Figure 6.3: mDSC thermograms of spray dried solid dispersions of NAP with different polymers 
(or combinations). In panel A, NAP-PVP 30-70% is represented in red, NAP-PVP-ERL 30-35-35% 
in green, and NAP-ERL 30-70% in pink. Reversing heat flows are given in full lines, the 1st 
derivative of the reversing heat flows in dotted lines. Panel B represents the total heat flow of 
NAP-ERL 30-70. Arrows indicate glass transitions. 
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Cinnarizine solid dispersions 
Thermograms of solid dispersions with CINN (30% drug loading w/w) are represented in 
Figure 6.4.  
 
Figure 6.4: mDSC thermograms of spray dried solid dispersions of CINN with different polymers 
(or combinations). In panel A, CINN-PVP 30-70% is represented in red, CINN-PVP-ERL 30-35-
35% in green, and CINN-ERL 30-70% in pink. Reversing heat flows are given in full lines, the 1st 
derivative of the reversing heat flows in dotted lines. Panel B represents the total heat flow of 
CINN-ERL 30-70 (red), CINN-PVP-ERL 30-35-35% (green), and CINN-ERL 30-70% (pink). 
Arrows indicate glass transitions. 
Figure 6.4A shows the reversing heat flow signals of CINN solid dispersions. Mean glass 
transitions were observed at 5.5°C, 6.7°C and 31.9°C for CINN-PVP 30-70%, CINN-PVP-ERL 
30-35-35% and CINN-ERL formulations respectively. Since all formulations showed CINN 
melting peaks in the total heat flow signals (Figure 6.4B), none of these solid dispersions could 
be categorized as a true glass solution. 
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Structural composition 
To confirm the semi-crystalline composition of the NAP-ERL 30-70% formulation, the spray 
dried powder was analyzed by XRPD. The diffractogram, shown in Figure 6.5, showed 
characteristic NAP Bragg peaks in the NAP-ERL 30-70% sample. 
 
Figure 6.5: XRPD diffractogram of NAP (blue), ERL (red) and spray dried NAP-ERL 30-70% 
(green). 
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6.3.2 In vitro dissolution 
Indomethacin solid dispersions 
Dissolution testing was performed on spray dried solid dispersions containing INDO in 
different drug loadings (Figure 6.6).  
 
Figure 6.6: INDO concentrations in function of time of spray dried solid dispersions of INDO 
with different polymers (or combinations) and INDO contents of 30% (A), 50% (B) and 10% (C). 
In panel A, INDO-PVP 30-70% is represented in blue, INDO-PVP-ERL 30-52.5-17.5% in grey, 
INDO-PVP-ERL 30-35-35% in orange, INDO-PVP-ERL 30-17.5-52.5% in green and INDO-ERL 
30-70% in yellow. In panel B, INDO-PVP 50-50% is represented in blue, INDO-PVP-ERL 50-25-
25% in grey, INDO-ERL 50-50% in orange and a physical mixture of INDO-PVP 50-50% and 
INDO-ERL 50-50% in green. In panel C, INDO-PVP 10-90% is represented in blue, INDO-PVP-
ERL 10-45-45% in grey and INDO-ERL 10-90% in orange. In panel A-C, dissolution is performed 
in an acetate buffer pH 4.5. In panel D dissolution is performed in an HCl solution pH 1.2. 
INDO-PVP 30-70% is represented in blue, INDO-PVP 50-50% in grey, INDO-PVP-ERL 30-35-
35% in yellow and INDO-ERL 30-70% in orange. In all dissolution profiles, INDO solubility in 
the respective medium is represented by a black dashed line. 
Concentrations in function of time of INDO 30% formulations are shown in Figure 6.6A. 
All formulations showed concentration levels above the INDO solubility level (0.013 mg/ml). 
All formulations reached a concentration level above INDO solubility within the first sampling 
time (5 min), except for INDO-PVP 30-70% (between 5 and 15 min) and INDO-ERL 30-70% 
(after 1h). INDO-PVP 30-70% shows the highest concentration level, 0.06 mg/ml after 2h, but 
also shows a steep concentration decline hereafter with concentrations approaching INDO 
solubility at 22h (0.016 mg/ml). Glass solutions where ERL is incorporated as a (co-)carrier on 
the other hand, did not reach the concentration level of INDO-PVP 30-70%. Depending on 
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the polymer composition, the highest concentration levels reached were 0.044 mg/ml for 
INDO-PVP-ERL 30-52.5-17.5% after 5h, 0.033 mg/ml for INDO-PVP-ERL 30-35-35% after 4h, 
0.024 mg/ml for INDO-PVP-ERL 30-17.5-52.5% after 4h and 0.021 mg/ml for INDO-ERL 30-
70% after 5h. However, in contrast to INDO-PVP 30-70%, no steep concentration decrease 
was observed. Concentrations at 24h only marginally declined or inclined, compared to the 
peak concentrations. 
Similar observations could be made at 50% INDO drug loadings as shown in Figure 6.6B. 
INDO-PVP 50-50% showed a steep concentration incline to 0.065 mg/ml at 2h, with a 
concentration decline to 0.020 mg/ml at 24h. INDO-PVP-ERL 50-25-25% reached a maximum 
concentration of 0.045 mg/ml at 5h, which declined to 0.039mg/ml at 24h. INDO-ERL 50-50% 
reached its highest concentration of 0.021 mg/ml at 24h. Finally, a 1:1 physical mixture of 
INDO-PVP 50-50% and INDO-ERL 50-50% was tested. This formulation reached a peak 
concentration of 0.078 mg/ml at 4h and a concentration of 0.031 mg/ml after 24h dissolution. 
At 10% INDO drug loading, shown in Figure 6.6C, INDO-PVP 90-10% reached the highest 
concentration (0.128 mg/ml) at 1h. This concentration declined to 0,035 mg/ml at 24h. INDO-
PVP-ERL 10-45-45% reached a maximum concentration of 0.030 mg/ml at 22h. INDO-ERL 10-
90% remained below INDO solubility for 24h. The maximum concentration reached was 0.009 
mg/ml at 22h. 
When INDO glass solutions with different polymer (mixtures) and drug loadings were 
tested in an HCl solution (pH 1.2), all formulations had similar release profiles (Figure 6.6D). 
Maximum concentrations reached were between 0.02 and 0.03 mg/ml at maximum 2h. After 
7h of dissolution, all formulations approached INDO solubility (0.010 mg/ml).  
Naproxen solid dispersions 
Dissolution tests on spray dried solid dispersions with NAP at 30% w/w drug loading were 
performed in an acetate buffer pH 4.5. NAP concentrations in function of time are shown in 
Figure 6.7.  
  Eudragit RL as a stabilizer  
139 
 
 
Figure 6.7: NAP concentrations in function of time of spray dried solid dispersions of NAP 30% 
with different polymers (or combinations). NAP-PVP 30-70% is represented in blue, NAP-PVP-
ERL 30-35-35% in grey and NAP-ERL 30-70% in orange. Dissolution is performed in an acetate 
buffer pH 4.5. NAP solubility is represented by a black dashed line. 
All tested formulations reached concentrations above NAP solubility (0.08 mg/ml). NAP-
PVP 30-70% formulation showed a rapid concentration increase to a maximum of 0.100 mg/ml 
at 1h. This concentration showed a limited decrease at 24h to a concentration of 0.090 mg/ml. 
NAP-PVP-ERL 30-35-35% and NAP-ERL 30-70% reached concentrations higher than NAP 
solubility after 2h and 3h respectively. Highest NAP concentrations were only measured at 
24h. NAP-PVP-ERL 30-35-35% reached a concentration of 0.128 mg/ml and NAP-ERL 30-70% 
a concentration of 0.121 mg/ml. 
Cinnarizine solid dispersions 
Spray dried solid dispersions of CINN, again at 30% w/w, showed very similar dissolution 
behavior when formulations with PVP, ERL, or a combination of both was applied (Figure 6.8). 
 
Figure 6.8: CINN concentrations in function of time of spray dried solid dispersions of CINN 
30% with different polymers (or combinations). CINN-PVP 30-70% is represented in blue, CINN-
PVP-ERL 30-35-35% in grey and CINN-ERL 30-70% in orange. Dissolution is performed in an 
acetate buffer pH 4.5. CINN solubility is represented by a black dashed line. 
 All formulations gave rise to concentrations above CINN solubility (0.033 mg/ml). Highest 
drug concentrations were measured immediately (at 5 min) for CINN-PVP 30-70% and CINN-
PVP-ERL 30-35-35 % and were 0.241 mg/ml and 0.209 mg/ml respectively. In CINN-ERL 30-
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70% the highest drug concentration (0.159 mg/ml) was reached after 30min. All formulations 
showed a steep concentration decline and reached concentrations of about 0.043-0.053 mg/ml 
at 24h, which is close to CINN solubility. 
6.3.3 Solid state characterization of dissolution precipitates 
Topography 
Dissolution precipitates were analyzed by SEM, after filtering and drying. Figure 6.9 
represents micrographs of INDO-PVP 30-70% (Figure 6.9A), INDO-PVP-ERL 30-35-35% 
(Figure 6.9B) and INDO-ERL 30-70% (Figure 6.9C) precipitates. The INDO-PVP precipitate 
clearly showed needle shaped structures which could represent crystalline INDO. The needle 
shaped crystals were clustered in a group of particles of around 30 µm. INDO-PVP-ERL and 
INDO-ERL did not show needle shaped structures, but spherical shaped particles which were 
more (INDO-PVP-ERL) or less (INDO-ERL) agglomerated into bigger particles. 
 
Figure 6.9: SEM micrographs of dissolution precipitates of INDO-PVP 30-70% (w/w) (A), INDO-
ERL-PVP 30-35-35% (w/w) (B) and INDO-ERL 30-70% (w/w) (C) 
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Thermal analysis  
 Precipitates from INDO solid dispersions 
After dissolution, filtered and dried precipitates of all INDO formulations were analyzed by 
mDSC. Thermograms are displayed in Figure 6.10.  
 
Figure 6.10: mDSC thermograms of dissolution precipitates of 30% INDO. In panel A, INDO-
PVP-ERL 30-52.5-17.5% is represented in blue, INDO-PVP-ERL 30-35-35% in green, INDO-PVP-
ERL 30-17.5-52.5% in black and INDO-ERL 30-70% in pink. Reversing heat flows are given in 
full lines, the 1st derivative of the reversing heat flows in dashed lines. Panel B represents the 
total heat flow of INDO-PVP 30-70% (red). Arrows indicate glass transitions. 
Figures 6.10 A and 6.10 B represent 30% INDO loading. Here all precipitates from 
formulations containing ERL showed to be single phase amorphous. Mean glass transition 
temperatures were 55.1 °C, 58,6°C, 57,3°C and 67.6°C for INDO-PVP-ERL 30-52.5-17.5%, 
INDO-PVP-ERL 30-35-35%, INDO-PVP-ERL 30-17.5-52.5% and INDO-ERL 30-70% 
respectively (Figure 6.10 A). INDO-PVP 30-70% showed 2 melting peaks (Figure 6.10 B). The 
largest peak was at 148.1°C and the smallest one at 157.7°C. 
INDO-ERL 50-50% showed a single glass transition temperature at 49.5°C, while INDO-
PVP-ERL 50-25-25% showed a double glass transition. The first Tg was at 52.8°C, the second 
at 77.1°C. INDO-PVP 50-50% showed 2 melting peaks The largest peak was at 146.8°C and 
the smallest one at 157.4°C. The thermograms of this analysis are displayed in the 
Supplementary data (Supp. Figures A1 and A1’). 
Both INDO-ERL 10-90% and INDO-PVP-ERL 10-45-45% showed one glass transition at 
52.9°C and 53.0°C respectively. INDO-PVP 10-90% showed 2 melting peaks of which the 
largest was at 145.4°C and the smallest at 155.9°C. These thermograms are shown in the 
supplementary data section (Supp. Figure A2 and A2’). 
Precipitates from NAP solid dispersions 
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In the mDSC precipitate analysis of NAP formulations, surprisingly, all total heat flow signals 
showed melting peaks at 154.7°C, 141.5°C and 150.9°C for NAP-PVP 30-70%, NAP-PVP-ERL 
30-35-35% and NAP-ERL 30-70% respectively. NAP-PVP 30-70% showed the largest peak and 
this was closest to the melting point of NAP (156°C). Formulations containing ERL showed 
significant melting point depression and were the smallest melting peaks. Thermograms 
concerning NAP precipitate analysis are presented in the supplementary data (Supp. Figure B). 
Precipitates from CINN solid dispersions 
Reversing heat flow signals of CINN-PVP-ERL 30-35-35% and CINN-ERL 30-70% showed 
single glass transitions at 48.8°C and 50.5°C respectively. All formulations showed a melting 
peak situated at 119.2°C, 118.2°C and 115.2°C for CINN-PVP 30-70%, CINN-PVP-ERL 30-
35-35% and CINN-ERL 30-70% respectively. The higher the amount of ERL in the formulation, 
the smaller and more depressed the precipitate melting peak was. Thermograms of 
precipitates of CINN formulations are presented in the supplementary data (Supp. Figure C1 
and C2). 
Presence of drug crystals 
INDO and NAP precipitates were analyzed by XRPD. Diffractograms of INDO precipitates, 
together with the γ - and α - polymorphic form of INDO, are shown in the supplementary 
data (Supp. Figure D). All solid dispersion precipitates consisting of (a mixture with) ERL were 
amorphous since Bragg peaks were not observed. Precipitates of INDO-PVP 30-70%, INDO-
PVP 50-50% and a physical mixture of INDO-PVP and INDO-ERL 50-50% all generated Bragg 
peaks matching the ones from α -INDO. 
Diffractograms of NAP precipitates are shown in the supplementary data (Supp. Figure E). 
Precipitates of NAP-PVP-ERL 30-35-35%, either filtered and dried before measurement or 
analyzed immediately after filtering generated Bragg peaks characteristic of crystalline NAP. In 
the former, the amorphous halo of ERL is visible. 
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6.3.4 Drug Sorption 
In a first set of experiments, NAP and CINN sorption onto/into ERL was tested. NAP 
(0.083mg/ml) and CINN (0.019 mg/ml) were tested in a concentration close to their solubility. 
A second NAP concentration (0.027 mg/ml) was tested close to CINN solubility. Figure 6.11 
A shows API concentrations in function of ERL concentration.  
 
Figure 6.11: Sorption plots of NAP and CINN in presence of ERL in acetate buffer pH 4.5. 
Orange line and bars represent a 0.083 mg/ml NAP concentration, Blue line and bars a 0.027 
mg/ml NAP concentration and grey line and bars a 0.019 mg/ml CINN concentration. Panel A 
plots API concentrations in function of ERL concentration. Panel B plots the amount of API 
sorbed per amount of ERL present in function of ERL concentration. 
Up until an ERL concentration of 2 mg/ml, NAP concentrations decreased greatly. The 
concentration decrease of the highly-concentrated NAP solution was higher than that from 
the low concentrated solution. CINN concentrations on the other hand only marginally 
decreased. In figure 6.11 B, the amount of API sorbed (µg) per amount of ERL (mg) is plotted 
in function of ERL concentration for all 3 solutions. The amount of API sorbed per amount 
ERL decreased in function of increasing ERL concentration for all solutions, although only 
marginally for the CINN solution. The decrease was largest for the highest NAP 
concentration. 
The sorption behavior was determined for INDO and NAP (Figure 6.12). The slope of the 
regression line represents 1/ym according to Eq.1. The ym value of the INDO sorption was 1.14 
mg INDO per mg ERL, and 1.51 mg NAP per mg ERL for the NAP sorption. 
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Figure 6.12: INDO (A) and NAP (B) sorption isotherms in presence of ERL in acetate buffer pH 
4.5, modelled to the Langmuir model 
6.3.5 Nanocrystal formation 
During solubility testing of INDO and NAP in presence of ERL, nanocrystal formation was 
observed after ca. 48h in case of NAP and after ca. 240h in case of INDO. Particle size were 
measured using DLS and size distributions are shown in Figure 6.13 for INDO and NAP 
nanocrystals.  
 
Figure 6.13: DLS particle size measurement of INDO (black full line) and NAP (red dashed line) 
nanocrystals in presence of 0.5 mg/ml ERL. 
Both API’s showed two particle size distributions. INDO nanocrystals showed two peaks 
with a mean peak position at 4.2 nm for the peak with the smallest intensity and at 32.0 nm 
for the peak with the largest intensity. For NAP nanocrystals, the smallest intensity peak had 
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a mean peak position of 16.1 nm and the largest intensity peak a mean peak position of 71.0 
nm. Nanocrystal formation was not observed for CINN. 
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 Discussion 
The rationale for the current study was to find an answer to the question to what extent 
ERL, being an insoluble but swellable polymer, can, as (part of) the solid dispersion carrier 
slow down or stabilize the drug precipitation which is hampering the full exploitation of the 
potential of amorphous solid dispersions to increase the oral bioavailability. Precipitation in 
the gastrointestinal tract is often observed after administration of solid dispersions that are 
only made up of a hydrophilic carrier. The combination of ERL with the hydrophilic PVP should 
also potentially allow for sufficiently high initial drug concentrations, which is lacking when only 
a hydrophobic polymer is used as a solid dispersion carrier. 
6.4.1 Phase behavior of solid dispersions containing ERL 
SEM images of INDO solid dispersions showed topographical differences as different 
polymers or combinations of polymers were used. When PVP was used as a carrier, the largest 
particles were generated which also had the most irregular surface. Spray drying a 10% ethanol 
solution of INDO-PVP-ERL 30-35-35% generated particles of roughly 1-4 µm. These particles 
were spherical and had a smooth surface. INDO-ERL particles had similar size and shape, but 
the surface was somewhat more irregular. Shape and size differences can be attributed to the 
different drying kinetics of the different formulations during spray drying. Polymers made up 
70% of all formulations, hence their properties will have a considerable influence on the final 
size, shape and topography of the produced particles. 
mDSC analysis showed that spray drying INDO-polymer 30-70% (w/w) combinations 
generated glass solutions, irrespective to the fact that the polymer fraction was ERL, PVP or a 
combination of both. All glass transitions were found between the Tg’s of the single 
components of INDO (47 °C), ERL (60.8 °C) and PVP K25 (156.8 °C) with 30% INDO loading. 
Moreover, glass transitions of all formulations corresponded well to theoretical glass transition 
temperatures calculated with the Gordon-Taylor (G-T) equation 22. Measured Tg of INDO-
PVP 30-70% showed the highest deviation compared to the G-T temperature, being 5°C 
lower. This was due to the hygroscopic properties of PVP, and hence the plasticization effect 
of water. When the INDO loading was changed to 50%, glass solutions were also formed in 
all carrier compositions. It was noted though, that Tg width was increased to 27,7°C for 
INDO-PVP 50-50% and 21,2°C for INDO-PVP-ERL 50-25-25%. INDO-ERL 50-50% had the 
narrowest Tg width of 15.9 °C. INDO-PVP 50-50% also showed to have 2 minima in the 
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thermogram of the 1st derivative of the reversing heat flow (Figure 6.2B). This, together with 
the wide Tg is the consequence of a more heterogeneous system 
23. INDO-ERL, on the other 
hand, still showed a homogeneous glass solution at 50% drug loading. When INDO loading 
was reduced to 10% (Figure 6.2C), glass solutions were still formed for INDO-PVP 10-90% 
and INDO-ERL 10-90% with glass transition temperatures moving closer to pure polymer Tg’s. 
INDO-ERL 10-90% even has a higher Tg (64.1°C) than the one of pure ERL, this can point to 
strong drug-polymer interactions. INDO-PVP-ERL 10-45-45% showed 2 Tg’s, one close to the 
Tg of ERL and one closer to the Tg of PVP. This formulation showed to be a phase separated 
system. This is understandable since the proportion of polymers in the system is the highest 
with only 10% drug loading and we recently showed that ERL and PVP as such are only partially 
miscible 24. Hence, when the drug loading was high enough (>10% w/w), INDO could make a 
partially miscible polymer system fully miscible and thus acts as a blending agent for PVP and 
ERL. 
Spray dried NAP solid dispersions presented different phase behavior (Figure 6.3 and 6.5). 
NAP-ERL 30-70% showed a melting peak pointing to the presence of a crystalline phase, as 
confirmed by XRPD where NAP-ERL 30-70% Bragg peaks matched the ones of crystalline 
naproxen. This solid dispersion was partly crystalline and partly amorphous since it still had a 
Tg at 33.0°C, which is between that of pure ERL and NAP (ca. 6°C 
25). Contrary to NAP-ERL 
30-70%, NAP-PVP 30-70% and NAP-PVP-ERL 30-35-35% did form glass solutions.  
CINN based solid dispersions all showed a melting peak in the total heat flow (Figure 6.4B) 
and a glass transition in the reversing heat flow (Figure 6.4A). None of the formulations was a 
glass solution, as they were partly amorphous and partly crystalline. It should be noted though 
that the melting peak in CINN-PVP 30-70% was much smaller compared to that in the other 
two formulations.  
Having tested different API’s and API ratios, it can be concluded that ERL can be used as a 
polymeric carrier for solid dispersions, either alone or in combination with a hydrophilic 
polymer like PVP K25.  
6.4.2 In vitro dissolution and supersaturation of solid dispersions containing ERL 
All formulations containing 30% INDO reach concentrations well above the INDO 
solubility level (Figure 6A). While the conventional solid dispersion using PVP as a carrier 
showed a fast concentration increase and a fast-subsequent precipitation of INDO, solid 
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dispersions containing ERL adequately retained elevated concentration levels (i.e. 
supersaturation). This hardly decreased during 24h. The higher the PVP ratio in carriers with 
PVP and ERL, the more the concentration dropped at 24h, but all were higher than the INDO-
PVP solid dispersion. Although INDO-ERL reached concentrations above INDO solubility, as 
already shown in the past 21, a mixture of ERL and PVP combined the higher concentration 
levels observed with PVP with the supersaturation stabilization observed with ERL. An ERL 
ratio of merely 17.5% could already effectively stabilize supersaturation level for 24h, which 
translated in an area under the curve (AUC) which was 42% higher compared to that of INDO-
PVP. It is well known that generation of supersaturated drug concentrations in the 
gastrointestinal tract can lead to enhanced flux across the intestinal wall and hence increased 
drug absorption27, 28. The higher AUC value observed with ERL based solid dispersions suggests 
their potential as supersaturation maintaining drug delivery systems and it may be worthwhile 
to explore this further in vivo. It has to be noted as well that initial drug dissolution is highest 
in glass solutions containing an ERL-PVP mixture as carrier. This effect, which is visible in the 
first 30 minutes of the in vitro drug dissolution (Figure 6A), can be attributed to a smaller 
particle size (Figure 1) and a the ability to avoid agglomeration of powder particles due to the 
presence of the hydrophobic ERL. These higher initial drug concentrations can be put forward 
as an additional advantage of incorporating ERL in these glass solutions (although this effect is 
only visible in 30% drug loading). 
At 50% INDO loading, similar observations could be made (Figure 6.6B), although INDO-
ERL 50-50% concentration never went above the INDO-PVP 50-50% concentration level. 
Interestingly, a 1:1 physical mixture of these two formulations generated a profile similar in 
shape to INDO-PVP, but at consistently higher concentration levels from 2 hours on. This is 
a large difference from the INDO-PVP-ERL 50-25-25% formulation, which has the same 
composition, but was spray dried as a single powder. In the physical mixture, it can be argued 
that INDO-PVP could immediately dissolve, resulting in higher concentrations, but there was 
also the stabilizing effect of INDO-ERL. 
When the INDO content in solid dispersions was further decreased to 10% (Figure 6.6C), 
INDO-PVP outperformed both INDO-PVP-ERL 10-45-45% and INDO-ERL 10-90%, with this 
last formulation not even surpassing the INDO solubility level. Because ERL is an insoluble 
polymer, its ratio in these formulations is simply too high. INDO cannot sufficiently diffuse out 
of the ERL matrix within reasonable time frames. Although a higher amount of carrier usually 
results in higher solubilization or stabilization during dissolution in case hydrophilic polymers 
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are used as carrier, a low drug content in the insoluble ERL containing solid dispersions leads 
to the opposite effect since the drug cannot diffuse out of the matrix. 
While formulations were previously tested in an acetate buffer pH 4.5, they were also 
tested in an HCl solution of pH 1.2 (Figure 6.6D). In this environment, INDO was completely 
unionized, which lowers its solubility. In this medium, all formulations performed equally, 
despite having different polymer compositions or drug loadings. A reason for this difference is 
the decreased solubility, and/or the inability of a charge interaction between INDO and ERL 
which has been shown previously 29. 
NAP solid dispersions performed slightly different (Figure 6.7). NAP-PVP had a much less 
pronounced solubility increase (above NAP solubility) with subsequent precipitation. But here 
a similar benefit of ERL as a carrier can be observed. While dissolution is not as fast as in case 
of NAP-PVP, the solubility increase after 24h is clearly higher than NAP-PVP. What is also 
noticeable is that NAP-ERL and NAP-PVP-ERL have similar dissolution profiles, while both 
clearly show different phase behavior with NAP-PVP-ERL being a glass solution and NAP-ERL 
being partly crystalline. It should be noted as well that NAP has a pKa of 4.15, so part of it will 
be ionized, with a possibility of a charge interaction with ERL. 
CINN solid dispersions have similar dissolution profiles with the different carriers tested. 
Drug concentrations start off high, but drug precipitation happens fast for all formulations. 
CINN as a fast crystallizer, does not seem to be suited to be formulated as a solid dispersion. 
There is also no possibility for a charge interaction between ERL and CINN, since it has a pKa 
of 8.4. This interaction seems to be beneficial for the performance of solid dispersions 
containing ERL. 
6.4.3 Phase behavior of dissolution precipitates 
The precipitation formed in the dissolution vessels was analyzed at the end of the in vitro 
dissolution tests (24h). From the SEM analysis, it can be clearly noticed that INDO-PVP 
precipitates contained INDO crystals (Figure 6.9A). In INDO-PVP-ERL (Figure 6.9B) and 
INDO-ERL (Figure 6.9C) these crystals are not visible. Moreover, the spherical particles seem 
to be preserved, although they have agglomerated to some extent. These findings were 
confirmed with mDSC. INDO-PVP 30-70% was crystalline as can be seen from the total heat 
flow curve (Figure 6.10B), where two melting peaks are visible, suggesting a polymorphic 
transition. All ERL containing precipitates remained completely amorphous (Figure 6.10A). 
Broadening the Scope of Amorphous Solid Dispersions 
 
150 
 
When a combination of ERL and PVP was used as a carrier, Tg’s of precipitates were lower 
than the Tg’s of the corresponding solid dispersions. This is because the PVP fraction dissolved 
and is not found in the precipitates. INDO-ERL 30-70% precipitate has a higher Tg, compared 
to the corresponding solid dispersion. Since solid dispersions are sprayed from an ethanol 
solution, no charge interaction could have taken place during the production of the solid 
dispersions. During dissolution on the other hand, INDO is partly ionized in the medium, 
allowing for a charge interaction with ERL. This strong interaction is the reason for a higher 
Tg in the precipitate. These amorphous precipitates can be beneficial in the situation were a 
poorly soluble drug has a high permeability. If the API is permeated through the gastro-
intestinal barrier easily, this could create a situation where amorphous drugs can be released 
from an ERL ‘reservoir’ system and this could lead to higher release than a crystalline 
precipitate that should overcome the crystal lattice energy to dissolve. The amorphous 
precipitate can also be the reason why no crystalline precipitation is observed during in vitro 
dissolution of INDO-(PVP-)ERL solid dispersions. Since INDO has to diffuse out of the ERL 
matrix, a more gradual release is achieved and the propensity for nucleation and crystallization 
is not as high as when all INDO is dissolved into the medium directly 21. 
In 50% and 10% INDO loadings, similar observations could be made (Supp. Figure A). 
Precipitates from PVP solid dispersions showed a double melting peak and solid dispersions 
containing ERL remained amorphous. Tg’s were generally lower because of the absence of PVP 
in ERL-PVP precipitates. INDO-PVP-ERL 50-25-25% precipitate showed to be a phase 
separated system (double Tg). It cannot be ruled out that a fraction of PVP was trapped in the 
ERL matrix or only part of ionized INDO formed a charge interaction with ERL, leading to a 
higher second Tg 
The double melting peak suggested a polymorphic transition of crystalline INDO. This was 
confirmed by XRPD analysis where crystalline precipitates showed Bragg peaks corresponding 
to the α -form of INDO (Supp. Figure D). This is a well-known and identified polymorphic 
transition during dissolution of amorphous INDO 30, 31. No Bragg peaks of the γ -form of 
INDO can be seen in XRPD results, so the double melting peak can be attributed to a 
polymorphic transition during heating in mDSC. XRPD also did not show Bragg peaks in 
precipitates containing ERL, confirming the presence of amorphous INDO in these carriers. 
NAP and CINN precipitates all showed melting peaks in the total heat flow signal (Supp. 
Figures B and C respectively). This shows that the crystallization of a drug in the medium is 
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highly dependent on its physicochemical properties like crystallization behavior 32. The 
crystallinity of NAP-PVP-ERL precipitates was confirmed in XRPD (Supp. Figure D). To 
exclude phase transformations during drying, the precipitates were analyzed after filtration 
(wet) and after filtration and drying (dry). Since the Bragg peaks can be observed in both 
samples, the crystallinity was not induced during drying. 
6.4.4 Sorption of drugs onto/into ERL 
INDO sorption has been extensively studied in a previous publication from our group 29. 
NAP sorption was confirmed for 2 starting concentrations. In the highest initial NAP 
concentration, the decrease in concentration was the highest with increasing ERL 
concentration (Figure 6.11A). On the other hand, the amount of NAP sorbed into/onto ERL 
decreased with increasing ERL concentration (Figure 6.11B), this leads to the identification of 
two driving forces for sorption into/onto ERL: the initial drug concentration and the 
concentration of ERL in the medium. By maximizing the former and minimizing the latter, 
optimal sorption can be achieved. CINN sorption was generally low which can be attributed 
to the absence of a charge interaction between drug and polymer, reducing the driving force 
for sorption. In a second sorption experiment, sorption of INDO and NAP was modelled to 
the Langmuir model (Figure 6.12). A higher ym value for NAP was observed, indicating its higher 
sorption potential, compared to INDO. 
6.4.5 Nanocrystal formation in presence of ERL 
Surprisingly, the formation of nanocrystals was observed during solubility measurements of 
INDO and NAP in presence of ERL in acetate buffer (pH 4.5). This nanocrystal formation was 
not observed in solubility measurements of pure INDO or NAP, or in presence of PVP. The 
difference in time it took to observe the nanocrystals varied between NAP and INDO, and 
this can most likely be attributed to their different crystallization behavior 32. It was also shown 
that the size of the formed nanocrystals is in the lower part of the nanometer range. It has to 
be noted that no stabilizer is added here, although this is generally recognized as an absolute 
necessity to produce stable nanosuspensions 33. The mechanism of formation of the 
nanocrystals is schematically explained in Figure 6.14.  
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Figure 14: Schematic representation of nanocrystal formation in presence of ERL. 
There are 3 steps in the formation of nanocrystals: dissolution of native drug crystals in the 
medium, sorption of the drug in or on (hydrated) ERL particles and desorption into the release 
medium. The desorption into the medium will result in nucleation and nanocrystal formation 
because the drug solubility has already been reached in the medium. It also means that an 
oversaturated drug solution is necessary to obtain nanocrystals, because the drug solubility 
has to be maintained at every moment, also when part of the drug in solution is sorbed into 
the ERL particles. Because sorption and desorption are dynamic processes, the desorbed drugs 
arrive in a saturated dissolution medium and crystallize upon arrival. This particular formation 
of nanocrystals can be seen as a start to develop new production methods for 
nanosuspensions. Moreover, not only has this method the potential to be further developed 
as a new method to produce nanocrystals, if drug and ERL are simultaneously introduced in 
the gastro intestinal tract in appropriate ratios, ERL could form nanocrystals ‘in-situ’. The main 
challenge will be the adjustment of nanocrystal formation within pharmaceutically relevant 
time scales. Since CINN did not form nanocrystals, high sorption into ERL and/or a charge 
interaction seem to be necessary requirements for this kind of nanocrystal formation.  
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 Conclusions 
The feasibility of Eudragit® RL as a carrier for solid dispersions was assessed in this paper. 
Phase behavior studies showed that ERL can form glass solutions, either alone or as part of a 
binary polymer mixture with a hydrophilic polymer (PVP K25). In vitro dissolution tests 
showed that ERL can form and stabilize supersaturated drug concentration levels. Optimal 
concentration profiles however, are observed in combination with PVP, where an ideal 
combination of high concentration and prolongation of these concentration levels are 
achieved. Dissolution precipitates of INDO formulations with ERL remained amorphous, 
which can be beneficial to obtain high drug permeability. 
The unexpected formation of INDO and NAP nanocrystals was observed in presence of 
ERL. Nanocrystals were on the lower end of the nanometer scale and were stable without 
addition of stabilizers. An interplay of dissolution, sorption and desorption is hypothesized as 
responsible for nanocrystal formation. Sorption of the drug into/onto ERL is a necessary 
condition for nanocrystal formation. Charge interactions between drug and ERL can enhance 
or promote sorption. Nanocrystal formation in presence of ERL can be further investigated 
as a potential new manufacturing method and/or can be exploited for ‘in-situ’ nanonization. 
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During this project, attempts were undertaken to tackle some of the shortcomings or 
disadvantages of amorphous solid dispersions, or more specifically, glass solutions. Some 
stability issues are caused by residual solvent presence or additional processing steps like 
milling or compression 1, 2. Fluid bed coating as a manufacturing method of solid dispersions 
can address these issues since efficient drying can be achieved during and post formation 
without additional transfer steps. While the solubility/dissolution rate of solid dispersions, 
produced with fluid bed coating has been investigated previously 3-5, not much is known about 
the phase behaviour of these coated solid dispersions around an inert carrier. 
Secondly, glass solution formulations can suffer from fast precipitation of supersaturated 
drug concentrations 6. In this context, an additional coating layer can be applied on top of the 
glass solution through fluid bed coating providing controlled drug release kinetics, to transform 
fast dissolving but fast precipitating delivery systems into sustained release formulations, 
effectively enhancing the window for absorption. Different formulation parameters can 
influence drug release. These complex coated systems do not generate formulations with a 
straight forward phase behaviour, therefore a combination of bulk and surface characterization 
methods was applied. 
Lastly, instead of using an additional coating layer to control the release of glass solutions, 
an aqueous insoluble but swellable polymer was incorporated as (part of) the carrier of a glass 
solution, prepared by spray drying. The influence of different formulation parameters on the 
phase behaviour and the generation and maintenance of supersaturation was tested. 
 mDSC method development for glass solutions coated on inert 
carriers 
To investigate the phase behaviour of coated glass solutions on inert carriers, mDSC 
analysis was performed (chapter 3). Since previously published research did not use mDSC, 
or sample preparation was not explicitly mentioned or discussed, in a first set of experiments 
beads were loaded as such into the DSC sample pans without any success. The very small 
contact area between the spherical beads and the surface of the sample pan resulted in 
undetectable phase transitions apart from the sucrose melting peak of the inert carriers. Softly 
grinding the beads to enhance the contact area did not result in visible glass solution transitions 
either. What did result in detectable glass transitions, was grinding and sieving the beads to 
obtain particles with different size ranges. From the resulting derivatives of the reversing heat 
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flows, it could be observed that the Tg decreased and broadened when particles increased in 
size. Because simply grinding the beads generates a collection of these particles with different 
sizes, all these glass transitions would be overlapping and less pronounced, hence resulting in 
a very broad and shallow glass transition which would be undetectable. The Tg shifting and 
broadening was confirmed in glass solution films prepared by rotary evaporation. Later, 
different API’s and even different solvents (or solvent mixtures) showed similar phenomena. 
The Tg shift and broadening was attributed to different residual solvent mass losses below and 
above the Tg of the sample, due to large differences in surface area to mass ratios. 
These findings highlight that it is tricky to analyse glass solutions which have high variations 
in particle size range. Because of the solvent involvement, the particle size influence on the Tg 
will only be a factor to take into consideration when analysing glass solutions prepared by 
rapid solvent evaporation. Some glass solutions, like KETO-PVP prepared from an ethanol 
solution or INDO-PVP prepared from DCM or DCM-MeOH solutions even showed double 
glass transitions in particles with an intermediate particle size range. This could be wrongly 
interpreted as a phase separated system since a double Tg is normally an indicator for different 
drug-polymer domains.  
It is very useful to take these findings into consideration when using different solvent based 
manufacturing methods as well. Since in spray drying, the particle size distribution is normally 
smaller, the effect will be less pronounced within one batch of spray dried glass solution. But 
since it is known that process and formulation parameters can influence the resulting particle 
size of spray dried powders7, varying these parameters or even using different spray dryers 
(e.g. in scaling up development), can result in unwanted shifting and broadening of glass 
transitions due to residual solvent mass loss. Often, small scale glass solution preparation by 
solvent evaporation is used for screening purposes. Here, glass solution films are prepared to 
have a quick idea about the feasibility of the preparation method and the phase behaviour of 
the produced glass solutions. When analysing these films by DSC, it is also possible that they 
are crushed, generating particles with a large size range and encountering these phenomena 
which can lead to false exclusion of the formulation for further research or development. 
Attention should be drawn as well to the use of TGA in this study. While a linear heating 
regiment provided residual solvent contents, which were comparable for particles with 
different size ranges, a differentiation between sub-Tg and above-Tg solvent loss allowed to 
correlate the (lack of) sub-Tg solvent loss to the observed glass transition shifting and 
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broadening. It is advised, when performing TGA analysis, to measure solvent mass loss below 
and above the glass transition of the glass solution. By doing this, more specific information is 
provided about the kinetic phenomena of solvent loss, and not just the total amount of residual 
solvent present in the sample, also providing possible links with observed thermal events or 
differences in thermal events of different samples. 
Is this mDSC method now the ideal method for characterizing the phase behaviour of glass 
solutions, coated on inert carriers? The answer to this question is twofold. First of all, the 
instrument set-up doesn’t allow to analyse the coated beads as such, due to the very small 
contact area between spherical beads and the flat bottom of the aluminium pans, so sample 
manipulations for mDSC analysis will always be necessary. Grinding and sieving the beads 
requires external forces to be applied to the glass solution which can potentially be detrimental 
to the system since solid state transformations can be provoked. To exclude crystallization of 
the system for example, XRPD analysis can be performed together with mDSC analysis. Here, 
beads can be analysed as such, and grinding or sieving induced crystallization can be excluded. 
Kovacevic et al. recently published an alternative mDSC method to analyse drug-polymer 
coated beads. They were able to perform mDSC experiments by analysing free films with 
identical composition to the layered beads 8. While this method doesn’t require external 
forces to be applied to the system, the film formation process is not identical compared to 
the film formation process in fluid bed coating. In the formation of free films, a different 
substrate, drying environment (temperature, pressure difference) and drying time are all 
different which can lead to films with different physicochemical properties. 
Instead of adjusting the sample to the needs of the analysis technique, the opposite can be 
done as well. When looking at alternative techniques that can cope with the coated bead 
geometry in a better way, microthermal analysis (MTA) techniques come into the picture 9. 
Because of the ‘scanning’ or spatially resolved nature of these techniques, not the whole 
sample is analysed, but a surface on the sample with micrometer dimensions by heating an 
AFM probe tip. This could be easily performed on the surface of a bead. It would be very 
interesting to compare one of these localized techniques to the mDSC method to investigate 
if differences in phase behaviour can be observed between the two techniques. On the other 
hand, it could also provide an alternative analysis technique to measure the solvent poor 
surface and the solvent rich bulk of the glass solution described in this chapter. 
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 Surface and cross-sectional chemical analysis of multilayer coated 
beads 
By adding an additional coating layer on top of the INDO-PVP glass solution to control the 
drug release, bulk characterization methods like mDSC were insufficient to investigate the 
physical structure of the obtained coated beads. To have an idea about the composition and 
distribution of the different compounds in these coated beads, imaging (or spatially resolved) 
techniques were applied. ToF-SIMS is very well suited to accommodate these needs, since it 
has a very low detection limit, and high spatial resolution. Furthermore, because the primary 
ion beam only removes the first few monolayers of a sample, the very limited penetration 
depth (1-2 nm)10 makes it an ideal method to even detect distributional changes at the upmost 
surface layer or within a coating layer when analysing cross sections, without possible blurring 
effects due to sample curvature. ToF-SIMS was also recently successfully applied in different 
studies concerning spray dried solid dispersions to form sustained release injectables 10-15. 
From the results described in chapter 4 it can be concluded that ToF-SIMS proved to be 
very useful in the characterization of complex coated beads. The analysis of the surface and 
cross-sections of the beads allowed for a complete chemical analysis of the presence and the 
distribution of all compounds. High specificity could be achieved through specific marker ions 
of all compounds, which were five in total in case of the cross sections. Even chemically similar 
compounds like EC and sucrose from the inert carriers could be successfully distinguished 
from one another. Because of the size and spherical shape of the beads, only the upmost part 
of the sample could be analysed with ToF-SIMS. Therefore, the entire 200×200 µm analysis 
area was not covered in the surface analysis. The available spectra and images could still 
provide an accurate compositional and distributional analysis of the surface. All surfaces were 
also analysed in triplicate to exclude artefacts on the surface. 
The presence of the PVP marker on the surface of the beads with an ERL or EC top coating 
can be explained by a coating contamination since both the glass solution and controlled 
release layer are coated consecutively without unloading the beads and cleaning the device in 
between the spraying cycles. It is highly unlikely to assume that the entire INDO-PVP solution 
was sprayed onto the beads. Some of the spraying solution was also sprayed on either the 
coating chamber walls or the inside of the Würster cylinder. Since the coated beads do not 
follow exactly the same patterns inside of the fluidized bed device, it is quite possible that they 
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collide with a dried glass solution powder particle residing inside of the coating device. This 
can explain the presence of PVP on the outer surface of the beads. The presence of the INDO 
marker ion of these outer surfaces is also seen but less clear compared to the PVP marker 
presence. This could be explained by the fact that in the glass solution, the ratio between 
INDO and PVP is 30% to 70% (w/w) of the respective compounds. Furthermore, the maker 
ion intensity in the control sample of PVP (5.2*10-2) is more than double compared to the 
intensity of the INDO marker in the control sample (2.37*10-2), hence the lower intensity and 
detection of this marker ion on the surface. ToF-SIMS analysis of the cross sections showed 
that there are no PVP channels being formed in the outer coating layer, excluding the 
possibility of polymer migration to the surface.  
Cross-section analysis showed a very limited migration of PVP and mainly INDO across 
controlled release membranes, irrespective of their constitutions, through a gradient in 
marker intensity from the inner part to the outer part of the membrane. The fact that this 
migration was most prominent in the ERL latex formulation, was explained by a combination 
of a higher coating temperature, additional curing and/or the slower evaporation of water 
compared to ethanol in the controlled release membranes sprayed from a solution. These 
factors lead to a limited migration which also disproves the PVP presence on the surface as a 
result of polymer migration. It does, however, point to the influence of the spraying liquid 
(water vs. ethanol) on this migration. It would be very interesting to further investigate the 
influence of different formulation and process parameters on this migration and to possibly 
correlate this to drug release phenomena.  
Another interesting observation made with ToF-SIMS was the distribution of INDO and 
PVP in the glass solution layer of the coated beads. In chapter 3 it was already established by 
mDSC that INDO-PVP 30-70% (w/w) forms glass solutions when layered on sucrose beads. 
When analysing the surface and cross-section of INDO-PVP coatings, clear moieties of both 
components are observed together with their distribution along the surface and cross-section, 
which results in an image of drug-polymer mixing. It would be interesting to analyse a solid 
dispersion that is simultaneously analysed with mDSC as a phase separated or crystallized 
system with ToF-SIMS to investigate distributional changes in the image. The link between 
phase separation/crystallization with distributional changes in ToF-SIMS images could result in 
a more profound understanding of this phenomenon The relatively large size of the coated 
beads (compared to spray dried powder particles) lends itself ideally to this kind of 
investigation. 
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 Polymer miscibility in controlled release coatings 
The importance of polymer miscibility in the release controlling outer membrane of the 
complex coated beads is demonstrated in chapter 4 and 5. The partial miscibility between ERL 
and PVP proved to be advantageous in the attachment of the controlled release membrane to 
the glass solution layer, the more homogeneous distribution of PVP along the surface when 
incorporated as a pore former and, finally, its influence on INDO release. When PVP was 
added as a pore former to EC in a ratio of 25% (w/w), this resulted in immediate release of 
INDO because of coating defects in the controlled release layer. These coating defects are 
isolated PVP domains in the controlled release layer, formed due to the immiscibility of both 
polymers. In ERL based rate controlling membranes, a 25% PVP incorporation as a pore former 
does not lead to such coating defects and the subsequent immediate release of INDO. This 
shows the impact of pore former miscibility on the ability of the controlled release coating 
layer to stay intact during dissolution and thus maintain its modified release properties. 
 Influence of formulation changes on the sustained in vitro release 
of INDO 
Coating layer thickness increase leads to slower and decreased INDO release with an 
increased lag time in all formulations (except a defective coating), irrespective of their 
constitution. This can be attributed to increased diffusion pathways16, a denser polymer 
network and sorption to the controlled release polymer. The influence of pore former 
concentration on the release of INDO was dependent on the controlled release polymer used. 
When ERL was applied there was little difference between 10% and 25% PVP, but in case that 
EC was used, there is a large difference in release. This can again be brought back to the 
difference in miscibility discussed in the previous section. Coating from an ethanol solution or 
an aqueous dispersion showed release differences at higher coating levels such as a lower level 
of burst release and quasi-zero order release after 90 minutes. Lastly, when comparing both 
controlled release polymers, ERL generally showed higher and faster release compared to EC 
samples, ERL also showed burst release while EC samples showed an extended lag time. In 
general, when choosing appropriate formulation parameters, adding a membrane to control 
or sustain drug release from glass solutions is a viable option to possibly extend the absorption 
window of solid dispersions. More extensive (in vivo) release studies, where direct and 
controlled release solid dispersions are compared, might elucidate this option even further.  
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Diffusion tests through rate controlling membranes generally show similar trends when 
varying formulation parameters compared to release tests, which lead to the conclusion that 
drug diffusion is the rate limiting step for drug release. On the other hand, it would also 
provide a good screening method for selecting the ideal controlled release coating formulation, 
depending on the requirements and needs of the drug delivery system. 
Another objective investigated in this chapter is the possibility of a charge interaction 
between the drug and rate controlling polymer influencing the release. When INDO is 
introduced in an aqueous medium with a pH above its pKa (4.5), it is ionized. ERL on the other 
hand possesses quaternary ammonium groups which give the polymer its swelling capacity in 
aqueous media 17. It has already been shown that drug release from ERL formulations can be 
sensitive to the presence of anionic species in the release buffer18 or organic acids 19. For this 
reason, it was hypothesized that INDO release would be altered by this charge interaction as 
well. While the interaction between both components was confirmed with solid-state NMR 
and drug sorption onto or into ERL particles and films was observed as well, no major influence 
could be seen on drug release. When comparing to the release from the neutral EC rate 
controlling membrane, it was found that the release through ERL membranes was generally 
faster. The same observation could be made from diffusion tests. However, because water 
vapour diffusion was also higher through ERL membranes, the higher diffusion rates can mainly 
be ascribed to the more hydrophilic nature of the polymer. It is very difficult to investigate the 
influence of a charge interaction on drug release. No comparison can be made for instance 
with other drugs that are not ionisable because these drugs would have different 
physicochemical properties, just like the difference in drug release through both polymers 
proved to be mainly due to their hydrophilic behaviour or swelling capacity instead of whether 
or not being ionic in nature. 
 Eudragit® RL as a carrier for solid dispersions 
Controlling drug release from solid dispersions was not only attempted from complex 
coated systems, the potential of ERL as a carrier for solid dispersions was also investigated 
through its phase behaviour and the generation and maintenance of supersaturated drug 
concentrations from spray dried formulations. ERL could be applied alone as a carrier or in 
combination with a hydrophilic polymer (in this case PVP). mDSC studies showed that ERL as 
a carrier could form glass solutions even in higher drug loadings (up to at least 50% w/w) or 
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with different ratios of PVP. Glass solution formation largely depended on the physicochemical 
characteristics of the drug and the ratio of this drug incorporated into the solid dispersion. 
Drug dissolution studies showed that drugs which formed solid dispersions with ERL as a 
carrier could remain in a supersaturated state for a longer time compared to solid dispersions 
with PVP as a carrier. However, when a combination of ERL and PVP were tested, this 
generated higher drug concentrations compared to pure ERL and these higher drug 
concentrations were far better maintained over the course of 24 hours compared to pure 
PVP as a carrier. Highest stabilized drug concentrations were even seen in a physical mixture 
of spray dried INDO-PVP and INDO-ERL, so when there was no interaction or mixing 
between both polymers. INDO-(PVP-)-ERL precipitates also proved to remain completely 
amorphous when analysed after 24 hours of dissolution. This could be seen as a ‘reservoir’ 
system of amorphous INDO. 
The potential of this approach seems to be enormous. The generality of these findings 
however, still needs to be further investigated. Weak acidic drugs for example seem to give 
the best results (in part) due to the charge interaction with ERL, but CINN which is a neutral 
compound in the tested conditions quickly precipitated to its thermodynamic solubility. Since 
this was also the case with the hydrophilic polymer PVP, the inability to maintain the 
supersaturated state could be entirely due to the characteristics of the drug. A large screening 
study of different API’s with different physicochemical properties could potentially clarify the 
necessary properties of a drug candidate to be formulated in a solid dispersion together with 
ERL. Furthermore, the combination of ERL with PVP showed to give the best compromise in 
high drug concentration with stabilization of this concentration. But it is still unclear if this 
would work for all hydrophilic polymers. A comparative study incorporating different 
hydrophilic polymers in combination with ERL, could shed some light on this matter. Also, it 
is believed that the more gradual drug release would somehow be responsible for the 
stabilisation of the supersaturated drug concentrations. A mechanistic study into the exact 
role of ERL into the stabilization of supersaturated states is necessary to fully understand the 
potential and possible pitfalls of this approach. The influence of the manufacturing technique 
could also be further investigated. Currently spray drying was chosen over, for example, fluid 
bed coating because the latter doesn’t create a high enough surface area for sufficiently fast 
diffusion out of the insoluble ERL matrix. Other technologies like electrospraying can create 
even smaller particles which could be beneficial for supersaturation generation. Other 
manufacturing methods like ball milling could prove to have some advantages as well. Lastly, 
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glass solutions have always been the class of solid dispersions showing the highest dissolution 
enhancing potential. However, for solid dispersions using an insoluble but swellable matrix this 
doesn’t necessarily have to be the case. Creating a one phase system of a drug and ERL means 
intimate mixing between both components which could result in a slower drug release (see 
comparison between INDO-PVP-ERL 50-25-25% and the physical mixture of INDO-PVP and 
INDO-ERL 50-50%).  
 Eudragit® RL as a substrate for nanocrystal formation 
The unexpected formation of INDO and NAP nanocrystals was observed during solubility 
studies in presence of ERL. The man size of the nanocrystals was smaller than 100nm for both 
drugs and did not need an additional stabilizer to avoid agglomeration. The proposed 
mechanism of nanoparticle formation is a combination of equilibrium dissolution, sorption and 
desorption of drug molecules which shifts into the formation of nanocrystals after desorption 
from ERL in a saturated solution. Sorption does seem to be a necessary condition to form 
nanocrystals and a charge interaction between drug and polymer enhances the driving force 
for this sorption. This is the reason why no CINN nanocrystals were observed. 
This novel way of forming stable nanocrystals could be exploited in a production technique 
or be used for ‘in situ’ nanocrystal formation, given the time scale of the formation can be 
shortened. Again here, the full potential of the nanocrystal formation has not been investigated 
yet. Is sorption a sufficient condition for the nanocrystal formation or is a charge interaction 
absolutely necessary? If it is, can this approach be inversed as a cationic drug forming 
nanocrystals with an anionic polymer as a substrate? Can the polymer be chemically modified 
to speed up the nanocrystal formation? Clearly ERL has never been envisioned or developed 
as a substrate for nanocrystal formation, so could its structure be improved to better 
accommodate this nanocrystal formation? Long term stability investigation of the nanocrystals 
could make or break the ERL substrate method as a viable alternative to current nanosizing 
methods. 
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SUMMARY 
A general introduction concerning the research topics is provided in chapter 1. It provides 
a brief historical overview of drug discovery and the evolution towards poor solubility in drug 
candidates. Different enabling strategies are discussed which can address poor solubility and 
dissolution rate. The amorphous state of drugs is introduced together with its application in 
solid dispersions. More detailed information about different carriers, manufacturing techniques 
and characterization methods is provided. 
The objectives of this thesis are given in chapter 2. Because of the different challenges still 
faced in solid dispersion research today, an alternative manufacturing approach was 
investigated in the form of fluid bed coating, which enables efficient drying and the omission 
of additional processing steps which can destabilize solid dispersions. Also, alternative 
formulation approaches are exploited by incorporating controlled release polymers into solid 
dispersions, either as a rate controlling membrane or as (part of) the solid dispersion carrier. 
Chapter 3 describes the search for an mDSC sample preparation method for the analysis 
of INDO-PVP glass solutions coated onto inert sucrose beads using fluid bed coating. The 
spherical shape of these beads compromises the contact area with the bottom of a DSC 
sample pan. Grinding the coated beads and separating the resulting particles into different 
particle size ranges, resulted in a visible glass transition signal. This glass transition, however, 
shifted and broadened in particle samples with increasing size range. This phenomenon was 
confirmed in glass solutions prepared as isolated films by rotary evaporation, with different 
API’s and from different solvent systems. Resulting from TGA analysis, where a difference was 
made between sub-Tg and above-Tg residual solvent evaporation, it could be concluded that 
the observed Tg shift and broadening could be ascribed to the differences in residual solvent 
mass loss from the bulk of the particles and from the surface. Since particles with a smaller 
size range exhibit a higher surface to mass ratio, they possess more solvent poor surface, as 
compared to particles with a larger size range, which possess more solvent rich bulk. These 
findings were confirmed by a correlation between the deviation from the Gordon-Taylor 
derived Tg and solvent mass loss from the Tg on. 
In order to control the release of INDO from coated glass solutions, an additional rate 
controlling coating was applied on top of the glass solution. This can be done consecutively 
using fluid bed coating. The resulting multilayer coated beads require a combination of surface 
and bulk characterization to understand the phase behaviour. Different rate controlling 
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membranes were applied on INDO-PVP glass solutions comprising two possible controlled 
release polymers, different amounts of pore former can be added and the rate controlling 
membrane can be applied from an ethanol solution or an aqueous dispersion. The investigation 
of these different formulations on the phase behaviour of the drug delivery system is described 
in chapter 4. Surface and cross-sectional topography was investigated by SEM. Chemical 
composition and distribution analysis of these surfaces and cross-sections was performed using 
ToF-SIMS. Polymer miscibility was assessed with mDSC and crystallinity with XRPD. 
Topography differences observed on the surface or in the cross-sections of the coated beads 
can be ascribed to polymer miscibility differences or coating from a solution or a dispersion. 
PVP presence at the surface of pure ERL or EC coatings is the result of a coating 
contamination. The distributional changes of PVP, when incorporated as a pore former can 
also be explained by polymer miscibility differences. Limited INDO and PVP migration into the 
rate controlling membrane can be evidenced from cross-sectional ToF-SIMS analysis. Lastly, 
XRPD analysis shows that INDO remains amorphous after application of a rate controlling 
membrane, even if it is coated from an aqueous dispersion. 
The influence of the above described formulation changes and rate controlling membrane 
thickness on the release of INDO was investigated in chapter 5. In addition to this, the role 
of a charge interaction between drug and controlled release polymer on the release of the 
former was investigated as well. Diffusion experiments showed a clear influence of the 
controlled release polymer used, pore former concentration and coating from a solution or 
suspension on the permeability of rate controlling membranes. These findings could be readily 
translated to their influence on drug release, pinpointing diffusion through the rate controlling 
membrane as the rate limiting step for drug release and showing the potential of these diffusion 
experiments for screening purposes of rate controlling membranes. A charge interaction 
between INDO and ERL was confirmed by ss-NMR but no clear influence of this interaction 
on the drug release was observed. The diffusion and release differences through ERL and EC 
coatings are mainly the result of the higher hydrophilicity of the former. 
In chapter 6, the use of ERL as a solid dispersion carrier is investigated, either alone or in 
combination with the hydrophilic polymer PVP. The solid dispersions are produced by spray 
drying and analysed with respect to their phase behaviour and in vitro drug dissolution. After 
in vitro dissolution, precipitates are collected and analysed again with mDSC. ERL solid 
dispersions with INDO and NAP showed extended supersaturated drug concentrations, when 
compared to the hydrophilic polymer PVP. Combinations of PVP and ERL as a carrier 
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combined this extended supersaturation with higher drug concentrations compared to ERL 
alone. Phase behaviour analysis showed that ERL can form glass solutions and, in the case of 
INDO, one phase systems are found after 24h dissolution as well. Low drug loadings in 
combination with ERL as a carrier resulted in slow diffusion out of the carrier making this 
approach unfavourable. Oversaturated INDO and NAP solutions formed stable nanocrystals 
in presence of ERL. This formation can be explained by a dynamic interplay of dissolution, 
sorption and desorption. High sorption levels are necessary for this nanocrystal formation, 
and a charge interaction between INDO/NAP and ERL provide the necessary driving force for 
sorption. 
An overall discussion on all these findings together with prospects of future studies are 
provided in chapter 7 of this thesis. 
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SAMENVATTING 
Een algemene introductie over de verschillende deelaspecten van dit onderzoek wordt 
weergegeven in hoofdstuk 1. Deze introductie behandelt een kort historisch overzicht 
omtrent de ontdekking van geneesmiddelen en de evolutie naar slechte wateroplosbaarheid 
van recente geneesmiddelkandidaten. Verscheidene strategieën worden besproken die deze 
slechte oplosbaarheid en oplossnelheid kunnen verhelpen. Een inleiding over de amorfe 
toestand van geneesmiddelen wordt gegeven, samen met zijn mogelijke toepassing in vaste 
dispersies. Vervolgens wordt er ook verder ingegaan op de verschillende carriers voor vaste 
dispersies, productietechnieken en mogelijkheden tot karakterizering. 
De doelstellingen van deze thesis worden besproken in hoofdstuk 2. Daar het onderzoek 
naar vaste dispersies tegenwoordig nog te maken heeft met verschillende uitdagingen, wordt 
een alternatieve productietechniek voorgesteld, namelijk wervelbed coating. Deze methode 
staat een efficiënte droging van de vaste dispersies toe en hoeft geen bijkomende 
behandelingsstappen te ondergaan die zouden kunnen leiden tot instabiliteit van deze vaste 
dispersies. Naast een alternatieve productiemethode wordt ook een alternatieve 
formuleringsstrategie onderzocht, die gebruik maakt van polymeren gebruikt voor 
gecontroleerde afgifte. Deze polymeren worden aangewend als een regulerend membraan of 
als (een deel) van de vaste dispersie carrier. 
Hoofdstuk 3 beschrijft de zoektocht naar een geschikte mDSC staalvoorbereidingsmethode 
voor de analyse van INDO-PVP glasoplossingen, gecoat op inerte sucrose pellets door middel 
van wervelbed coating. De sferische vorm van deze pellets zorgt voor een zeer beperkt 
contactoppervlak met de platte bodem van DSC monsterhouders. Het verbrijzelen van deze 
gecoate pellets en scheiding naargelang partikelgrootte zorgde voor een zichtbaar 
glastransitiesignaal. De glastransitie verschoof en verbreedde echter bij partikels met een 
grotere partikelgrootte. Dit fenomeen werd bevestigd in geïsoleerde glasoplossingsfilmen, 
gemaakt door rotavaporisatie, met verschillende geneesmiddelen en verschillende solventen 
of mengsels van solventen. TGA maakte het mogelijk om een onderscheid te maken tussen 
solventverdamping onder en boven de Tg van de vaste dispersie. Deze aanpak leidde 
uiteindelijk tot de conclusie dat de glastransitie verschuiving en verbreding terug te brengen is 
tot verschillen in solventverdamping aan het oppervlak of vanuit de bulk van de partikels. 
Kleinere partikels hebben meer oppervlak per massa en bezitten dus meer solventarm 
oppervlak. Grotere partikels daarentegen bezitten dan weer meer solventrijke bulk. Deze 
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bevindingen werden bevestigd door een correlatie tussen de afwijking van de Tg, bepaald door 
de Gordon-Taylor vergelijking en het massaverlies door solventverdamping vanaf de 
glastransitie. 
Om een controle te hebben over de afgifte van INDO werd een bijkomende coatinglaag 
over deze glasoplossingen aangebracht. Deze handeling kan worden uitgevoerd direct na het 
coaten van de glasoplossing in hetzelfde coating toestel. Om het fasegedrag van deze veellagige 
coating ten volle te kunnen onderzoeken is een combinatie nodig van oppervlakte- en 
bulkkarakterizering. Verschillende van deze gecontroleerde afgifte membranen werden 
aangebracht op de INDO-PVP glasoplossing met verschillende polymeren voor 
gecontroleerde afgifte, verschillende concentraties aan porievormer en deze membranen 
kunnen worden gecoat uit een ethanol oplossing of uit een waterige dispersie. Het onderzoek 
naar de invloed van deze formuleringsmogelijkheden op het fasegedrag van deze systemen 
wordt beschreven in hoofdstuk 4. De topografie van het oppervlak en de dwarsdoorsnedes 
wordt onderzocht met SEM. De chemische samenstelling en verdeling op het oppervlak en 
langs de dwarsdoorsnedes wordt geanalyseerd door middel van ToF-SIMS. Tenslotte wordt 
polymeermengbaarheid onderzocht met mDSC en de aanwezigheid van kristallen met XRPD. 
Topografieverschillen konden worden verklaard door verschillen in polymeermengbaarheid of 
door het feit dat er werd gecoat vanuit een oplossing of dispersie. De aanwezigheid van PVP 
aan het oppervlak van coatings die enkel zouden mogen bestaan uit ERL of EC was het resultaat 
van een coating contaminatie. De verdeling van PVP, wanneer toegevoegd als porievormer, 
aan het oppervlak was eens te meer te wijten aan polymeermengbaarheidsverschillen. Er werd 
ook een zeer beperkte migratie van INDO en PVP vastgesteld in de coatinglaag voor 
gecontroleerde afgifte door analyse van de dwarsdoorsneden. De analyse door middel van 
XRPD gaf aan dat INDO volledig amorf blijft na toevoeging van een gecontroleerde vrijgave 
membraan, zelfs wanneer deze laatste wordt aangebracht vanuit een waterige dispersie. 
De invloed van voorgenoemde formuleringsvariaties, en de invloed van de dikte van de 
coatinglaag op de vrijgave van INDO wordt onderzocht in hoofdstuk 5. Ook wordt de rol 
nagegaan van een ladingsinteractie tussen geneesmiddel en gecontroleerde vrijgave polymeer 
op de vrijgave van het geneesmiddel. Diffusie experimenten duiden op een duidelijke invloed 
van het gebruikte gecontroleerde vrijgave polymeer, de porievormer concentratie en het 
coaten vanuit oplossing of dispersie op de permeabiliteit van gecontroleerde vrijgave 
membranen. Deze invloeden kunnen makkelijk worden doorgetrokken naar de 
geneesmiddelvrijgave, wat wijst op het feit dat diffusie de snelheidsbepalende stap is in de 
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vrijgave van het geneesmiddel, en dat deze diffusietesten potentieel hebben in screeningtesten 
van gecontroleerde vrijgave membranen. Een ladingsinteractie tussen INDO en ERL werd 
bevestigd door middel van ss-NMR, maar er werd geen duidelijke invloed van deze interactie 
gevonden op de vrijzetting van het geneesmiddel. Het grootste verschil tussen ERL en EC 
coatings ligt waarschijnlijk in het feit dat deze eerste hydrofieler is dan de tweede. 
In hoofdstuk 6 werd het gebruik van ERL als carrier in vaste dispersies nagegaan. Ofwel 
alleen of in combinatie met het hydrofiel polymeer PVP. Vaste dispersies werden 
geproduceerd door middel van sproeidrogen en geanalyseerd op hun fasegedrag en in vitro 
dissolutie. Na de dissolutie wordt de gevormde neerslag in het dissolutiemedium verzameld 
en opnieuw geanalyseerd met mDSC. Vaste dispersies, bestaande uit ERL en INDO of NAP 
vertonen verlengde supersaturatie in vergelijking met PVP als carrier. Wanneer ERL en PVP 
gecombineerd werden als carrier werden hogere geneesmiddelconcentraties bekomen (t.o.v. 
ERL alleen). Deze verhoogde concentraties konden gedurende langere tijd worden 
aangehouden. Analyse van het fasegedrag toont aan dat ERL glasoplossingen kan vormen en 
dat, in geval van combinatie met INDO, een éénfasig systeem nog steeds wordt gevormd na 
dissolutie gedurende 24 uur. Lage geneesmiddelconcentraties in combinatie met ERL zorgen 
voor een trage diffusie uit de carrier en zijn bij deze toepassing dan ook ongewenst. Een 
interessante en eerder onverwachte bevinding was dat oversaturatie van INDO of NAP 
oplossingen in combinatie met de aanwezigheid van ERL leidt tot vorming van stabiele 
nanokristallen wat kan worden verklaard door een dynamische wisselwerking van dissolutie, 
sorptie en desorptie. Hoge sorptie is nodig voor de vorming van nanokristallen en een 
ladingsinteractie tussen INDO/NAP en ERL kan zulke sorptie in de hand werken. 
Een algemene discussie over al deze bevindingen, samen met mogelijkheden voor 
toekomstig onderzoek worden besproken in hoofdstuk 7 van deze thesis. 
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SUPPLEMENTARY DATA CHAPTER 4 
 
Figure A: Ion intensities and spectra of the component selective ion markers opposed to the 
other compound controls. 
 
 
Figure B: SEM micrograph of a bead with INDO-PVP glass solution and EC-TEC top coating 
(left) and a detailed view on the coating layers (right). 
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Figure C: ToF-SIMS ion spectra of ERL based outer layer coatings at the marker ion masses of 
ERL, PVP and INDO 
 
 
Figure D: ToF-SIMS ion spectra of EC based outer layer coatings at the marker ion masses of 
EC, PVP and INDO 
 
 
Figure E: ToF-SIMS ion spectra of INDO-PVP glass solution coating cross-sections at the marker 
ion masses of PVP, INDO and sucrose. 
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Figure F: Secondary ion spectra (1) and intensities (2) for the sucrose control sample. EC and 
ERL marker intensity is represented in striped blue bars, PVP marker intensity is a red bar, INDO 
marker intensity is a green bar and sucrose marker intensity is a purple bar. Ion intensities area 
is normalized by total ion statistics. 
 
 
Figure G: ToF-SIMS ion spectra of ERL based outer layer coating cross-sections at the marker 
ion masses of ERL, PVP, INDO and Sucrose 
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Figure H: ToF-SIMS ion spectra of EC based outer layer coating cross-sections at the marker 
ion masses of EC, PVP, INDO and Sucrose 
 
 
Figure I: Secondary ion intensities for the sucrose control sample. EC and ERL marker intensity 
is represented in striped blue bars, PVP marker intensity is a red bar, INDO marker intensity is 
a green bar and sucrose marker intensity is a purple bar. Ion intensities area is normalized by 
total ion statistics. 
 
 
Figure J: Secondary ion intensities (1) of the EC marker intensity is represented in blue bars, 
PVP marker intensity in red bars, INDO marker intensity in green bars and sucrose marker 
intensity in purple bars. Ion intensities area is normalized by total ion statistics. The region of 
interest creation (2), the purple colored region represents the outer layer of the EC 100% 
coating, the yellow colored region the middle layer and the blue colored region the inner layer. 
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SUPPLEMENTARY DATA CHAPTER 6 
 
Figure A: . INDO concentration in function of time for INDO-PVP 30-70% (w/w) glass solution 
and an EC-PVP 75-25% (w/w) rate controlling membrane. Different coating levels were tested: 
9.5% (blue), 18.6% (red) and 35.8% (purple). 
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SUPPLEMENTARY DATA CHAPTER 6 
 
 
Figure A: mDSC thermograms of dissolution precipitates of INDO formulations with different 
polymers (or combinations) and INDO contents of 50% (1, 1’) and 10% (2, 2’). In panel 1, INDO-
PVP-ERL 50-25-25% is represented in green and INDO-ERL 50-50% in pink 
 
 
Figure B: Total heat flow thermograms of dissolution precipitates of 30% NAP formulations 
with different polymers (or combinations). NAP-PVP-ERL 30-35-35% is represented in green, 
NAP-ERL 30-70% in pink and NAP-PVP 30-70% in red. 
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Figure C: mDSC thermograms of dissolution precipitates of 30% NAP formulations with 
different polymers (or combinations). In panel 1 CINN-PVP-ERL 30-35-35% is represented in 
green and CINN-ERL 30-70% in pink. Full lines represent the reversing heat flow 
 
Figure D: XRPD diffractogram of γ -INDO (red) and α -INDO (light pink) together with 
dissolution precipitates of INDO formulations with varying drug loadings and polymer 
compositions. INDO-PVP 30-70% diffractogram is in green, INDO-PVP 50-50% in dark pink, a 
physical mixture of INDO-PVP and INDO-ERL 50-50% in orange, INDO-PVP-ERL 30-52.5-
17.5% in teal, INDO-PVP-ERL 30-17.5-52.5% in brown, INDO-PVP-ERL 30-35-35% in blue and 
INDO-ERL 30-70% in dark blue 
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